

CITATION REPORT

List of articles citing

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

DOI: 10.1016/j.ijantimicag.2020.105949

International Journal of Antimicrobial Agents, 2020, 56, 105949.

Source: <https://exaly.com/paper-pdf/84416187/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2286	Anti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8+ T effector levels in Han Chinese pulmonary TB patients. 2020 , 22, 119-126		5
2285	Treating COVID-19 With Hydroxychloroquine (TEACH): A Multicenter, Double-Blind Randomized Controlled Trial in Hospitalized Patients. 2020 , 7, ofaa446		34
2284	Treatment of coronavirus disease 2019. 2020 , 15, 336-340		3
2283	Hydroxychloroquine for prophylaxis of COVID-19 physicians survey: Despite lack of evidence, many would take or give to dear ones, and despite the perceived necessity of an RCT, few would participate. 2020 , 26, 1579-1582		3
2282	Immunomodulation for Severe COVID-19 Pneumonia: The State of the Art. 2020 , 11, 577442		16
2281	Therapeutic Options Against the New Coronavirus: Updated Clinical and Laboratory Evidences. 2020 , 7, 546		5
2280	Pharmaconutrition in the Clinical Management of COVID-19: A Lack of Evidence-Based Research But Clues to Personalized Prescription. 2020 , 10,		8
2279	The prophylaxis and treatment potential of supplements for COVID-19. 2020 , 887, 173530		29
2278	Pharmacological Advances of Chloroquine and Hydroxychloroquine: From Antimalarials to Investigative Therapies in COVID-19. 2020 , 15, 1934578X2095364		1
2277	Extracorporeal Treatment for Chloroquine, Hydroxychloroquine, and Quinine Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup. 2020 , 31, 2475-2489		6
2276	Drug Weaponry to Fight Against SARS-CoV-2. 2020 , 7, 204		2
2275	Actualizaci3n de la Declaraci3n de consenso en medicina critica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. 2020 , 20, 1-112		2
2274	Declaraci3n consenso de la Asociaci3n Colombiana de Medicina Cr3tica y Cuidados Intensivos (AMCI) para atenci3n y manejo del paciente pedi3trico con sospecha o confirmaci3n de infecci3n severa por SARS-CoV-2. 2020 , 20, 113-127		0
2273	COVID-19 outbreak: Challenges in pharmacotherapy based on pharmacokinetic and pharmacodynamic aspects of drug therapy in patients with moderate to severe infection. 2020 , 49, 763-773		13
2272	Methylene blue inhibits replication of SARS-CoV-2 in vitro. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106202	14.3	29
2271	COVID-19 therapies and their impact on QT interval prolongation: A multicentre retrospective study on 196 patients. 2020 , 30, 100637		3
2270	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. 2020 , 101, 290-297		26

2269	Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics. 2020 , 89, 107082	10
2268	Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2. 2020 , 4, 759-763	3
2267	First evaluation of hydroxychloroquine recommendations in treating SARS-CoV-2. 2020 , 38, 100759	2
2266	Analytical insights of COVID-19 pandemic. 2020 , 133, 116072	10
2265	The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents. 2020 , 4, e288-e299	15
2264	Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control. 2020 , 77, 168-184	6
2263	Upholding morality and honesty in global scientific research during the coronavirus disease pandemic. 2020 , 133, 2401-2402	
2262	SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies. 2020 , 13, 255-260	12
2261	Psychological State and Associated Factors During the 2019 Coronavirus Disease (COVID-19) Pandemic Among Filipinos with Rheumatoid Arthritis or Systemic Lupus Erythematosus. 2020 , 12, 215-222	28
2260	Natural Plant Products: A Less Focused Aspect for the COVID-19 Viral Outbreak. 2020 , 11, 568890	13
2259	Coronavirus Historical Perspective, Disease Mechanisms, and Clinical Outcomes: JACC Focus Seminar. 2020 , 76, 1999-2010	13
2258	Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. 2020 , 45, 703-713	7
2257	The role of biosensors in coronavirus disease-2019 outbreak. 2020 , 23, 174-184	61
2256	Azithromycin: The First Broad-spectrum Therapeutic. 2020 , 207, 112739	25
2255	Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. 2020 , 887, 173561	8
2254	Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus. 2020 , 79, 153333	31
2253	Antimalarial drugs inhibit the replication of SARS-CoV-2: An in vitro evaluation. 2020 , 37, 101873	38
2252	Clinical evidences on the antiviral properties of macrolide antibiotics in the COVID-19 era and beyond. 2020 , 28, 2040206620961712	12

2251	An Overview of the Temporal Shedding of SARS-CoV-2 RNA in Clinical Specimens. 2020 , 8, 487	9
2250	Oxidative Stress, Proton Fluxes, and Chloroquine/Hydroxychloroquine Treatment for COVID-19. 2020 , 9,	9
2249	"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey". 2020 , 14, 1413-1418	2
2248	No benefit of hydroxychloroquine in COVID-19: Results of Systematic Review and Meta-Analysis of Randomized Controlled Trials". 2020 , 14, 1673-1680	31
2247	Assessment of effective imidazole derivatives against SARS-CoV-2 main protease through computational approach. 2020 , 262, 118469	5
2246	Síndrome DRESS en paciente con enfermedad por SARS-CoV-2. 2020 , 2, 205-206	
2245	Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review. 2020 , 12, 1759720X20947296	2
2244	Chloroquine against malaria, cancers and viral diseases. 2020 , 25, 2012-2012	23
2243	An open-label, randomized trial of the combination of IFN- γ plus TFF2 with standard care in the treatment of patients with moderate COVID-19. 2020 , 27, 100547	17
2242	Synergistic bactericidal profiling of prodigiosin extracted from <i>Serratia marcescens</i> in combination with antibiotics against pathogenic bacteria. 2020 , 149, 104508	7
2241	Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19. 2020 , 216, 107672	31
2240	SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus. 2020 , 11, 1224	17
2239	Coronavirus Disease 2019 Related Clinical Studies: A Cross-Sectional Analysis. 2020 , 11, 540187	2
2238	Facile Synthesis of Antimicrobial Aloe Vera-"Smart" Triiodide-PVP Biomaterials. 2020 , 5,	10
2237	Curcumin (a constituent of turmeric): New treatment option against COVID-19. 2020 , 8, 5215-5227	46
2236	Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. 2021 , 8, 385-400	18
2235	Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy. 2020 , 22, e00962	9
2234	Nanomedicine strategies to target coronavirus. 2020 , 35, 100961	28

2233	Leukotrienes, a potential target for Covid-19. 2020 , 161, 102174	5
2232	Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach. 2020 , 406, 115237	12
2231	Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. 2020 , 117, 25543-25552	23
2230	[Clinical spectrum and risk factors for complicated disease course in children admitted with SARS-CoV-2 infection]. 2020 , 93, 323-333	11
2229	A review of medications used to control and improve the signs and symptoms of COVID-19 patients. 2020 , 887, 173568	2
2228	COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic. 2020 , 261, 118336	35
2227	COVID-19 pneumonia identified by CT of the abdomen: A report of three emergency patients presenting with abdominal pain. 2020 , 15, 2090-2094	4
2226	Revisiting the cardiovascular risk of hydroxychloroquine in RA. 2020 , 16, 671-672	3
2225	Therapeutic options for the management of severe COVID-19: A rheumatology perspective. 2021 , 17, 431-436	1
2224	Potential Therapeutic Options for COVID-19. 2020 , 2, 89-95	
2223	Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors. 2021 , 25, 1731-1744	4
2222	Safety and Effectiveness of Hydroxychloroquine and Azithromycin Combination Therapy for Treatment of Hospitalized Patients with COVID-19: A Propensity-Matched Study. 2020 , 9, 523-534	11
2221	Clinical spectrum and risk factors for complicated disease course in children admitted with SARS-CoV-2 infection. 2020 , 93, 323-333	2
2220	Complex dynamics in susceptible-infected models for COVID-19 with multi-drug resistance. 2020 , 140, 110257	20
2219	The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review and Meta-Analysis. 2020 , 2020, 4312519	16
2218	Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study. 2020 , 14, 1753466620963016	9
2217	Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. 2020 , 17, 154	38
2216	Convalescent Plasma: The Relay Baton in the Race for Coronavirus Disease 2019 Treatment. 2020 , 11, 570063	8

2215	A stance data set on polarized conversations on Twitter about the efficacy of hydroxychloroquine as a treatment for COVID-19. 2020 , 33, 106401	9
2214	Preparation and physicochemical stability of 50 mg/mL hydroxychloroquine oral suspension in SyrSpend SF PH4 (dry). <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106201	14.3 1
2213	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. 2020 , 262, 118541	4
2212	Bibliometric Analysis of Early COVID-19 Research: The Top 50 Cited Papers. 2020 , 13, 1178633720962935	16
2211	Inhibiting the two-component system GraXRS with verteporfin to combat Staphylococcus aureus infections. 2020 , 10, 17939	6
2210	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. 2020 , 383, 2030-2040	628
2209	Fractures in Patients With COVID-19 Infection: Early Prognosis and Management. A Case Series of 20 Patients in a Single Institution in Lombardy, Northern Italy. 2020 , 34, e389-e397	9
2208	Current treatment of COVID-19 in renal patients: hope or hype?. 2020 , 15, 1389-1398	6
2207	Hydroxy-chloroquine to treat COVID-19 - infected patients: Some lessons from medical anthropology and history of medicine. 2020 , 15, 100587	
2206	Potential Inhibitors for SARS-CoV-2 and Functional Food Components as Nutritional Supplement for COVID-19: A Review. 2020 , 75, 458-466	19
2205	Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome. 2020 , 93, 132-133	4
2204	A perspective on potential target proteins of COVID-19: Comparison with SARS-CoV for designing new small molecules. 2020 , 104, 104326	12
2203	Pragmatic, adaptive clinical trials: Is 2020 the dawning of a new age?. 2020 , 19, 100614	6
2202	Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment. 2020 , 889, 173634	21
2201	A comprehensive strategy for the early treatment of COVID-19 with azithromycin/hydroxychloroquine and/or corticosteroids: Results of a retrospective observational study in the French overseas department of Réunion Island. 2020 , 23, 1-3	7
2200	[Treatment of Sars-Cov2 with hydroxychloroquine is ineffective and potentially harmful]. 2020 , 2020, 25-27	0
2199	Hydroxychloroquine and Potential Drug Interactions in Older Adults. 2020 , 56, 679-681	2
2198	COVID-19 and thrombosis: Beyond a casual association. 2020 , 155, 44	3

2197	Nullane salus extra ecclesiam. 2020 , 37, 100714	2
2196	Editorial commentary: Hitting a moving target: The challenge of creating consensus treatment protocols for cardiovascular care during the coronavirus pandemic. 2020 , 30, 326-327	
2195	Apparent inefficacy of hydroxychloroquine combined with azithromycin on SARS-CoV-2 clearance in an incident cohort of geriatric patients with COVID-19. 2020 , 37, 101826	2
2194	Hydroxychloroquine for Early Treatment of Adults With Mild Coronavirus Disease 2019: A Randomized, Controlled Trial. 2021 , 73, e4073-e4081	150
2193	Hydroxychloroquine in Hospitalized Patients with COVID-19: Real-World Experience Assessing Mortality. 2020 , 40, 1072-1081	9
2192	Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia: JACC Focus Seminar. 2020 , 76, 2011-2023	74
2191	Outcomes and Laboratory and Clinical Findings of Asthma and Allergic Patients Admitted With Covid-19 in a Spanish University Hospital. 2020 , 11, 570721	2
2190	Hydroxychloroquine and Potential Drug Interactions in Older Adults. 2020 , 56, 679-681	
2189	Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106192	14.3 8
2188	A systematic review of SARS-CoV-2 vaccine candidates. 2020 , 5, 237	257
2187	Novel corona virus (COVID-19) pandemic: current status and possible strategies for detection and treatment of the disease. 2020 , 1-24	11
2186	Pathophysiology and Potential Therapeutic Candidates for COVID-19: A Poorly Understood Arena. 2020 , 11, 585888	7
2185	Observational study of people infected with SARS-Cov-2, treated with amantadine. 2020 , 72, 1538-1541	20
2184	Extracorporeal membrane oxygenation for COVID-19 induced hypoxia: Single-center study. 2021 , 36, 564-572	7
2183	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. 2020 , 225, 152008	39
2182	Chloroquine and hydroxychloroquine for combating COVID-19: Investigating efficacy and hypothesizing new formulations using Bio/chemoinformatics tools. 2020 , 21, 100446	11
2181	Potential Therapeutic Effect of Traditional Chinese Medicine on Coronavirus Disease 2019: A Review. 2020 , 11, 570893	5
2180	Chloroquine to fight COVID-19: A consideration of mechanisms and adverse effects?. 2020 , 6, e04900	9

2179	The C-C Chemokine Receptor Type 4 Is an Immunomodulatory Target of Hydroxychloroquine. 2020 , 11, 1253		1
2178	SARS-CoV-2: From Structure to Pathology, Host Immune Response and Therapeutic Management. 2020 , 8,		3
2177	Peptides: Prospects for Use in the Treatment of COVID-19. 2020 , 25,		13
2176	A multimodal deep learning-based drug repurposing approach for treatment of COVID-19. 2021 , 25, 1717-1730		13
2175	Management Considerations for the COVID-19 Patient with Severe Disease: a Case Scenario and Literature Review. 2020 , 1-7		1
2174	TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.. 2020 , 13, 8069-8079		8
2173	Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. 2020 , 131, 110668		59
2172	The Clinical Utility of Continuous QT Interval Monitoring in Patients Admitted With COVID-19 Compared With Standard of Care: A Prospective Cohort Study. 2020 , 2, 592-598		
2171	Glucose-6-phosphate dehydrogenase deficiency and SARS-CoV-2 mortality: Is there a link and what should we do?. 2020 , 86, 31-33		2
2170	Predictive factors for cardiac conduction abnormalities with hydroxychloroquine-containing combinations for COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106142	14.3	5
2169	Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106143	14.3	51
2168	Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106144	14.3	76
2167	Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials. 2020 , 165, 18-43		27
2166	Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?. 2020 , 101, 107-120		5
2165	Biological, molecular and pharmacological characteristics of chloroquine, hydroxychloroquine, convalescent plasma, and remdesivir for COVID-19 pandemic: A comparative analysis. 2020 , 32, 3159-3166		9
2164	Azithromycin: The First Broad-spectrum Therapeutic. 2020 , 100062		1
2163	Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges. 2020 , 259, 118275		44
2162	Hydroxychloroquine is effective, and consistently so when provided early, for COVID-19: a systematic review. 2020 , 38, 100776		20

2161	The immuno-oncological challenge of COVID-19.. 2020 , 1, 946-964	52
2160	Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. 2020 , 13, 1183-1190	5
2159	[Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection]. 2020 , 155, 448-453	7
2158	[Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality]. 2020 , 155, 375-381	5
2157	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. 2020 , 17, 543-558	560
2156	Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19. 2020 , 47, 305-308	4
2155	RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS". 2020 , 189, 1442-1443	5
2154	Maternal and perinatal outcomes and pharmacological management of Covid-19 infection in pregnancy: a systematic review protocol. 2020 , 9, 161	9
2153	Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19. 2020 , 6, 2304-2318	25
2152	Natural derivatives with dual binding potential against SARS-CoV-2 main protease and human ACE2 possess low oral bioavailability: a brief computational analysis. 2021 , 39, 5819-5830	9
2151	Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. 2021 , 87, 3439-3450	14
2150	The hazard of (sub)therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: The Padua province experience. 2020 , 18, 2629-2635	53
2149	Repurposing Existing Drugs for the Treatment of COVID-19. 2020 , 17, 1186-1194	15
2148	Potential Fast COVID-19 Containment With Trehalose. 2020 , 11, 1623	9
2147	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. 2020 , 8, 384	7
2146	Azithromycin in COVID-19 Patients: Pharmacological Mechanism, Clinical Evidence and Prescribing Guidelines. 2020 , 43, 691-698	59
2145	Micro and nanoscale technologies in oral drug delivery. 2020 , 157, 37-62	45
2144	Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?. 2020 , 216, 153086	26

2143	COVID-19 Infection in Kidney Transplant Recipients: A Single-Center Case Series of 22 Cases From Belgium. 2020 , 2, 459-466		23
2142	SARS-CoV-2 infection in dialysis patients in northern Italy: a single-centre experience. 2020 , 13, 334-339		14
2141	Cardiac Arrest Risk During Acute Infections: Systemic Inflammation Directly Prolongs QTc Interval via Cytokine-Mediated Effects on Potassium Channel Expression. 2020 , 13, e008627		21
2140	COVID-19 Pandemic in India: Present Scenario and a Steep Climb Ahead. 2020 , 11, 2150132720939402		23
2139	Targeting the Immune System for Pulmonary Inflammation and Cardiovascular Complications in COVID-19 Patients. 2020 , 11, 1439		16
2138	A Hypothesis for the Possible Role of Zinc in the Immunological Pathways Related to COVID-19 Infection. 2020 , 11, 1736		26
2137	Characteristics of the Coronavirus Disease 2019 and related Therapeutic Options. 2020 , 18, 367-375		15
2136	Concerns about pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) studies in the new therapeutic area of COVID-19 infection. 2020 , 181, 104866		24
2135	Reply to Gautret et al: hydroxychloroquine sulfate and azithromycin for COVID-19: what is the evidence and what are the risks?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106056	14.3	18
2134	Update I. A systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. 2020 , 59, 176-190		44
2133	Immune response in COVID-19: A review. 2020 , 13, 1619-1629		143
2132	Five variable that rule your life - Home mortgage and biostatistical power. 2020 , 18, 533-536		1
2131	Generating translatable evidence to improve patient care: the contribution of human factors. 2020 , 41, 353-356		4
2130	Current Status of Multiple Drug Molecules, and Vaccines: An Update in SARS-CoV-2 Therapeutics. 2020 , 57, 4106-4116		29
2129	Ozone (O ₃) and SARS-CoV-2: Physiological Bases and Their Therapeutic Possibilities According to COVID-19 Evolutionary Stage. 2020 , 2, 1-9		19
2128	FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. 2020 , 53, 100719		79
2127	COVID-19 treatment: Much research and testing, but far, few magic bullets against SARS-CoV-2 coronavirus. 2020 , 203, 112647		17
2126	Publishing in face of the COVID-19 pandemic. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106081	14.3	10

2125	Targeting zinc metalloenzymes in coronavirus disease 2019. 2020 , 177, 4887-4898	17
2124	Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. 2020 , 64,	44
2123	The Cardiovascular Effects of Treatment with Hydroxychloroquine and Azithromycin. 2020 , 40, 978-983	4
2122	Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. 2020 , 2, 1-12	11
2121	Advances in the possible treatment of COVID-19: A review. 2020 , 883, 173372	38
2120	Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. 2020 , 883, 173375	49
2119	Recommendations of the Working Groups from the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) for the management of adult critically ill patients in the coronavirus disease (COVID-19). 2020 , 44, 371-388	3
2118	Kidney allograft recipients, immunosuppression, and coronavirus disease-2019: a report of consecutive cases from a New York City transplant center. 2020 , 35, 1250-1261	49
2117	Atypical Presentation of COVID-19 Leading to ARDS. 2020 , 2020, 1070249	2
2116	Coronavirus Disease 2019 (COVID-19) and Transplantation: Pharmacotherapeutic Management of Immunosuppression Regimen. 2020 , 16, 617-629	24
2115	COVID-19/SARS-CoV-2 Infection: Lysosomes and Lysosomotropism Implicate New Treatment Strategies and Personal Risks. 2020 , 21,	22
2114	Immunomodulatory Effects of Hydroxychloroquine and Chloroquine in Viral Infections and Their Potential Application in Retinal Gene Therapy. 2020 , 21,	11
2113	Clinical presentation and management of COVID-19. 2020 , 213, 134-139	24
2112	Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106101	14.3 52
2111	COVID-19 and the Heart. 2020 , 51, e4320	8
2110	Pathogenesis and management of myocardial injury in coronavirus disease 2019. 2020 , 22, 1994-2006	19
2109	Safety perspectives on presently considered drugs for the treatment of COVID-19. 2020 , 177, 4353-4374	9
2108	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. 2020 , 108, 1135-1149	17

2107	Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19. 2020 , 97, 872-881	6
2106	Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19. 2020 , 1-16	3
2105	Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making. 2020 , 46, 574-578	8
2104	Weather the Cytokine Storm: A Report of Successful Management of a Colon Cancer Survivor and a Critically Ill Patient with COVID-19. 2020 , 13, 754-759	2
2103	Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. 2020 , 24, 418	36
2102	SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings. 2020 , 9,	23
2101	Communicating Science in the Time of a Pandemic. 2020 ,	29
2100	Pharmacist's perspective on HCQ treatment of COVID-19. 2020 , 36, 660	
2099	Emerging pharmacological therapies for ARDS: COVID-19 and beyond. 2020 , 46, 2265-2283	27
2098	QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin. 2020 , 59, 337-345	17
2097	The 'president's drug'. 2020 , 28, 363-365	0
2096	Antimicrobial Resistance in Agri-Food Chain and Companion Animals as a Re-emerging Menace in Post-COVID Epoch: Low-and Middle-Income Countries Perspective and Mitigation Strategies. 2020 , 7, 620	9
2095	Pharmacogenomics of genetic polymorphism within the genes responsible for SARS-CoV-2 susceptibility and the drug-metabolising genes used in treatment. 2021 , 31, e2194	6
2094	Bioengineered Tissue Models to Study SARS-CoV-2 Pathogenesis and Therapeutic Validation. 2020 , 6, 6540-6555	13
2093	Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety. 2020 , 28, 1760-1776	14
2092	Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m): a molecular docking, molecular dynamics and structure-activity relationship studies. 2020 , 1-19	24
2091	Hydroxychloroquine Controversies: Clinical Trials, Epistemology, and the Democratization of Science. 2020 , 34, 525-541	11
2090	Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. 2020 , 25,	2

2089	Structure-guided discovery approach identifies potential lead compounds targeting M of SARS-CoV-2. 2020 , 31, 1-5	2
2088	Efficacy and safety of transfusing plasma from COVID-19 survivors to COVID-19 victims with severe illness. A double-blinded controlled preliminary study. 2020 , 36, 264-272	12
2087	Ophthalmic complaints in face-mask wearing: prevalence, treatment, and prevention with a potential protective effect against SARS-CoV-2. 2020 , 34, 1323-1335	6
2086	Advances in the treatment of novel coronavirus disease (COVID-19) with Western medicine and traditional Chinese medicine: a narrative review. 2020 , 12, 6054-6069	7
2085	Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. 2020 , 27, 434-441	2
2084	Hydroxychloroquine Inhibits the Trained Innate Immune Response to Interferons. 2020 , 1, 100146	13
2083	FDALabel for drug repurposing studies and beyond. 2020 , 38, 1378-1379	3
2082	Immunopathology, host-virus genome interactions, and effective vaccine development in SARS-CoV-2. 2020 , 18, 3774-3787	11
2081	Randomized double-blinded placebo-controlled trial of hydroxychloroquine with or without azithromycin for virologic cure of non-severe Covid-19. 2020 , 29, 100645	34
2080	Outcomes and clinical practice in patients with COVID-19 admitted to the intensive care unit in Montréal, Canada: a descriptive analysis. 2020 , 8, E788-E795	15
2079	Knowing more about chloroquine/hydroxychloroquine in COVID-19 patients. 2020 , 15, 1523-1526	3
2078	An asthmatic pregnant woman with COVID-19: A case report study. 2020 , 31, 101296	0
2077	Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology. 2020 , 16, 437-446	78
2076	COVID-19: lessons to date from China. 2020 , 105, 1146-1150	7
2075	Evaluating the efficacy and safety of the myrtle (<i>Myrtus communis</i>) in treatment and prognosis of patients suspected to novel coronavirus disease (COVID-19): study protocol for a randomized controlled trial. 2020 , 21, 978	1
2074	Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. 2021 , 199, 3642-3646	28
2073	COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development. 2020 , 45, 1	24
2072	Prescribing practices of lopinavir/ritonavir, hydroxychloroquine and azithromycin during the COVID-19 epidemic crisis and pharmaceutical interventions in a French teaching hospital. 2021 , 28, 242-247	1

2071	Update Alert 2: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. 2020 , 173, W128-W129	12
2070	Electrical storm in a patient with COVID-19 treated with hydroxychloroquine: A case report. 2020 , 8, 2050313X20974217	2
2069	Milestones in Personalized Medicine: From the Ancient Time to Nowadays-the Provocation of COVID-19. 2020 , 11, 569175	6
2068	Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. 2020 , 10, 20834	33
2067	Clinical course of novel COVID-19 infection in pregnant women. 2020 , 1-7	18
2066	Status of Novel Coronavirus Disease 2019 (COVID-19) and Animal Production. 2020 , 7, 586919	7
2065	In silico studies evidenced the role of structurally diverse plant secondary metabolites in reducing SARS-CoV-2 pathogenesis. 2020 , 10, 20584	29
2064	. 2020 , 192, E1242-E1246	
2063	Update Alert 3: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. 2020 , 173, W156-W157	17
2062	Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. 2020 , 172, 754-755	142
2061	Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1). 2020 , 173, 137-142	21
2060	Biomedical Research in Times of Emergency: Lessons From History. 2020 , 173, 297-299	8
2059	Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians. 2020 , 173, W48-W51	8
2058	The Saga of Hydroxychloroquine and COVID-19: A Cautionary Tale. 2020 , 173, 662-663	7
2057	A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19. 2020 , 172, 819-821	132
2056	Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. 2020 , 37, 925-933	12
2055	First Wave of COVID-19 in French Patients with Cystic Fibrosis. 2020 , 9,	14
2054	Comprehensive Literature Review and Evidence evaluation of Experimental Treatment in COVID 19 Contagion.. 2020 , 14, 1179548420964140	3

2053	SARS coronavirus 2: from genome to infectome. 2020 , 21, 318	30
2052	COVID-19 in Elderly Adults: Clinical Features, Molecular Mechanisms, and Proposed Strategies. 2020 , 11, 1481-1495	6
2051	Is Machine Learning a Better Way to Identify COVID-19 Patients Who Might Benefit from Hydroxychloroquine Treatment?-The IDENTIFY Trial. 2020 , 9,	6
2050	Effect of chloroquine and hydroxychloroquine on COVID-19 virological outcomes: An updated meta-analysis. 2020 , 38, 265-272	3
2049	Convalescent plasma - Is it useful for treating SARS Co-V2 infection?. 2020 , 38, 252-260	4
2048	Therapeutic agents tested in 238 COVID-19 hospitalized patients and their relationship with mortality. 2020 , 155, 375-381	1
2047	FDA efficiency for approval process of COVID-19 therapeutics. 2020 , 15, 73	5
2046	Natural bioactive substances for the control of food-borne viruses and contaminants in food. 2020 , 2,	5
2045	Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. 2020 , 7, 606393	17
2044	The "sex gap" in COVID-19 trials: a scoping review. 2020 , 29, 100652	21
2043	Similarity and Specificity of Traditional Chinese Medicine Formulas for Management of Coronavirus Disease 2019 and Rheumatoid Arthritis. 2020 , 5, 30519-30530	3
2042	The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review. 2020 , 88, 55	3
2041	Biology of COVID-19 and related viruses: Epidemiology, signs, symptoms, diagnosis, and treatment. 2021 , 35, 269-292	4
2040	A Systematic Review of the Cardiovascular Manifestations and Outcomes in the Setting of Coronavirus-19 Disease. 2020 , 14, 1179546820977196	23
2039	Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2. 2020 , 3, 2000156	9
2038	Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106224	14.3 5
2037	Drug repurposing for Alzheimer's disease: and investigation of FDA-approved drugs as acetylcholinesterase inhibitors. 2020 , 1-15	3
2036	Combined Interventions for Severe Novel Coronavirus Disease (COVID-19): Experience from 350 Patients. 2020 , 13, 3907-3918	2

2035	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. 2020 , 8,		4
2034	Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March-June 2020. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106219	14.3	28
2033	Update Alert: Hydroxychloroquine or Chloroquine for the Treatment or Prophylaxis of COVID-19. 2020 , 173, W78-W79		15
2032	Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. 2020 , 173, 287-296		129
2031	Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review. 2020 , 6, 1-9		10
2030	Pandémie ^SARS-CoV-2: éthique et intégrité oubliées devant la précipitation pour publier. 2020 , 1, 572-581		1
2029	Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection. 2020 , 155, 448-453		0
2028	Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline. 2020 , 6,		0
2027	Dissecting the Drug Development Strategies Against SARS-CoV-2 Through Diverse Computational Modeling Techniques. 2020 , 329		4
2026	COVID-19: a review. 2020 , 5, e07-e07		
2025	Coronavirus Disease 2019: A Brief Review of the Clinical Manifestations and Pathogenesis to the Novel Management Approaches and Treatments. 2020 , 10, 572329		3
2024	SARS-CoV-2 Infected Patient: from a Hematologist's Perspective. 2020 , 12, e2020078		2
2023	The importance of patients' case-mix for the correct interpretation of the hospital fatality rate in COVID-19 disease. 2020 , 100, 67-74		7
2022	Retracted COVID-19 articles: a side-effect of the hot race to publication. 2020 , 125, 1-4		39
2021	Value of electrocardiography in coronavirus disease 2019 (COVID-19). 2020 , 62, 39-45		31
2020	The COVID-19 pandemic: A community approach. 2020 , 34, e14059		7
2019	COVID-19 and immunological regulations - from basic and translational aspects to clinical implications. 2020 , 18, 795-807		25
2018	World Lung Day 2020 at the and the. 2020 , 319, L534-L537		0

2017	COVID-19: The Immune Responses and Clinical Therapy Candidates. 2020 , 21,	16
2016	30-Year-Old Woman With Cough, Dyspnea, and Anosmia. 2020 , 95, 1775-1779	
2015	Reprogramming of antibiotics to combat antimicrobial resistance. 2020 , 353, e2000168	5
2014	Bacterial co-infections with SARS-CoV-2. 2020 , 72, 2097-2111	82
2013	Updated information on new coronavirus disease 2019 occurrence, drugs, and prediction of a potential receptor. 2020 , 34, e22594	2
2012	Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. 2020 , 30, 1-13	12
2011	Challenges and management of neurological and psychiatric manifestations in SARS-CoV-2 (COVID-19) patients. 2020 , 41, 2353-2366	33
2010	Molecular effects and retinopathy induced by hydroxychloroquine during SARS-CoV-2 therapy: Role of CYP450 isoforms and epigenetic modulations. 2020 , 886, 173454	7
2009	What to expect from different drugs used in the treatment of COVID-19: A study on applications and in vivo and in vitro results. 2020 , 887, 173467	12
2008	Effects of Hydroxychloroquine on Covid-19 in Intensive Care Unit Patients: Preliminary Results. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106136	14.3 11
2007	Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments. 2020 , 88, 106885	20
2006	COVID-19: Pharmacology and kinetics of viral clearance. 2020 , 161, 105114	11
2005	Comorbidities, clinical signs and symptoms, laboratory findings, imaging features, treatment strategies, and outcomes in adult and pediatric patients with COVID-19: A systematic review and meta-analysis. 2020 , 37, 101825	78
2004	The trade-off dilemma in pharmacotherapy of COVID-19: systematic review, meta-analysis, and implications. 2020 , 21, 1821-1849	3
2003	Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. 2020 , 13, 957-975	5
2002	Tracking clinical resources for coronavirus disease 2019. 2020 , 32, 441-448	2
2001	Chloroquine or Hydroxychloroquine for Management of Coronavirus Disease 2019: Friend or Foe?. 2020 , 28, 266-271	8
2000	Covid-19 pandemic and pregnancy. 2020 , 46, 1958-1966	15

1999	Correspondence on 'hydroxychloroquine, COVID-19 and the role of the rheumatologist' by Graef. 2020 ,	4
1998	Rheumatology Drugs and COVID-19. 2020 , 20, 1-3	
1997	Emerging Therapeutic Modalities against COVID-19. 2020 , 13,	11
1996	Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management. 2020 , 21, 760-763	5
1995	Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19. 2020 , 130, 110582	18
1994	Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin. 2020 , 6, e04647	8
1993	Drugs against SARS-CoV-2: What do we know about their mode of action?. 2020 , 30, 1-10	20
1992	Potential strategies for combating COVID-19. 2020 , 165, 2419-2438	3
1991	Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention. 2020 , 45, 715-723	15
1990	Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space. 2020 , 6, e04639	35
1989	The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients. 2020 , 62, 59-64	13
1988	Chloroquine and COVID-19: Should We Care about Ototoxicity?. 2020 , 24, e359-e363	2
1987	Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study. 2021 , 39, 7322-7334	14
1986	Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects. 2020 , 11, 1704	12
1985	OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath. 2020 , 884, 173381	9
1984	Care for Patients with Stroke During the COVID-19 Pandemic: Physical Therapy and Rehabilitation Suggestions for Preventing Secondary Stroke. 2020 , 29, 105182	14
1983	Identification of a potential SARS-CoV2 inhibitor via molecular dynamics simulations and amino acid decomposition analysis. 2021 , 39, 6633-6648	17
1982	Potential Drugs and Remedies for the Treatment of COVID-19: a Critical Review. 2020 , 22, 15	12

1981	Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. 2020 , 15, e0236778	14
1980	A Review on Currently Available Potential Therapeutic Options for COVID-19. 2020 , 13, 443-467	11
1979	An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. 2020 , 144, 111639	28
1978	Rapid Adaptation of a Surgical Research Unit to Conduct Clinical Trials During the COVID-19 Pandemic. 2020 , 256, 76-82	2
1977	Remdesivir for Severe Coronavirus Disease 2019 (COVID-19) Versus a Cohort Receiving Standard of Care. 2021 , 73, e4166-e4174	72
1976	Management of patients with Behçet's disease during the COVID-19 pandemic. 2020 , 33, e14063	10
1975	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. 2020 , 10, 1514-1527	80
1974	Evaluation of Current Therapies for COVID-19 Treatment. 2020 , 8,	9
1973	Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. 2020 , 11, 1841	6
1972	Ventricular Arrhythmia Risk Based on Ethnicity in COVID-19 Patients on Hydroxychloroquine and Azithromycin Combination: Viewpoint. 2020 , 2, 1-6	5
1971	Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2. 2020 , 180, 114169	19
1970	Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.. 2020 , 10, 26895-26916	20
1969	Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. 2020 , 383, 2041-2052	620
1968	Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads. 2021 , 39, 6324-6337	16
1967	THE AUTHOR REPLIES. 2020 , 189, 1444-1449	3
1966	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS-CoV-2 infection. 2020 , 50, e13358	2
1965	Kidney transplant recipients infected by COVID-19: Review of the initial published experience. 2020 , 22, e13426	7
1964	Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia. 2020 , 25, 497-502	2

1963	COVID-19, State of the Adult and Pediatric Heart: From Myocardial Injury to Cardiac Effect of Potential Therapeutic Intervention. 2020 , 7, 140	7
1962	Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine. 2020 , 11, 1409	27
1961	The Potential Effect of Novel Coronavirus SARS-CoV-2 on NK Cells; A Perspective on Potential Therapeutic Interventions. 2020 , 11, 1692	13
1960	Leveraging the United States Epicenter to Provide Insights on COVID-19 in Patients With Systemic Lupus Erythematosus. 2020 , 72, 1971-1980	35
1959	Pipeline Pharmacological Therapies in Clinical Trial for COVID-19 Pandemic: a Recent Update. 2020 , 6, 1-13	10
1958	Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. 2020 , 2, 100159	22
1957	COVID-19: A Multidisciplinary Review. 2020 , 8, 383	61
1956	Potential Anti-COVID-19 Therapeutics that Block the Early Stage of the Viral Life Cycle: Structures, Mechanisms, and Clinical Trials. 2020 , 21,	27
1955	A clinical pilot study on the safety and efficacy of aerosol inhalation treatment of IFN- γ plus TFF2 in patients with moderate COVID-19. 2020 , 25, 100478	12
1954	Potential treatment methods targeting 2019-nCoV infection. 2020 , 205, 112687	20
1953	Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. 2020 , 22, 782-784	27
1952	An overview of key potential therapeutic strategies for combat in the COVID-19 battle. 2020 , 10, 28243-28266	25
1951	Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment. 2020 , 2020, 7527953	87
1950	COVID-19 therapeutics: how to sow confusion and break public trust during international public health emergencies. 2020 , 13, 47	7
1949	COVID-19 and the Kidneys: An Update. 2020 , 7, 423	48
1948	Efficacy and Safety of Anti-malarial Drugs (Chloroquine and Hydroxy-Chloroquine) in Treatment of COVID-19 Infection: A Systematic Review and Meta-Analysis. 2020 , 7, 482	22
1947	COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. 2020 , 72, 1981-1989	66
1946	Organ-specific manifestations of COVID-19 infection. 2020 , 20, 493-506	194

1945	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. 2020 , 59, 1195-1216	18
1944	El médico frente a la COVID-19: lecciones de una pandemia. 2020 , 21, 265-271	2
1943	In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106119	14.3 24
1942	Predictors of adverse prognosis in COVID-19: A systematic review and meta-analysis. 2020 , 50, e13362	144
1941	Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients. 2020 , 14, 3001-3013	15
1940	Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection. 2020 , 28, 745-764	9
1939	Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?. 2020 , 99, 75-76	8
1938	Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology. 2020 , 16, 437-446	4
1937	Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs. 2020 , 13, 945-956	2
1936	Management of Severe COVID-19 in Pregnancy. 2020 , 2020, 8852816	4
1935	Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. 2020 ,	96
1934	Supply Chain Manipulation, Misrepresentation, and Magical Thinking During the COVID-19 Pandemic. 2020 , 50, 628-634	12
1933	Desperate times call for evidence-based measures: Prioritizing science during the COVID-19 pandemic. 2020 , 5, 127-129	
1932	[Pharmacological treatment in uncertainty times: Hydroxychloroquine/chloroquine use in the COVID-19 treatment]. 2020 , 46 Suppl 1, 20-27	0
1931	The Effects of Chloroquine and Hydroxychloroquine on ACE2-Related Coronavirus Pathology and the Cardiovascular System: An Evidence-Based Review. 2020 , 1,	10
1930	Review: An insight into coronaviruses: Challenges, security and scope. 2020 , 30, 1-8	3
1929	Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106129	14.3 7
1928	Investigating the potential antiviral activity drugs against SARS-CoV-2 by molecular docking simulation. 2020 , 318, 113968	9

1927	Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. 2021 , 39, 6828-6841	24
1926	Searching for COVID-19 treatments: First, do no harm. 2020 , 77, 1899-1905	2
1925	Changing the Paradigm of Surgical Research During a Pandemic. 2020 , 272, e170-e171	6
1924	Review on the coronavirus disease (COVID-19) pandemic: Its outbreak and current status. 2020 , 74, e13637	24
1923	The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19. 2020 , 11, 1991	56
1922	Secondary Bacterial Infections in Patients With Viral Pneumonia. 2020 , 7, 420	41
1921	Is Antioxidant Therapy a Useful Complementary Measure for Covid-19 Treatment? An Algorithm for Its Application. 2020 , 56,	24
1920	COVID-19: Rational discovery of the therapeutic potential of Melatonin as a SARS-CoV-2 main Protease Inhibitor. 2020 , 17, 2133-2146	28
1919	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. 2020 , 72, e1-e12	49
1918	Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19. 2020 , 43, 765-772	36
1917	At High Altitude COVID-19 Is Less Frequent: The Experience of Peru. 2020 , 56, 760-761	13
1916	Risks to the community pharmacists and pharmacy personnel during COVID-19 pandemic: perspectives from a low-income country. 2020 , 13, 42	9
1915	Clinical Research in Hepatology in the COVID-19 Pandemic and Post-Pandemic Era: Challenges and the Need for Innovation. 2020 , 72, 1819-1837	12
1914	COVID-19: An overview of the current pharmacological interventions, vaccines, and clinical trials. 2020 , 180, 114184	32
1913	Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. 2020 , 258, 118202	22
1912	Chloroquine in fighting COVID-19: good, bad, or both?. 2020 , 16, 2273-2275	9
1911	Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review. 2020 , 15, 350-358	17
1910	[Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome]. 2020 , 93, 132-133	5

1909	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. 2020 , 26, 2181-2189	27
1908	Impact of Small-N Studies During a Pandemic. 2020 , 158, 1338-1340	1
1907	Interaction of Drug Candidates with Various SARS-CoV-2 Receptors: An in Silico Study to Combat COVID-19. 2020 , 19, 4567-4575	23
1906	Clinical characteristics and risk factors for severe COVID-19 in hospitalized kidney transplant recipients: A multicentric cohort study. 2020 , 20, 3030-3041	45
1905	Pandemic publishing: Medical journals strongly speed up their publication process for COVID-19. 2020 , 1, 1056-1067	54
1904	"Tomorrow Never Dies": Recent Advances in Diagnosis, Treatment, and Prevention Modalities against Coronavirus (COVID-19) amid Controversies. 2020 , 8,	12
1903	High affinity interaction of Solanum tuberosum and Brassica juncea residue smoke water compounds with proteins involved in coronavirus infection. 2020 , 34, 3400-3410	4
1902	Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study. 2020 , 15, e0237693	84
1901	Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. 2020 , 26, 1436-1446	53
1900	Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. 2020 , 25, 1822-1838	5
1899	Protein reliability analysis and virtual screening of natural inhibitors for SARS-CoV-2 main protease (M) through docking, molecular mechanic & dynamic, and ADMET profiling. 2021 , 39, 6810-6827	11
1898	The pharmacological development of direct acting agents for emerging needed therapy against severe acute respiratory syndrome coronavirus-2. 2020 , 83, 712-718	1
1897	Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity. 2020 , 13, 439-452	26
1896	A scientificity and feasibility evaluation of COVID-19 clinical studies registered in China. 2020 , 8, 817	2
1895	A Focus on the Nowadays Potential Antiviral Strategies in Early Phase of Coronavirus Disease 2019 (Covid-19): A Narrative Review. 2020 , 10,	4
1894	Cardiovascular manifestation and treatment in COVID-19. 2020 , 83, 704-709	16
1893	Cardiac arrhythmias in patients with COVID-19. 2020 , 36, 827-836	44
1892	Antimalarials as Antivirals for COVID-19: Believe it or Not!. 2020 , 360, 618-630	14

1891	Ongoing non-industry-sponsored COVID-19 clinical trials in the first trimester of the pandemic: significant differences between the European and the USA approaches. 2020 , 13, 1067-1072	0
1890	The 11th Trial of a Cardiovascular Clinical Trialist: Coronavirus-2: Part 2. 2020 , 28, 217-218	
1889	Understanding COVID-19: From Origin to Potential Therapeutics. 2020 , 17,	8
1888	Protease Inhibitor Use in COVID-19. 2020 , 2, 1-8	2
1887	Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate. 2020 , 99, 437-440	46
1886	Drug Interactions and Side Effects of Co-Administration of Chloroquine/Hydroxychloroquine and Azithromycin: on the Issue of Rational Pharmacotherapy of Patients with COVID-19 with Antimalarial Drugs. 2020 , 16, 481-486	1
1885	Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. 2020 , 13, 531-542	5
1884	A Modern Library of Babel. 2020 , 26, 643-644	
1883	Evaluation of mechanisms of action of re-purposed drugs for treatment of COVID-19. 2020 , 358, 104240	4
1882	Clinical course of COVID-19 among immunocompromised children: a clinical case series. 2020 , 13,	12
1881	Cytokine Response in SARS-CoV-2 Infection in the Elderly. 2020 , 13, 737-747	11
1880	Current Options in the Treatment of COVID-19: A Review. 2020 , 13, 1999-2010	5
1879	SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. 2020 , 11, 570927	21
1878	System biological investigations of hydroxychloroquine and azithromycin targets and their implications in QT interval prolongation. 2020 , 332, 109299	1
1877	COVID-19 outpatients: early risk-stratified treatment with zinc plus low-dose hydroxychloroquine and azithromycin: a retrospective case series study. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106214	14.3 53
1876	Chinese guidelines related to novel coronavirus pneumonia. 2020 , 8, 1818446	17
1875	US Food and Drug Administration (FDA) Emergency Use Authorization: Glass Half Full or Glass Half Empty?. 2021 , 73, 549-552	1
1874	What is the novel coronavirus disease 2019 (COVID-19) that paralyze the world?. 2020 , 31, 234-241	0

1873	Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. 2020 , 371, m3869	8
1872	Is clinical effectiveness in the eye of the beholder during the COVID-19 pandemic?. 2021 , 26, 307-308	
1871	Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxis. 2020 , 21, 815	1
1870	Current Understanding of COVID-19 Clinical Course and Investigational Treatments. 2020 , 7, 555301	13
1869	The impact of COVID-19 pandemic on malaria elimination. 2020 , 11, e00187	13
1868	Meta-analysis on outcome-worsening comorbidities of COVID-19 and related potential drug-drug interactions. 2020 , 161, 105250	21
1867	Changes in antimicrobial utilization during the coronavirus disease 2019 (COVID-19) pandemic after implementation of a multispecialty clinical guidance team. 2021 , 42, 810-816	11
1866	Hypoxia, HIF-1 β and COVID-19: from pathogenic factors to potential therapeutic targets. 2020 , 41, 1539-1546	65
1865	A critical analysis and review of Lancet COVID-19 hydroxychloroquine study. 2020 , 8, 1809236	0
1864	COVID-19: An overview for dermatologists. 2020 , 59, 1437-1449	12
1863	Traditional Herbal Medicine Candidates as Complementary Treatments for COVID-19: A Review of Their Mechanisms, Pros and Cons. 2020 , 2020, 2560645	61
1862	COVID-19 Pneumonia in Patients with Chronic Myocarditis (Recurrent Infectious Immune): Specifics of the Diseases Course, the Role of Basic Therapy (Part 1). 2020 , 16, 550-556	0
1861	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. 2020 , 11, 562264	5
1860	Molecular Basis of SARS-CoV-2 Infection and Rational Design of Potential Antiviral Agents: Modeling and Simulation Approaches. 2020 , 19, 4291-4315	36
1859	COVID-19 Pneumonia in Patients on Chronic Hydroxychloroquine Therapy: Three Cases of COVID-19 Pneumonia. 2020 , 2020, 8822753	3
1858	COVID-19 multidisciplinary high dependency unit: the Milan model. 2020 , 21, 260	14
1857	Identification of SARS-CoV-2 entry inhibitors among already approved drugs. 2021 , 42, 1347-1353	27
1856	Neonatal Infection Due to SARS-CoV-2: An Epidemiological Study in Spain. 2020 , 8, 580584	12

1855	Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19. 2020 , 11, 554172	4
1854	Early epidemiological indicators, outcomes, and interventions of COVID-19 pandemic: A systematic review. 2020 , 10, 020506	20
1853	Risk of hospitalization for Covid-19 outpatients treated with various drug regimens in Brazil: Comparative analysis. 2020 , 38, 101906	15
1852	[Development of an information website on the proper use of medicines during the pandemic]. 2020 , 59, 34-39	
1851	Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. 2020 , 5, 17	26
1850	Hydroxychloroquine for coronavirus: how not to repurpose a drug during a pandemic. 2020 , 50, 1307-1310	2
1849	Novel Coronavirus (SARS-CoV-2): Current and future aspects of pharmacological treatments. 2020 , 28, 1243-1252	3
1848	Inpatient cardiac monitoring using a patch-based mobile cardiac telemetry system during the COVID-19 pandemic. 2020 , 31, 2803-2811	6
1847	How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. 2020 , 10, e044566	4
1846	Ocular Findings in COVID-19 Patients: A Review of Direct Manifestations and Indirect Effects on the Eye. 2020 , 2020, 4827304	47
1845	Compassionate drug (mis)use during pandemics: lessons for COVID-19 from 2009. 2020 , 18, 265	7
1844	Biochemical and Computational Approach of Selected Phytocompounds from in the Management of COVID-19. 2020 , 25,	37
1843	Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. 2020 , 35, 1353-1361	52
1842	Repurposing Interleukin-6 Inhibitors to Combat COVID-19. 2020 , 3, 52-55	3
1841	Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients. 2020 , 20, 220	3
1840	Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-19. 2020 , 9,	19
1839	COVID-19: an update on diagnostic and therapeutic approaches. 2020 , 53, 191-205	48
1838	Comparing outcomes of hospitalized patients with moderate and severe COVID-19 following treatment with hydroxychloroquine plus atazanavir/ritonavir. 2020 , 28, 625-634	12

1837	Publication Rate and Journal Review Time of COVID-19-Related Research. 2020 , 95, 2290-2291	9
1836	Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin. 2020 , 40, 469-471	17
1835	COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology. 2020 , 17, e1003252	55
1834	Observational study of azithromycin in hospitalized patients with COVID-19. 2020 , 15, e0238681	14
1833	A Review on Current Repurposing Drugs for the Treatment of COVID-19: Reality and Challenges. 2020 , 2, 1-13	26
1832	Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis. 2020 , 35, 3308-3314	59
1831	Recommendations for prenatal, intrapartum, and postpartum care during COVID-19 pandemic in India. 2020 , 84, e13336	3
1830	COVID-19: In the Eye of the Cytokine Storm. 2020 , 11, 558898	57
1829	Natural Flavonoids as Potential Angiotensin-Converting Enzyme 2 Inhibitors for Anti-SARS-CoV-2. 2020 , 25,	46
1828	Zinc(II)-The Overlooked Minence Grise of Chloroquine's Fight against COVID-19?. 2020 , 13,	13
1827	Drug repurposing approach to fight COVID-19. 2020 , 72, 1479-1508	165
1826	Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. 2020 , 396, 959-967	183
1825	Drug Repositioning: New Approaches and Future Prospects for Life-Debilitating Diseases and the COVID-19 Pandemic Outbreak. 2020 , 12,	28
1824	Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain. 2020 , 17,	2
1823	Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study. 2020 , 2, e689-e697	29
1822	Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.. 2020 , 1, 965-975	58
1821	Treatment of children with COVID-19: position paper of the Italian Society of Pediatric Infectious Disease. 2020 , 46, 139	35
1820	[COVID-19, management, therapeutic and vaccine approaches]. 2020 , 59, 27-33	1

1819	Forecasting of COVID-19 pandemic: From integer derivatives to fractional derivatives. 2020 , 141, 110283	50
1818	Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. 2020 , 886, 173546	33
1817	Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2. 2020 , 101, 107716	40
1816	Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives. 2020 , 41, 1377-1386	11
1815	Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. 2020 , 22, 1855-1863	19
1814	Review of Clinical Trials in COVID-19: Trying to Solve the Clinicians's Conundrum. 2020 , 56, 119-125	
1813	COVID-19 and Pregnancy: A Review. 2020 , 56, 183-188	1
1812	Brief Report: Retrospective Evaluation on the Efficacy of Lopinavir/Ritonavir and Chloroquine to Treat Nonsevere COVID-19 Patients. 2020 , 85, 239-243	14
1811	How Partisanship Affected Public Reaction to Potential Treatments for COVID-19. 2020 , 12, 482	1
1810	Treatment Options Available for COVID-19 and an Analysis on Possible Role of Combination of rhACE2, Angiotensin (1-7) and Angiotensin (1-9) as Effective Therapeutic Measure. 2020 , 2, 1-6	10
1809	COVID-19 in Children: Present and Future Perspective, An Interim Review. 2020 , 10, e53-e62	3
1808	A Systematic Review of COVID-19 Infection in Kidney Transplant Recipients: A Universal Effort to Preserve Patients' Lives and Allografts. 2020 , 9,	21
1807	Potential sources, modes of transmission and effectiveness of prevention measures against SARS-CoV-2. 2020 , 106, 678-697	50
1806	Investigation on the impacts of COVID-19 quarantine on society and environment: Preventive measures and supportive technologies. 2020 , 10, 393	18
1805	Treatment Armamentarium of COVID-19: Evolving Strategies and Evidence So Far. 2020 , 10, 599-609	3
1804	Implications of antibiotics use during the COVID-19 pandemic: present and future. 2020 , 75, 3413-3416	32
1803	A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial. 2020 , 21, 718	15
1802	Renin-Angiotensin System and Coronavirus Disease 2019: A Narrative Review. 2020 , 7, 143	23

1801	The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19. 2020 , 8, 937	10
1800	SARS-CoV-2 and rhinovirus/enterovirus co-infection in a critically ill young adult patient in Colombia. 2020 , 40, 34-43	3
1799	Flexibilization of Science, Cognitive Biases, and the COVID-19 Pandemic. 2020 , 95, 1842-1844	4
1798	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). 2020 , 63, 13205-13227	18
1797	Hydroxychloroquine and azithromycin tolerance in haemodialysis patients during COVID-19 infection. 2020 , 35, 1346-1353	12
1796	COVID-19 und Immunregulation – von grundlegenden und translationalen Aspekten zu klinischen Implikationen. 2020 , 18, 795-809	6
1795	Case Report: Benign Infantile Seizures Temporally Associated With COVID-19. 2020 , 8, 507	14
1794	Balancing Scientific Rigor With Urgency in the Coronavirus Disease 2019 Pandemic. 2020 , 7, ofaa304	5
1793	A Review of the Dermatological Manifestations of Coronavirus Disease 2019 (COVID-19). 2020 , 2020, 9360476	22
1792	The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19. 2020 , 18, 322	56
1791	Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?. 2020 , 11, 1818	50
1790	Can We Test Our Way Out of the COVID-19 Pandemic?. 2020 , 58,	22
1789	Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?. 2020 , 11, 1969	5
1788	Knowledge, Attitude, and Practice of the Lebanese Community Toward COVID-19. 2020 , 7, 542	9
1787	Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection. 2020 , 9,	6
1786	Emergency Use Authorizations During the COVID-19 Pandemic: Lessons From Hydroxychloroquine for Vaccine Authorization and Approval. 2020 , 324, 1282-1283	32
1785	Handling the COVID-19 crisis: Toward an agile model-based systems approach. 2020 , 23, 656	5
1784	Hydroxychloroquine in COVID-19: Potential Mechanism of Action Against SARS-CoV-2. 2020 , 6, 1-9	37

1783	An Ounce of Prevention and a Pound of Cure: Randomized Clinical Trials of Therapeutics Against COVID-19 and an Assessment of Personal Protective Equipment and Distancing. 2020 , 108, 333-336	1
1782	Pharmacogenomics of COVID-19 therapies. 2020 , 5, 35	36
1781	Healthcare professionals' knowledge, perception and practice towards COVID-19: A cross-sectional web-survey. 2020 , 11, 355-363	0
1780	Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?. 2020 , 18, 17	13
1779	Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. 2020 , 12, 80	45
1778	A Simple Bayesian Method for Evaluating Whether Data From Patients With Rheumatic Diseases Who Have Been Under Chronic Hydroxychloroquine Medication Since Before the COVID-19 Outbreak Can Speak to Hydroxychloroquine's Prophylactic Effect Against Infection With SARS-CoV-2. 2020 , 7, 188	
1777	Managing rheumatoid arthritis during COVID-19. 2020 , 39, 3237-3244	21
1776	Artificial intelligence, drug repurposing and peer review. 2020 , 38, 1127-1131	35
1775	Effect of Combination Therapy of Hydroxychloroquine and Azithromycin on Mortality in Patients With COVID-19. 2020 , 13, 1071-1076	22
1774	COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications. 2020 , 77, 459-504	39
1773	Coronavirus Disease 2019 (COVID-19) Spread and Pharmacovigilance Implications: Expert Opinion. 2020 , 54, 1359-1362	1
1772	Available Compounds With Therapeutic Potential Against COVID-19: Antimicrobial Therapies, Supportive Care, and Probable Vaccines. 2020 , 11, 582025	11
1771	What are the drugs having potential against COVID-19?. 2020 , 1-21	4
1770	SARS-CoV-2/COVID-19: Evolving Reality, Global Response, Knowledge Gaps, and Opportunities. 2020 , 54, 416-437	22
1769	The New Coronavirus COVID-19 Infection. 2020 , 35, 53-60	3
1768	Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda. 2020 , 7,	16
1767	Cold agglutinin disease following SARS-CoV-2 and co-infections. 2020 , 8, 2402	7
1766	Clinical improvement in a patient with severe coronavirus disease 2019 after administration of hydroxychloroquine and continuous hemodiafiltration with nafamostat mesylate. 2020 , 26, 1319-1323	5

1765	Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19. 2020 , 42, 25	8
1764	The Dual Role of Echocardiography in the Diagnosis of Acute Cardiac Complications and Treatment Monitoring for Coronavirus Disease 2019 (COVID-19). 2020 , 7, 129	9
1763	Knowledge, Attitude, and Practices of Healthcare Professionals on COVID-19 and Risk Assessment to Prevent the Epidemic Spread: A Multicenter Cross-Sectional Study from Punjab, Pakistan. 2020 , 17,	18
1762	Treatment of COVID-19 Patients Post-Bariatric Surgery: Issues for Consideration. 2020 , 9,	2
1761	Managing rheumatic diseases during COVID-19. 2020 , 39, 3245-3254	10
1760	Qingfei Paidu decoction for treating COVID-19: A protocol for a meta-analysis and systematic review of randomized controlled trials. 2020 , 99, e22040	4
1759	COVID-19 related deaths in an urban academic medical center in Brooklyn - a descriptive case series. 2020 , 5, 12	2
1758	Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety. 2020 , 12, 115-121	1
1757	[COVID-19 infection-update]. 2020 , 25, 1-8	
1756	Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa. 2020 , 18, 690-704	23
1755	Methodological Issues and Controversies in COVID-19 Coagulopathy: A Tale of Two Storms. 2020 , 26, 1076029620945398	3
1754	Genetic and pathogenic characterization of SARS-CoV-2: a review. 2020 , 15, 533-549	7
1753	The New Coronavirus (SARS-CoV-2): A Comprehensive Review on Immunity and the Application of Bioinformatics and Molecular Modeling to the Discovery of Potential Anti-SARS-CoV-2 Agents. 2020 , 25,	4
1752	It Takes a Village—Contending With Drug Shortages During Disasters. 2020 , 158, 2414-2424	11
1751	Methods of Synthesis of Remdesivir, Favipiravir, Hydroxychloroquine, and Chloroquine: Four Small Molecules Repurposed for Clinical Trials during the Covid-19 Pandemic. 2020 , 52, 3735-3750	9
1750	Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation. 2020 , 13, e008686	6
1749	COVID-19: an update and cardiac involvement. 2020 , 15, 239	7
1748	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. 2020 , 11, 1205	68

1747	COVID-19 Pandemic: A Case for Phytomedicines. 2020 , 15, 1934578X20945086	14
1746	Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection. 2020 , 57, 4856-4877	20
1745	The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19). 2020 , 35, 1-12	9
1744	Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review. 2020 , 37, 4107-4131	2
1743	COVID-19 Pandemic: from Molecular Biology, Pathogenesis, Detection, and Treatment to Global Societal Impact. 2020 , 6, 1-16	21
1742	COVID-19 Therapeutic Options Under Investigation. 2020 , 11, 1196	49
1741	Repurposing Drugs, Ongoing Vaccine, and New Therapeutic Development Initiatives Against COVID-19. 2020 , 11, 1258	61
1740	Natural products as home-based prophylactic and symptom management agents in the setting of COVID-19. 2020 , 34, 3148-3167	31
1739	Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy. 2020 , 9,	10
1738	Is there any potential management against COVID-19? A systematic review and meta-analysis. 2020 , 28, 765-777	9
1737	Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?. 2020 , 137, 235-239	5
1736	Animal and translational models of SARS-CoV-2 infection and COVID-19. 2020 , 13, 877-891	106
1735	An perception for newly isolated flavonoids from peach fruit as privileged avenue for a countermeasure outbreak of COVID-19.. 2020 , 10, 29983-29998	16
1734	Efficacy of various treatment modalities for nCoV-2019: A systematic review and meta-analysis. 2020 , 50, e13383	12
1733	Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?. 2020 , 7,	10
1732	Treatment Options for COVID-19: A Review. 2020 , 7, 480	46
1731	Pharmacological treatments of COVID-19. 2020 , 72, 1446-1478	16
1730	Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. 2020 , 2, e698-e711	71

1729	Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review. 2020 , 7, 2049936120947517	9
1728	Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. 2020 , 8,	61
1727	Novel Antiviral Strategies in the Treatment of COVID-19: A Review. 2020 , 8,	10
1726	A Narrative Review of Emerging Therapeutics for COVID-19. 2020 , 4, 745-758	5
1725	Nano-Biomimetic Drug Delivery Vehicles: Potential Approaches for COVID-19 Treatment. 2020 , 25,	15
1724	Modulation of Autophagy by SARS-CoV-2: A Potential Threat for Cardiovascular System. 2020 , 11, 611275	12
1723	Taming the Autophagy as a Strategy for Treating COVID-19. 2020 , 9,	29
1722	A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment. 2020 , 10, 22139	41
1721	Lethal Arrhythmia () in COVID-19: An Event Synergistically Induced by Viral Associated Cardiac Injury, Hyperinflammatory Response, and Treatment Drug?. 2020 , 13, 1179547620972397	3
1720	Favipiravir-based regimen for coronavirus disease 2019 pneumonia for a 47-day-old male newborn. 2020 , 8, 2050313X20964046	1
1719	Late-onset myocardial infarction and autoimmune haemolytic anaemia in a COVID-19 patient without respiratory symptoms, concomitant with a paradoxical increase in inflammatory markers: a case report. 2020 , 14, 246	6
1718	A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. 2020 , 11, 584956	30
1717	Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives. 2020 , 11, 606097	4
1716	Pharmacotherapy of Acute COVID-19 Infection and Multisystem Inflammatory Syndrome in Children: Current State of Knowledge. 2020 , 33, 177-189	0
1715	Identifying side effects of commonly used drugs in the treatment of Covid 19. 2020 , 10, 21508	9
1714	Trials of treatments for COVID-19: Review of drugs are tested. 2020 , 1664, 012086	1
1713	Obstacles and Considerations Related to Clinical Trial Research During the COVID-19 Pandemic. 2020 , 7, 598038	4
1712	Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL. 2020 , 7, 613401	18

1711	The contribution of the observational research design to COVID-19 research. 2020 , 2, e650-e652	1
1710	Causal inference methods for small non-randomized studies: Methods and an application in COVID-19. 2020 , 99, 106213	4
1709	Understanding clinical decision-making during the COVID-19 pandemic: A cross-sectional worldwide survey. 2020 , 27, 100539	6
1708	Liver transplant immunosuppression during the COVID-19 pandemic. 2020 , 43, 457-463	1
1707	A simple approach to estimate the instantaneous case fatality ratio: Using the publicly available COVID-19 surveillance data in Canada as an example. 2020 , 5, 575-579	3
1706	It is time to drop hydroxychloroquine from our COVID-19 armamentarium. 2020 , 144, 110198	5
1705	Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology. 2020 , 27, 230-241	1
1704	[Geriatric patient with covid-19 infection and common complications]. 2020 , 55, 365-366	1
1703	Rise and Fall: Hydroxychloroquine and COVID-19 Global Trends: Interest, Political Influence, and Potential Implications. 2020 , 2, 760-766	7
1702	Absence of relevant QT interval prolongation in not critically ill COVID-19 patients. 2020 , 10, 21417	6
1701	Recent progress in the repurposing of drugs/molecules for the management of COVID-19. 2021 , 19, 889-897	9
1700	Defining the Syrian hamster as a highly susceptible preclinical model for SARS-CoV-2 infection. 2020 , 9, 2673-2684	91
1699	COVID-19;-The origin, genetics,and management of the infection of mothers and babies. 2020 , 7, 371-388	
1698	Current Trends in Analytical Methods for the Determination of Hydroxychloroquine and Its Application as Treatment for COVID-19. 2020 , 5, 14602-14612	4
1697	Molecular docking, molecular dynamics, and studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease. 2020 , 6, e05641	48
1696	An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. 2021 , 19, 877-888	59
1695	Is it prime time to consider a clinical trial of doxycycline for the management of COVID-19?. 2020 ,	2
1694	Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2. 2020 , 11, 586572	30

1693	Fighting Strategies Against the Novel Coronavirus Pandemic: Impact on Global Economy. 2020 , 8, 606129	10
1692	Lectin Protein as a Promising Component to Functionalize Micelles, Liposomes and Lipid NPs against Coronavirus. 2020 , 8,	11
1691	Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules. 2020 , 13,	12
1690	Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20 years of drug safety surveillance reports. 2020 , 10, 19199	7
1689	A Note From the Editors. 2020 , 189, 1215-1217	1
1688	Coronavirus pandemic: treatment and future prevention. 2020 , 15, 1507-1521	1
1687	Trials and tribulations of coronavirus disease-2019 research: with a few bright lights in the fog. 2020 , 21, 841-844	3
1686	NLRP3 Inflammasome: The Stormy Link Between Obesity and COVID-19. 2020 , 11, 570251	32
1685	COVID-19 Pandemic: Epidemiology, Etiology, Conventional and Non-Conventional Therapies. 2020 , 17,	23
1684	Liquid and Solid Self-Emulsifying Drug Delivery Systems (SEDDs) as Carriers for the Oral Delivery of Azithromycin: Optimization, In Vitro Characterization and Stability Assessment. 2020 , 12,	13
1683	At High Altitude COVID-19 Is Less Frequent: The Experience of Peru. 2020 , 56, 760-761	2
1682	Integrative Transcriptome Analyses Empower the Anti-COVID-19 Drug Arsenal. 2020 , 23, 101697	11
1681	Antimicrobial Management of Respiratory Infections in Severe Acute Respiratory Syndrome Coronavirus 2 Patients: Clinical and Antimicrobial Stewardship Programs Conundrums. 2020 , 7, ofaa517	2
1680	7-Hydroxy-4-phenyl-1, 2-dihydroquinoline derivatives: synthesis via one-pot, three-component reaction and structure elucidation. 2020 , 6, e05035	0
1679	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial. 2020 , 324, 2165-2176	206
1678	Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach. 2020 , 10, 19125	28
1677	A Perspective on Nigeria's Preparedness, Response and Challenges to Mitigating the Spread of COVID-19. 2020 , 11, 22	6
1676	Coronavirus (SARS-CoV-2) Pandemic: Future Challenges for Dental Practitioners. 2020 , 8,	26

1675	In-line treatments and clinical initiatives to fight against COVID-19 outbreak. 2020 , 106192	6
1674	Coronavirus in human diseases: Mechanisms and advances in clinical treatment. 2020 , 1, 270	11
1673	Immunotherapeutics for Covid-19 and post vaccination surveillance. 2020 , 10, 527	11
1672	SARS-CoV-2: A critical review of its history, pathogenesis, transmission, diagnosis and treatment. 2020 , 2, 217-225	12
1671	Effects of COVID-19 on healthcare practice, medical education, and pre-medical educational experiences. 2020 , 12, 186-192	0
1670	Stress and Fear: Clinical Implications for Providers and Patients (in the Time of COVID-19 and Beyond). 2020 , 95, 2487-2498	11
1669	COVID-19: the epidemiology and treatment. 2020 , 81, 1-9	3
1668	Comprehensive review on the prevailing COVID-19 therapeutics and the potential of repurposing SARS-CoV-1 candidate drugs to target SARS-CoV-2 as a fast-track treatment and prevention option. 2020 , 8, 1247	2
1667	Predicting Clinical Outcome with Phenotypic Clusters in COVID-19 Pneumonia: An Analysis of 12,066 Hospitalized Patients from the Spanish Registry SEMI-COVID-19. 2020 , 9,	29
1666	In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2. 2020 , 25,	42
1665	Ivermectin and COVID-19: Keeping Rigor in Times of Urgency. 2020 , 102, 1156-1157	86
1664	Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing. 2020 , 71, 2459-2468	589
1663	A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19. 2020 , 27, 493-504	78
1662	Asthma and COVID-19: Is asthma a risk factor for severe outcomes?. 2020 , 75, 1543-1545	58
1661	Cardiovascular manifestations and treatment considerations in COVID-19. 2020 , 106, 1132-1141	194
1660	The Immunocompromised Transplant Recipient and SARS-CoV-2 Infection. 2020 , 31, 1147-1149	25
1659	The Zebrafish Disease and Drug Screening Model: A Strong Ally Against Covid-19. 2020 , 11, 680	11
1658	A current review of COVID-19 for the cardiovascular specialist. 2020 , 226, 29-44	66

1657	Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. 2020 , 19, 102567	375
1656	Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. 2020 , 19, 102569	121
1655	Seven recommendations to rescue the patients and reduce the mortality from COVID-19 infection: An immunological point of view. 2020 , 19, 102570	22
1654	Combating devastating COVID-19 by drug repurposing. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 105984	14.3 42
1653	Amantadine as a drug to mitigate the effects of COVID-19. 2020 , 140, 109755	38
1652	Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2. 2020 , 145, 104236	110
1651	Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis. 2020 , 157, 104872	58
1650	Nitazoxanide/azithromycin combination for COVID-19: A suggested new protocol for early management. 2020 , 157, 104874	59
1649	Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19. 2020 , 9, 85-87	23
1648	The Novel Coronavirus - Latest Findings. 2020 , 13, 819-828	4
1647	Drug reaction with eosinophilia and systemic symptoms syndrome to hydroxychloroquine, an old drug in the spotlight in the COVID-19 era. 2020 , 33, e13499	13
1646	COVID-19 pneumonia in kidney transplant recipients-Where we are?. 2020 , 22, e13306	19
1645	Medical treatment options for COVID-19. 2020 , 9, 209-214	27
1644	The Covid-19, Epidemiology, Clinic and Prevention. 2020 , 21, 157	5
1643	Considerations for pharmacoepidemiological analyses in the SARS-CoV-2 pandemic. 2020 , 29, 825-831	18
1642	An environmental and health perspective for COVID-19 outbreak: Meteorology and air quality influence, sewage epidemiology indicator, hospitals disinfection, drug therapies and recommendations. 2020 , 8, 104006	111
1641	Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. 2020 , 35, 101738	300
1640	News Feature: To counter the pandemic, clinicians bank on repurposed drugs. 2020 , 117, 10616-10620	5

1639	Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report. 2020 , 113, 569-572	7
1638	The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications. 2020 , 34, 7253-7264	51
1637	Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). 2020 , 251, 228-248	473
1636	Early experience with remdesivir in SARS-CoV-2 pneumonia. 2020 , 48, 779-782	15
1635	COVID-19 Management and Arrhythmia: Risks and Challenges for Clinicians Treating Patients Affected by SARS-CoV-2. 2020 , 7, 85	13
1634	The Rationale for Potential Pharmacotherapy of COVID-19. 2020 , 13,	27
1633	Three months of COVID-19: A systematic review and meta-analysis. 2020 , 30, e2113	25
1632	Old and re-purposed drugs for the treatment of COVID-19. 2020 , 18, 843-847	36
1631	Commentary on "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial" by Gautret et al. 2020 , 8, 1758390	8
1630	Accelerating Drug Development through Repurposed FDA-Approved Drugs for COVID-19: Speed Is Important, Not Haste. 2020 , 64,	2
1629	The management of patients with metastatic prostate cancer during the COVID-19 pandemic. 2020 , 16, 1455-1461	4
1628	COVID-19 as an Acute Inflammatory Disease. 2020 , 205, 12-19	74
1627	The liver in times of COVID-19: What hepatologists should know. 2020 , 19, 353-358	46
1626	Psychopharmacology of COVID-19. 2020 , 61, 411-427	33
1625	Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. 2020 , 79, 837-839	161
1624	The Evolution of Computational Chemistry Along with Coronaviruses. 2020 , 20, 1339-1341	
1623	Therapeutic Options for Coronavirus Disease 2019 (COVID-19) - Modulation of Type I Interferon Response as a Promising Strategy?. 2020 , 8, 185	7
1622	COVID-19: An Update About the Discovery Clinical Trial. 2020 , 13,	8

1621	Recent Insight into SARS-CoV2 Immunopathology and Rationale for Potential Treatment and Preventive Strategies in COVID-19. 2020 , 8,	31
1620	A comprehensive review on drug repositioning against coronavirus disease 2019 (COVID19). 2020 , 393, 1137-1152	26
1619	COVID-19 and Chloroquine/Hydroxychloroquine: Is There Ophthalmological Concern?. 2020 , 216, A1-A2	13
1618	Covid-19 Pandemic and Current Medical Interventions. 2020 , 51, 473-481	9
1617	Improvisation in times of pandemic, a reason for reflection. 2020 , 96, 361-362	2
1616	Plant Solutions for the COVID-19 Pandemic and Beyond: Historical Reflections and Future Perspectives. 2020 , 13, 803-807	13
1615	Hydroxychloroquine hitting the headlines-retinal considerations. 2020 , 34, 1158-1160	5
1614	Cardiac Arrhythmias in COVID-19 Infection. 2020 , 13, e008719	73
1613	COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation. 2020 , 12,	225
1612	Prevention and treatment of COVID-19 disease by controlled modulation of innate immunity. 2020 , 50, 932-938	44
1611	Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. 2020 , 382, 2411-2418	1063
1610	Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. 2020 , 9, 215-221	79
1609	Role of adjunctive treatment strategies in COVID-19 and a review of international and national clinical guidelines. 2020 , 7, 22	33
1608	Clinical trials on drug repositioning for COVID-19 treatment. 2020 , 44, e40	226
1607	In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs. 2020 , 92, 2105-2113	194
1606	Chloroquine for COVID-19: rationale, facts, hopes. 2020 , 24, 210	15
1605	COVID-19: Present and Future Challenges for Dental Practice. 2020 , 17,	56
1604	COVID-19 and Cancer: a Comprehensive Review. 2020 , 22, 53	147

1603	Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. 2020 , 323, 2493-2502	749
1602	COVID-19 in patients with myasthenia gravis. 2020 , 62, 254-258	66
1601	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. 2020 , 67, 1201-1211	15
1600	A Precision Medicine Approach to SARS-CoV-2 Pandemic Management. 2020 , 7, 1-19	18
1599	Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. 2020 , 395, 1695-1704	948
1598	Convalescent plasma in Covid-19: Possible mechanisms of action. 2020 , 19, 102554	295
1597	COVID-19 and diabetes mellitus: An unholy interaction of two pandemics. 2020 , 14, 513-517	115
1596	The current understanding and potential therapeutic options to combat COVID-19. 2020 , 254, 117765	55
1595	Current development of COVID-19 diagnostics, vaccines and therapeutics. 2020 , 22, 231-235	34
1594	The CoV-2 outbreak: how hematologists could help to fight Covid-19. 2020 , 157, 104866	25
1593	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. 2020 , 35, 101735	71
1592	Severe Acute Respiratory Syndrome Coronavirus 2: Genomic Observations and Emerging Therapies. 2020 , 33, 49-52	0
1591	Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics. 2020 , 71, 2962-2964	8
1590	Novel coronavirus 2019 (COVID-19): A case report and review of treatments. 2020 , 99, e20207	32
1589	Early experience of COVID-19 in 2 heart transplant recipients: Case reports and review of treatment options. 2020 , 20, 2916-2922	37
1588	Practical advice for management of inflammatory bowel diseases patients during the COVID-19 pandemic: World Endoscopy Organization Statement. 2020 , 32, 658-662	7
1587	Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS-CoV-2 (COVID-19) pandemic emergency: A quick review for a quick consultation. 2020 , 33, e13537	2
1586	Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection. 2020 , 8, 2324709620925571	32

1585	Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?. 2020 , 26, 42	121
1584	SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment. 2020 , 7, 184	19
1583	Coronavirus Pandemic-Therapy and Vaccines. 2020 , 8,	37
1582	Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine. 2020 , 95, E194-E196	14
1581	Covid-19 and drug therapy, what we learned. 2020 , 42, 833-836	7
1580	[What can we learn from the COVID-19 pandemic in general and about ourselves as dermatologists?]. 2020 , 147, 413-417	
1579	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. 2020 , 19, 102574	29
1578	[Informations on psychotropics and their adaptations for patients suffering from mental disorders in France during the SARS-CoV-2 epidemic]. 2020 , 46, S14-S34	7
1577	Position Statement on the Management of Cardiac Electrophysiology and Cardiac Implantable Electronic Devices in Australia During the COVID-19 Pandemic: A Living Document. 2020 , 29, e57-e68	10
1576	Enhanced electrocardiographic monitoring of patients with Coronavirus Disease 2019. 2020 , 17, 1417-1422	31
1575	QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. 2020 , 17, 1425-1433	176
1574	Excessive lysosomal ion-trapping of hydroxychloroquine and azithromycin. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 106007	14-3 18
1573	Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106012	14-3 131
1572	COVID-19: Wait for a novel drug or act with the age old drug - Do we have a choice?. 2020 , 13, 899-900	2
1571	COVID-19: clinical course and outcomes of 36 hemodialysis patients in Spain. 2020 , 98, 27-34	170
1570	Lessons From COVID-19 in Children: Key Hypotheses to Guide Preventative and Therapeutic Strategies. 2020 , 71, 2006-2013	22
1569	The impact of hydroxychloroquine shortages on patients with dermatological conditions during COVID-19 pandemic. 2020 , 33, e13524	1
1568	Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. 2020 , 94,	98

1567	Fulminant Acute Kidney Injury in a Young Patient with Novel Coronavirus 2019. 2020 , 10, 217-222	11
1566	Otologic and Audiologic Considerations for COVID-19. 2020 , 163, 110-111	11
1565	Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19. 2020 , 54, 827-831	10
1564	Sample sizes in COVID-19-related research. 2020 , 192, E461	2
1563	Potential Drugs Targeting Early Innate Immune Evasion of SARS-Coronavirus 2 via 2'-O-Methylation of Viral RNA. 2020 , 12,	48
1562	Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. 2020 ,	14
1561	The Clinical Pharmacology Sections in Drug Package Inserts: Do We Need to Reexamine the Basis?. 2020 , 60, 683-687	
1560	An Update on Current Therapeutic Drugs Treating COVID-19. 2020 , 6, 1-15	300
1559	Novel coronavirus (COVID-19) infection: What a doctor on the frontline needs to know. 2020 , 55, 24-29	11
1558	Advances in the relationship between coronavirus infection and cardiovascular diseases. 2020 , 127, 110230	38
1557	Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients. 2020 , 53, 43-52	58
1556	COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons. 2020 , 53, 66-70	212
1555	The challenges of urgent radical sigmoid colorectal cancer resection in a COVID-19 patient: A case report. 2020 , 71, 147-150	1
1554	COVID-19 and thrombosis: Beyond a casual association. 2020 , 155, 44	1
1553	Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection. 2020 , 142, 109783	29
1552	Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today's battle against COVID-19?. 2020 , 142, 109815	106
1551	[Living evidence in response to controversies about the use of antimalarials in COVID-19]. 2020 , 73, 693-694	
1550	Gaucher disease and SARS-CoV-2 infection: Emerging management challenges. 2020 , 130, 164-169	14

1549	Fast and frugal innovations in response to the COVID-19 pandemic. 2020 , 26, 814-817	47
1548	Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury. 2020 , 382, 2147-2156	47
1547	COVID-19 and toxicity from potential treatments: Panacea or poison. 2020 , 32, 697-699	5
1546	Chloroquine and hydroxychloroquine for COVID-19: A word of caution. 2020 , 25, 683-684	3
1545	Dietary therapy and herbal medicine for COVID-19 prevention: A review and perspective. 2020 , 10, 420-427	93
1544	COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support. 2020 , 66, 603-606	29
1543	Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. 2020 , 12, e12697	135
1542	Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. 2020 , 43, 341-354	50
1541	Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements. 2020 , 256, 117883	62
1540	Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19. 2020 , 95, 300-310	1
1539	Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic. 2020 , 30, 315-325	25
1538	Early experience with COVID-19 patients at academic hospital in Southwestern United States. 2020 , 52, 596-599	12
1537	Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?. 2020 , 71, 2965-2967	2
1536	Information and Disinformation: Social Media in the COVID-19 Crisis. 2020 , 27, 640-641	47
1535	Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic. 2020 , 190, 346-357	8
1534	Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices. 2020 , 22, 125	13
1533	Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?. 2020 , 11, 791	8
1532	SARS-CoV-2 (COVID-19): New Discoveries and Current Challenges. 2020 , 10, 3641	20

1531	Rapid publishing in the era of coronavirus disease 2019 (COVID-19). 2020 , 212, 535-535.e1	4
1530	Overview: The history and pediatric perspectives of severe acute respiratory syndromes: Novel or just like SARS. 2020 , 55, 1584-1591	20
1529	Anticoagulation, immortality, and observations of COVID-19. 2020 , 4, 674-676	7
1528	The endosomal lipid bis(monoacylglycero) phosphate as a potential key player in the mechanism of action of chloroquine against SARS-CoV-2 and other enveloped viruses hijacking the endocytic pathway. 2020 , 179, 237-246	12
1527	SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. 2020 , 54, 62-75	447
1526	Fatal arrhythmias: Another reason why doctors remain cautious about chloroquine/hydroxychloroquine for treating COVID-19. 2020 , 17, 1445-1451	17
1525	A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response. 2020 , 96, 464-466	11
1524	[SARS-CoV-2, COVID-19 and the eye: An update on published data]. 2020 , 43, 642-652	2
1523	Inhibitory activity of hydroxychloroquine on COVID-19 main protease: An insight from MD-simulation studies. 2020 , 1219, 128595	41
1522	Discovery of New Hydroxyethylamine Analogs against 3CL Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies. 2020 , 60, 5754-5770	56
1521	Quest for a COVID-19 Cure by Repurposing Small-Molecule Drugs: Mechanism of Action, Clinical Development, Synthesis at Scale, and Outlook for Supply. 2020 , 24, 940-976	48
1520	Current Perspective of Antiviral Strategies against COVID-19. 2020 , 6, 1624-1634	31
1519	Biosensors for Managing the COVID-19 Cytokine Storm: Challenges Ahead. 2020 , 5, 1506-1513	44
1518	Antimicrobial use, drug-resistant infections and COVID-19. 2020 , 18, 409-410	84
1517	Systemic lupus erythematosus and risk of infection. 2020 , 16, 527-538	12
1516	Efficacy and safety of Chinese herbal medicine for Coronavirus disease 2019: A protocol for systematic review and meta-analysis. 2020 , 99, e20157	2
1515	May Polyphenols Have a Role Against Coronavirus Infection? An Overview of Evidence. 2020 , 7, 240	40
1514	Cancer and COVID-19: Unmasking their ties. 2020 , 88, 102041	48

1513	HyPE study: hydroxychloroquine prophylaxis-related adverse events' analysis among healthcare workers during COVID-19 pandemic: a rising public health concern. 2020 , 42, 493-503	13
1512	SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment. 2020 , 21,	34
1511	Impact of COVID-19 on the Cardiovascular System: A Review. 2020 , 9,	31
1510	SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions. 2020 , 12,	129
1509	COVID-19 pandemic: an overview of epidemiology, pathogenesis, diagnostics and potential vaccines and therapeutics. 2020 , 11, 245-268	69
1508	Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature. 2020 , 63, 1440-1452	81
1507	Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome. 2020 , 47, 187-188	15
1506	Child with liver transplant recovers from COVID-19 infection. A case report. 2020 , 27, 275-276	25
1505	The quality of the reported sample size calculation in clinical trials on COVID-19 patients indexed in PubMed. 2020 , 77, 139-140	5
1504	Status of SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN). 2020 , 40, 272-278	13
1503	Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19. 2020 , 95, 300-310	8
1502	Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases. 2020 , 158, 104901	51
1501	The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?. 2020 , 158, 104904	72
1500	Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. 2020 , 369, m1844	266
1499	What every orthopaedic surgeon should know about COVID-19: A review of the current literature. 2020 , 28, 2309499020923499	3
1498	Severe Pediatric COVID-19 Presenting With Respiratory Failure and Severe Thrombocytopenia. 2020 , 146,	25
1497	Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation. 2020 , 11, 796	9
1496	Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. 2020 , 128, 147-150	21

1495	"Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis." 2020 , 14, 589-596	78
1494	Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106020	143 61
1493	COVID-19: Learning from Lessons To Guide Treatment and Prevention Interventions. 2020 , 5,	44
1492	Drug repurposing in the era of COVID-19: a call for leadership and government investment. 2020 , 212, 450-452.e1	8
1491	Current evidence for directed and supportive investigational therapies against COVID-19. 2020 , 26,	0
1490	Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. 2020 , 63, 1515-1521	85
1489	Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?. 2020 , 15, 174-180	21
1488	Immunology of COVID-19: Current State of the Science. 2020 , 52, 910-941	962
1487	COVID-19: an unexpected indication for anti-rheumatic therapies?. 2020 , 59, 1200-1203	5
1486	Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic. 2020 , 34, 389-396	9
1485	COVID-19, chronic inflammatory rheumatic disease and anti-rheumatic treatments. 2020 , 39, 2069-2075	15
1484	Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?. 2020 , 15, 801-812	40
1483	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. 2020 , 395, 1907-1918	880
1482	Treatment of Coronavirus Disease 2019 (COVID-19) Patients with Convalescent Plasma. 2020 , 190, 1680-1690	185
1481	Targeting Nprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost. 2020 , 178, 114057	22
1480	COVID-19: Transmission, prevention, and potential therapeutic opportunities. 2020 , 508, 254-266	319
1479	Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review. 2020 , 98, 115094	152
1478	Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. 2020 , 159, 104960	38

1477	A review of potential treatments to date in COVID-19 patients according to the stage of the disease. 2020 , 68, 93-104	13
1476	Opciones terapéuticas en el manejo de la COVID-19 grave: una perspectiva de Reumatología. 2020 ,	2
1475	[COVID-19: Pathogenesis of a multi-faceted disease]. 2020 , 41, 375-389	12
1474	Azithromycin Should Not Be Used to Treat COVID-19. 2020 , 7, ofaa207	11
1473	Coronavirus Disease 2019 and the Pediatric Gastroenterologist. 2020 , 70, 720-726	11
1472	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. 2020 , 79, 859-866	575
1471	The immunology of COVID-19: is immune modulation an option for treatment?. 2020 , 2, e428-e436	139
1470	A review of therapeutic agents and Chinese herbal medicines against SARS-COV-2 (COVID-19). 2020 , 158, 104929	53
1469	Molecular docking reveals the potential of flavonoids to inhibit COVID-19 virus main protease.. 2020 , 10, 19570-19575	56
1468	Efficacy, safety and cost-effectiveness of hydroxychloroquine in children with COVID-19: A call for evidence. 2020 , 109, 1711-1712	4
1467	Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials. 2020 , 13, e008688	10
1466	Potential specific therapies in COVID-19. 2020 , 14, 1753466620926853	13
1465	Prescription Fill Patterns for Commonly Used Drugs During the COVID-19 Pandemic in the United States. 2020 , 323, 2524-2526	81
1464	Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019: A Review. 2020 , 77, 1018-1027	461
1463	Management of heart failure patients with COVID-19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. 2020 , 22, 941-956	60
1462	A Comprehensive Updated Review on SARS-CoV-2 and COVID-19. 2020 , 60, 954-975	7
1461	COVID-19: a brief history and treatments in development. 2020 , 31, 23-28	14
1460	Treatment algorithm for COVID-19: a multidisciplinary point of view. 2020 , 39, 2077-2084	25

1459	An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19 (COVID-19). 2020 , 40, 591-601	55
1458	SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention. 2020 , 175, 93-98	37
1457	Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. 2020 , 26, 979-987	33
1456	COVID-19 - Does This Disease Kill Due to Imbalance of the Renin Angiotensin System (RAS) Caused by Genetic and Gender Differences in the Response to Viral ACE 2 Attack?. 2020 , 29, 964-972	12
1455	Managing patients with rheumatic diseases during the COVID-19 pandemic: The French Society of Rheumatology answers to most frequently asked questions up to May 2020. 2020 , 87, 431-437	12
1454	Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection. 2020 , 95, 1696-1700	15
1453	Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials. 2020 , 143, 109851	31
1452	Docking study of chloroquine and hydroxychloroquine interaction with RNA binding domain of nucleocapsid phospho-protein - an insight into the comparative efficacy of repurposing antiviral drugs. 2021 , 39, 4243-4255	12
1451	Care for patients with rheumatic diseases during COVID-19 pandemic: A position statement from APLAR. 2020 , 23, 717-722	17
1450	Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?. 2020 , 9, e016887	25
1449	Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring. 2020 , 9, e017144	85
1448	Repurposed Drugs Against COVID-19: Safety Concerns and Stockout. 2020 , 55, 218-219	3
1447	COVID-19 and Spine Surgery: A Review and Evolving Recommendations. 2020 , 10, 528-533	13
1446	Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. 2020 , 11, 1130	51
1445	Clinical Implications of Chloroquine and Hydroxychloroquine Ototoxicity for COVID-19 Treatment: A Mini-Review. 2020 , 8, 252	26
1444	Recomendaciones sobre el manejo de pacientes adultos con enfermedades reumáticas en el contexto de la infección por SARS-CoV-2/COVID-19. Asociación Colombiana de Reumatología. 2020 , 27, 230-241	1
1443	Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China. 2020 , 286, 198057	24
1442	Overview of lethal human coronaviruses. 2020 , 5, 89	128

1441	Open questions for harnessing autophagy-modulating drugs in the SARS-CoV-2 war: hope or hype?. 2020 , 16, 2267-2270	13
1440	Practice considerations on the use of investigational anti-COVID-19 medications: Dosage, administration and monitoring. 2020 , 45, 1199-1205	8
1439	SARS-CoV-2 COVID-19 susceptibility and lung inflammatory storm by smoking and vaping. 2020 , 17, 21	46
1438	Novel Coronavirus (COVID-19) Outbreak: Hope and Search for Effective Therapeutic Agent. 2020 , 17, 940-942	4
1437	Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. 2020 , 61, 381-395	29
1436	Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106053	14.3 56
1435	Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma. 2020 , 415, 116972	2
1434	Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19. 2020 , 256, 117963	37
1433	Autophagy as an emerging target for COVID-19: lessons from an old friend, chloroquine. 2020 , 16, 2260-2266	40
1432	Covid-19: a comprehensive review of a formidable foe and the road ahead. 2020 , 14, 869-879	9
1431	Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy. 2020 , 22, 86	15
1430	Effective Use of Angiotensin II in Coronavirus Disease 19-Associated Mixed Shock State: A Case Report. 2020 , 14, e01221	7
1429	Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19). 2020 , 12,	34
1428	From the trenches: inpatient management of coronavirus disease 2019 in pregnancy. 2020 , 2, 100154	6
1427	Possible therapeutic agents for COVID-19: a comprehensive review. 2020 , 18, 1005-1020	13
1426	Potential implications of SARS-CoV-2 epidemic in Africa: where are we going from now?. 2020 , 20, 412	7
1425	Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies. 2020 , 14, 809-814	68
1424	COVID-19: What you need to know. 2020 , 20, 100756	7

1423	Fatal SARS-CoV-2 infection in a renal transplant recipient. 2020 , 9, 409-412	8
1422	COVID-19 Drug Treatment in China. 2020 , 6, 1-9	7
1421	Current Status of COVID-19 Therapies and Drug Repositioning Applications. 2020 , 23, 101303	54
1420	Coronaviruses and SARS-CoV-2: A Brief Overview. 2020 , 131, 93-96	121
1419	nCOVID-19 Pandemic: From Molecular Pathogenesis to Potential Investigational Therapeutics. 2020 , 8, 616	36
1418	Tackling SARS-CoV-2: proposed targets and repurposed drugs. 2020 , 12, 1579-1601	32
1417	The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. 2020 , 43, 699-709	31
1416	The pivotal role of pharmacists during the 2019 coronavirus pandemic. 2020 , 60, e73-e75	9
1415	COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. 2020 , 286, 198070	75
1414	SARS-CoV-2 infection in kidney transplant recipients: Experience of the italian marche region. 2020 , 22, e13377	15
1413	Targeting the NLRP3 Inflammasome in Severe COVID-19. 2020 , 11, 1518	185
1412	The Effect of Anti-COVID-19 Policies on the Evolution of the Disease: A Complex Network Analysis of the Successful Case of Greece. 2020 , 2, 325-339	21
1411	What if the worst consequences of COVID-19 concerned non-COVID patients?. 2020 , 13, 1237-1239	9
1410	Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?. 2020 , 214, 107618	120
1409	Screening of Chloroquine, Hydroxychloroquine and its derivatives for their binding affinity to multiple SARS-CoV-2 protein drug targets. 2021 , 39, 4949-4961	19
1408	Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19. 2020 , 17, 1144-1153	13
1407	Risk of using hydroxychloroquine as a treatment of COVID-19. 2020 , 31, 111-116	17
1406	A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions. 2020 , 9,	38

1405	Novel therapeutic approaches for treatment of COVID-19. 2020 , 98, 789-803	27
1404	Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?. 2020 , 39, 2461-2465	19
1403	Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?. 2020 , 155, 23-25	0
1402	Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19. 2020 , 132, 604-613	19
1401	SARS-CoV-2 and COVID-19: From the Bench to the Bedside. 2020 , 100, 1455-1466	75
1400	Implications of COVID-19 in pediatric rheumatology. 2020 , 40, 1193-1213	26
1399	SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. 2020 , 29, 973-987	68
1398	Diacerein: A potential multi-target therapeutic drug for COVID-19. 2020 , 144, 109920	13
1397	Clinical update on COVID-19 in pregnancy: A review article. 2020 , 46, 1235-1245	51
1396	Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus. 2020 , 22, e13351	8
1395	COVID-19 Presenting as Acute Hepatitis. 2020 , 115, 941-942	61
1394	A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. 2020 , 201, 112527	52
1393	Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106044	14-3 33
1392	Need of the Hour- COVID-19 for Cardiologists. 2020 , 5, 4-7	1
1391	Potential therapeutic agents against COVID-19: What we know so far. 2020 , 83, 534-536	111
1390	Efficacy and safety of Lian-Hua Qing-Wen granule for COVID-2019: A protocol for systematic review and meta-analysis. 2020 , 99, e20203	5
1389	IL-15 immunotherapy is a viable strategy for COVID-19. 2020 , 54, 24-31	18
1388	The Novel Coronavirus Disease (COVID-19) and Its Impact on Cardiovascular Disease. 2020 , 28, 163-176	12

1387	Treatment of COVID 19-Repurposing drugs commonly used in dermatology. 2020 , 33, e13829	3
1386	COVID-19 research: an opinion piece. 2020 , 21, 536-540	3
1385	Spatial Disparities in Coronavirus Incidence and Mortality in the United States: An Ecological Analysis as of May 2020. 2020 , 36, 433-445	124
1384	Deciphering the Role of Host Genetics in Susceptibility to Severe COVID-19. 2020 , 11, 1606	27
1383	Liver transplant immunosuppression during the covid-19 pandemic. 2020 , 43, 457-463	12
1382	The broad-spectrum antiviral recommendations for drug discovery against COVID-19. 2020 , 52, 408-424	12
1381	SARS-CoV-2 in multiple myeloma: initial observation and management. 2020 , 61, 2763-2766	1
1380	Confirmed Coronavirus Disease-19 (COVID-19) in a Male with Chronic Myeloid Leukemia Complicated by Febrile Neutropenia and Acute Respiratory Distress Syndrome. 2020 , 13, 569-577	3
1379	Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications. 2020 , 14, 1753466620933508	58
1378	Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing. 2020 , 35, 2826-2828	3
1377	Literature-based review of the drugs used for the treatment of COVID-19. 2020 , 10, 100-109	24
1376	COVID-19 research: pandemic "paperdemic", integrity, values and risks of the "speed science". 2020 , 5, 174-187	42
1375	Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study. 2020 , 79, 1163-1169	20
1374	COVID-19 in the Cancer Patient. 2020 , 131, 16-23	29
1373	Potential effectiveness and safety of antiviral agents in children with coronavirus disease 2019: a rapid review and meta-analysis. 2020 , 8, 624	9
1372	Potential Treatments for SARS-CoV-2 Infection. 2020 , 15, 181-186	4
1371	Genetic variability of human angiotensin-converting enzyme 2 (hACE2) among various ethnic populations. 2020 , 8, e1344	35
1370	COVID-19 and the elderly: insights into pathogenesis and clinical decision-making. 2020 , 32, 1599-1608	138

1369	Doxycycline as a potential partner of COVID-19 therapies. 2020 , 21, e00864	51
1368	Overview of therapeutic drug research for COVID-19 in China. 2020 , 41, 1133-1140	23
1367	Natural products' role against COVID-19. 2020 , 10, 23379-23393	95
1366	Natural compounds from spp. as possible therapeutic candidates against SARS-CoV-2: An investigation. 2021 , 39, 4774-4785	25
1365	Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital. 2021 , 73, e4064-e4072	34
1364	Knowledge and Information Sources About COVID-19 Among University Students in Jordan: A Cross-Sectional Study. 2020 , 8, 254	67
1363	A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation. 2020 , 9,	16
1362	Pregnant Women in Trials of Covid-19: A Critical Time to Consider Ethical Frameworks of Inclusion in Clinical Trials. 2020 , 42, 17-23	20
1361	Amantadine Treatment for People with COVID-19. 2020 , 51, 739-740	30
1360	[Coronavirus, emerging viruses]. 2020 , 36, 633-641	1
1359	Ocular Manifestations of COVID-19 (SARS-CoV-2): A Critical Review of Current Literature. 2020 , 34, 1619-1628	29
1358	Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID-19 Clinical Trials. 2020 , 9, 435-443	2
1357	Using GRADE in situations of emergencies and urgencies: certainty in evidence and recommendations matters during the COVID-19 pandemic, now more than ever and no matter what. 2020 , 127, 202-207	22
1356	Experience of short-term hydroxychloroquine and azithromycin in COVID-19 patients and effect on QTc trend. 2020 , 81, e117-e119	8
1355	Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. 2020 , 38, 100709	48
1354	Special Article - Acute myocardial injury in patients hospitalized with COVID-19 infection: A review. 2020 , 63, 682-689	126
1353	COVID-19: from epidemiology to treatment. 2020 , 41, 2092-2112	45
1352	Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper. 2020 , 75, 2775-2793	13

1351	Azithromycin and COVID-19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration. 2020 , 33, e13785	9
1350	The hopes for a cure for COVID-19. 2020 , 2020, 6-8	1
1349	Three Cases of COVID-19 Disease With Colonic Manifestations. 2020 , 115, 948-950	31
1348	Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury. 2020 , 9,	45
1347	Drug allergy labeling and delabeling in the coronavirus disease 2019 era: What is important and what do we need to know. 2020 , 124, 523-525	1
1346	Influence of conflicts of interest on public positions in the COVID-19 era, the case of Gilead Sciences. 2020 , 38, 100710	6
1345	Additive treatment considerations in COVID-19-The clinician's perspective on extracorporeal adjunctive purification techniques. 2020 , 44, 918-925	14
1344	The Good, the Bad, and the Hoax: When Publication Instantaneously Impacts Treatment Strategies for COVID-19. 2020 , 64,	3
1343	Characteristics of COVID-19 Clinical Trials in China Based on the Registration Data on ChiCTR and ClinicalTrials.gov. 2020 , 14, 2159-2164	7
1342	COVID-19 Immunopathology and the Central Nervous System: Implication for Multiple Sclerosis and Other Autoimmune Diseases with Associated Demyelination. 2020 , 10,	27
1341	How likely are COVID-19 interventions to benefit the sickest patients?. 2020 , 46, 1441-1444	2
1340	Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin. 2020 , 125, 349-350	20
1339	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106054	143 168
1338	Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19. 2020 , 1, 114-127.e3	315
1337	Effet bñfique de lâassociation hydroxychloroquine/azithromycine dans le traitement des patients bñs atteints de la COVID-19 : rñsultats dâune tñde observationnelle. 2020 , 55, 398-403	2
1336	Case 18-2020: A 73-Year-Old Man with Hypoxemic Respiratory Failure and Cardiac Dysfunction. 2020 , 382, 2354-2364	9
1335	Guidance on Short-Term Management of Atrial Fibrillation in Coronavirus Disease 2019. 2020 , 9, e017529	17
1334	Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. 2020 , 108, 17-41	354

1333	Azithromycin for COVID-19: More Than Just an Antimicrobial?. 2020 , 40, 683-686	54
1332	Cytokine storm induced by SARS-CoV-2. 2020 , 509, 280-287	247
1331	The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence. 2020 , 77, 163-164	1
1330	Applying the ethical principles of resource allocation to drugs in limited supply during a public health crisis. 2020 , 83, 170-171	1
1329	A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis. 2020 , 125, 170-178	18
1328	Synergistic antiviral effects against SARS-CoV-2 by plant-based molecules. 2020 , 39, 1109-1114	29
1327	COVID-19 and the cardiovascular system: A review of current data, summary of best practices, outline of controversies, and illustrative case reports. 2020 , 226, 174-187	8
1326	Pirfenidone: A novel hypothetical treatment for COVID-19. 2020 , 144, 110005	30
1325	COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests. 2020 , 41, 3045-3054	109
1324	Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options. 2020 , 7, ofaa105	190
1323	Rising to the Challenge of COVID-19: Advice for Pulmonary and Critical Care and an Agenda for Research. 2020 , 201, 1019-1022	21
1322	Potential Effects of Coronaviruses on the Cardiovascular System: A Review. 2020 , 5, 831-840	1027
1321	Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. 2020 , 14, 241-246	267
1320	COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern?. 2020 , 213, A3-A4	27
1319	Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. 2020 , 100, 1065-1075	223
1318	Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs. 2020 , 40, 825-826	28
1317	Why the immune system fails to mount an adaptive immune response to a COVID-19 infection. 2020 , 33, 824-825	96
1316	Thoughts on COVID-19 and autoimmune diseases. 2020 , 7, e000396	23

1315	To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic. 2020 , 79, 666-667	37
1314	Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence. 2020 , 369, m1335	73
1313	COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?. 2020 , 94, 1367-1369	66
1312	Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients. 2020 , 71, 2227-2229	72
1311	Combating COVID-19 with Chloroquine. 2020 , 12, 249-250	12
1310	COVID-19 and Older Adults: What We Know. 2020 , 68, 926-929	419
1309	Chloroquine and hydroxychloroquine in covid-19. 2020 , 369, m1432	231
1308	The short-term impact of COVID-19 pandemic on spine surgeons: a cross-sectional global study. 2020 , 29, 1806-1812	9
1307	Current pharmacological treatments for SARS-COV-2: A narrative review. 2020 , 882, 173328	24
1306	Could there be a link between oral hygiene and the severity of SARS-CoV-2 infections?. 2020 , 228, 971-975	59
1305	Attenuated early inflammatory response in solid organ recipients with COVID-19. 2020 , 34, e14027	15
1304	Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications. 2020 , 93, 60.e1-60.e7	2
1303	Drug treatment of coronavirus disease 2019 (COVID-19) in China. 2020 , 883, 173326	15
1302	SARS-CoV, MERS-CoV and SARS-CoV-2 infections in pregnancy and fetal development. 2020 , 101846	15
1301	Rethinking interleukin-6 blockade for treatment of COVID-19. 2020 , 144, 110053	20
1300	Coronavirus lockdown helped the environment to bounce back. 2020 , 742, 140573	82
1299	Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim Guidelines: A Consensus Document from an International Group of Interdisciplinary Extracorporeal Membrane Oxygenation Providers. 2020 , 66, 707-721	163
1298	Coronavirus Disease Pandemic (COVID-19): Challenges and a Global Perspective. 2020 , 9,	76

1297	Emerging pharmacotherapy for COVID-19. 2020 , 50, 133-137	3
1296	The rise and evolution of COVID-19. 2020 , 6, 248-254	2
1295	Cardiac sequelae of novel coronavirus disease 2019 (COVID-19): a clinical case series. 2020 , 4, 1-6	11
1294	Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. 2020 , 74, e13600	21
1293	SARS-CoV-2 Dissemination Through Peripheral Nerves Explains Multiple Organ Injury. 2020 , 14, 229	42
1292	Class A G Protein-Coupled Receptor Antagonist Famotidine as a Therapeutic Alternative Against SARS-CoV2: An In Silico Analysis. 2020 , 10,	33
1291	SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. 2020 , 10, 7448-7464	102
1290	The strategy for controlling COVID-19 in Kurdistan Regional Government (KRG)/Iraq: Identification, epidemiology, transmission, treatment, and recovery. 2020 , 25, 41-46	4
1289	A Comprehensive Analysis of Clinical Trials in the COVID-19 Pandemic Era. 2020 , 56,	2
1288	Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. 2020 , 97, 396-403	330
1287	Molecular mechanisms and epidemiology of COVID-19 from an allergist's perspective. 2020 , 146, 285-299	28
1286	SARS-CoV-2 detection, viral load and infectivity over the course of an infection. 2020 , 81, 357-371	389
1285	Natural history of COVID-19 and current knowledge on treatment therapeutic options. 2020 , 129, 110493	59
1284	Hydroxychloroquine and COVID-19 - A narrative review. 2020 , 67, S147-S154	5
1283	CORDITE: The Curated CORona Drug InTERactions Database for SARS-CoV-2. 2020 , 23, 101297	19
1282	Coronavirus disease 2019 (COVID-19): an evidence map of medical literature. 2020 , 20, 177	42
1281	Trajectory of the COVID-19 pandemic: chasing a moving target. 2020 , 8, 694	24
1280	Within a large healthcare system, the incidence of positive COVID-19 results and mortality are lower in patients on chronic hydroxychloroquine therapy. 2020 , 36, 1-2	2

1279 Endemic and Emerging Coronavirus Pulmonary Infections. **2020**, 360, 728-732

1278 Janus sword actions of chloroquine and hydroxychloroquine against COVID-19. **2020**, 73, 109706 13

1277 COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). *International Journal of Antimicrobial Agents*, **2020**, 56, 106080 14.3 96

1276 No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France". **2020**, 36, 101819 2

1275 SARS, MERS and COVID-19: clinical manifestations and organ-system complications: a mini review. **2020**, 78, 31

1274 Clinical Trials of Repurposed Antivirals for SARS-CoV-2. **2020**, 64, 26

1273 SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening. **2020**, 9, 29

1272 Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review. **2020**, 12, 27

1271 Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. **2020**, 39, 1059-1061 494

1270 Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors. **2020**, 88, 107325 47

1269 Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus. **2020**, 883, 173348 45

1268 Pandemic COVID-19: Current status and challenges of antiviral therapies. **2020**, 7, 502-519 7

1267 COVID-19 in Italian paediatric patients: The experience of a tertiary children's hospital. **2020**, 109, 2311-2312 13

1266 Canonical and Noncanonical Autophagy as Potential Targets for COVID-19. **2020**, 9, 34

1265 Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2. **2020**, 12, 1565-1578 19

1264 Perinatal-Neonatal Management of COVID-19 Infection - Guidelines of the Federation of Obstetric and Gynaecological Societies of India (FOGSI), National Neonatology Forum of India (NNF), and Indian Academy of Pediatrics (IAP). **2020**, 57, 536-548 68

1263 Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19. **2020**, 28, 742-754 17

1262 Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. **2020**, 18, 1119-1133 16

1261	COVID-19 fulminant myocarditis: a case report. 2020 , 4, 1-6	18
1260	A Postpartum Death Due to Coronavirus Disease 2019 (COVID-19) in the United States. 2020 , 136, 52-55	36
1259	Efficacy of chloroquine versus lopinavir/ritonavir in mild/general COVID-19 infection: a prospective, open-label, multicenter, randomized controlled clinical study. 2020 , 21, 622	12
1258	Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU. 2020 , 21, 631	5
1257	Immunopathology of SARS-CoV-2 Infection: Immune Cells and Mediators, Prognostic Factors, and Immune-Therapeutic Implications. 2020 , 21,	50
1256	. 2020 , 162, 20-23	
1255	Chloroquine: A Potential Drug in the COVID-19 Scenario. 2020 , 5, 399-410	7
1254	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review. 2020 , 2, 1-6	25
1253	Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae. 2020 , 61, 597-606	17
1252	Living evidence in response to controversies about the use of antimalarials in COVID-19. 2020 , 73, 693-694	
1251	Cutaneous manifestations in hospitalized patients diagnosed as COVID-19. 2020 , 33, e13896	32
1250	Coronavirus Disease 2019-COVID-19. 2020 , 33,	386
1249	COVID-19 in an international European liver transplant recipient cohort. 2020 , 69, 1832-1840	81
1248	Potential Role of Nrf2 Activators with Dual Antiviral and Anti-Inflammatory Properties in the Management of Viral Pneumonia. 2020 , 13, 1735-1741	11
1247	Deaths in SARS-Cov-2 Positive Patients in Italy: The Influence of Underlying Health Conditions on Lethality. 2020 , 17,	23
1246	Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. 2020 , 36, 101791	162
1245	Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection. 2020 , 286, 198073	25
1244	Could Coronavirus Disease 2019 (COVID-19) Render Natural Immunity to Re-infections? A Spotlight on the Therapeutic Pipeline. 2020 , 11, 1294	15

1243	A Perspective on Emerging Therapeutic Interventions for COVID-19. 2020 , 8, 281	33
1242	Coronavirus in Continuous Flux: From SARS-CoV to SARS-CoV-2. 2020 , 7, 2001474	8
1241	Are hydroxychloroquine and chloroquine effective in the treatment of SARS-COV-2 (COVID-19)?. 2020 , 21, 64-65	6
1240	COVID-19 in Children: An Ample Review. 2020 , 13, 661-669	26
1239	Emerging Prevention and Treatment Strategies to Control COVID-19. 2020 , 9,	19
1238	SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries. 2020 , 8,	29
1237	When science goes viral: The research response during three months of the COVID-19 outbreak. 2020 , 129, 110451	34
1236	Identification and classification of differentially expressed genes reveal potential molecular signature associated with SARS-CoV-2 infection in lung adenocarcinoma cells. 2020 , 20, 100384	5
1235	Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19. 2020 , 8, 2777-2779.e1	14
1234	Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). 2020 , 56,	42
1233	The Emerging Role of Convalescent Plasma in the Treatment of COVID-19. 2020 , 4, e409	30
1232	Systemic autoimmune diseases, anti-rheumatic therapies, COVID-19 infection risk and patient outcomes. 2020 , 40, 1353-1360	19
1231	Guidance for Healthcare Providers Managing COVID-19 in Rural and Underserved Areas. 2020 , 7, 817-821	6
1230	Minimum costs to manufacture new treatments for COVID-19. 2020 , 6, 61-69	33
1229	A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection. 2020 , 153, 105465	87
1228	Tackling the cytokine storm in COVID-19, challenges and hopes. 2020 , 257, 118054	39
1227	Diabetes and COVID-19: Global and regional perspectives. 2020 , 166, 108303	19
1226	Application of Artificial Intelligence in COVID-19 drug repurposing. 2020 , 14, 1027-1031	75

1225	Case report study of the first five COVID-19 patients treated with remdesivir in France. 2020 , 98, 290-293	19
1224	Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease. 2020 , 148, 104365	49
1223	COVID-19 in systemic lupus erythematosus: Data from a survey on 417 patients. 2020 , 50, 1150-1157	29
1222	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. 2020 , 16, 659-666	40
1221	Clinical trials for the prevention and treatment of COVID-19: current state of play. 2020 , 213, 86-93	16
1220	COVID-19: Progress in diagnostics, therapy and vaccination. 2020 , 10, 7821-7835	77
1219	Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going. 2020 , 22, 680-684	11
1218	Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches. 2020 , 84, 104451	56
1217	Emerging and experimental treatments for COVID-19 and drug interactions with psychotropic agents. 2020 , 10, 2045125320935306	26
1216	Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review. 2020 , 81, 919	17
1215	Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk. 2020 , 17, 1480-1486	18
1214	A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 56, 106078	14.3 29
1213	Dual antiplatelet therapy in patients with acute coronary syndrome during the coronavirus disease of 2019 pandemic: the right choice at the right time. 2020 , 21, 535-537	6
1212	Cardiovascular disease management during the coronavirus disease 2019 pandemic. 2020 , 17, 1340-1344	1
1211	The trinity of COVID-19: immunity, inflammation and intervention. 2020 , 20, 363-374	2173
1210	On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges. 2020 , 10,	76
1209	Treatment of SARS-CoV-2: How far have we reached?. 2020 , 14, 67-72	25
1208	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1. 2020 , 72, 1241-1251	105

1207	Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. 2020 , 108, 766-769	34
1206	Balancing evidence and frontline experience in the early phases of the COVID-19 pandemic: current position of the Italian Society of Anti-infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). 2020 , 26, 880-894	23
1205	[Real-life data and Covid-19: The third avenue of reseach]. 2020 , 46, S114-S115	2
1204	Response to: "Risks of hydroxychloroquine use for COVID-19 prophylaxis". 2020 , 83, e75-e76	
1203	Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase. 2020 , 10, 320-328	147
1202	Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York. 2020 , 383, 85-88	278
1201	Can melatonin reduce the severity of COVID-19 pandemic?. 2020 , 39, 153-162	97
1200	Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety. 2020 , 6, 256-257	19
1199	Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. 2020 , 52, 54-72	59
1198	COVID-19 diagnosis and management: a comprehensive review. 2020 , 288, 192-206	532
1197	Shining a light on the evidence for hydroxychloroquine in SARS-CoV-2. 2020 , 24, 182	7
1196	SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. 2020 , 27, 4536-4541	164
1195	Repurposing Antiviral Protease Inhibitors Using Extracellular Vesicles for Potential Therapy of COVID-19. 2020 , 12,	76
1194	Recommendations for the organization of electrophysiology and cardiac pacing services during the COVID-19 pandemic : Latin American Heart Rhythm Society (LAHRS) in collaboration with: Colombian College Of Electrophysiology, Argentinian Society of Cardiac Electrophysiology (SADEC), Brazilian Society Of Cardiac Arrhythmias (SOBRAC), Mexican Society Of Cardiac Electrophysiology (SOMEEC). 2020 , 59, 307-313	7
1193	Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action. 2020 , 37, 2575-2579	22
1192	Use of drugs with potential cardiac effect in the setting of SARS-CoV-2 infection. 2020 , 113, 293-296	11
1191	Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof). 2020 , 95, 1454-1466	57
1190	COVID-19: treating and managing severe cases. 2020 , 30, 370-371	12

1189	Antibody therapies for the treatment of COVID-19. 2020 , 3, 101-108	7
1188	Rethinking the role of hydroxychloroquine in the treatment of COVID-19. 2020 , 34, 6027-6037	82
1187	COVID-19 in kidney transplant recipients. 2020 , 20, 1819-1825	145
1186	Increasing the Signal-to-Noise Ratio: COVID-19 Clinical Synopsis for Outpatient Providers. 2020 , 11, 215013272092295	145
1185	Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy. 2020 , 7, 78	17
1184	The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. 2020 , 9,	112
1183	Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). 2020 , 5, 1036-1041	424
1182	COVID-19: Therapeutics and Their Toxicities. 2020 , 16, 284-294	57
1181	When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 Pandemic. 2020 , 158, 892-895	27
1180	Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19. 2020 , 6, 100042	14
1179	Candidate drugs against SARS-CoV-2 and COVID-19. 2020 , 157, 104859	304
1178	Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context. 2020 , 729, 139088	97
1177	Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients. 2020 , 1, 100016	79
1176	Chloroquine, hydroxychloroquine and COVID-19. 2020 , 4, 40-42	16
1175	Cutaneous side-effects of the potential COVID-19 drugs. 2020 , 33, e13476	34
1174	Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19. 2020 , 11, 1021	90
1173	[SARS-CoV-2 infection in patients on renal replacement therapy. Report of the COVID-19 Registry of the Spanish Society of Nephrology (SEN)]. 2020 , 40, 272-278	61
1172	An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study. 2021 , 39, 3347-3357	208

1171	Macrolide treatment for COVID-19: Will this be the way forward?. 2020 , 14, 159-160	40
1170	Cardiovascular risks of hydroxychloroquine in treatment and prophylaxis of COVID-19 patients: A scientific statement from the Indian Heart Rhythm Society. 2020 , 20, 117-120	52
1169	COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies. 2020 , 5, 518-536	162
1168	Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease. 2020 , 52, 217-221	56
1167	Global interim guidance on coronavirus disease 2019 (COVID-19) during pregnancy and puerperium from FIGO and allied partners: Information for healthcare professionals. 2020 , 149, 273-286	145
1166	Epidemiological analysis of COVID-19 and practical experience from China. 2020 , 92, 755-769	66
1165	COVID-19: The Uninvited Guest in the Intensive Care Unit - Implications for Pharmacotherapy. 2020 , 40, 382-386	4
1164	COVID-19: Important Therapy Considerations and Approaches in this Hour of Need. 2020 , 40, 379-381	3
1163	Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. 2020 , 39, 2055-2062	157
1162	Chloroquine for COVID-19 Infection. 2020 , 43, 393-394	27
1161	Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. 2020 , 8, 506-517	812
1160	The French response to COVID-19: intrinsic difficulties at the interface of science, public health, and policy. 2020 , 5, e255	20
1159	Care of the pregnant woman with coronavirus disease 2019 in labor and delivery: anesthesia, emergency cesarean delivery, differential diagnosis in the acutely ill parturient, care of the newborn, and protection of the healthcare personnel. 2020 , 223, 66-74.e3	72
1158	[COVID-19 pandemia: Impact on the cardiovascular system. Data of 1 April 2020]. 2020 , 69, 107-114	3
1157	Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. 2020 , 36, 948-951	85
1156	Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic. 2020 , 215, 108409	142
1155	An overview of coronaviruses including the SARS-2 coronavirus - Molecular biology, epidemiology and clinical implications. 2020 , 10, 54-64	55
1154	Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in Co-morbid diseases (Hypertension, diabetes etc). 2020 , 14, 251-254	81

1153	Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. 2020 , 5, 580-585		145
1152	An algorithm for managing QT prolongation in coronavirus disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine. 2020 , 6, 244-248		45
1151	Inpatient use of mobile continuous telemetry for COVID-19 patients treated with hydroxychloroquine and azithromycin. 2020 , 6, 241-243		24
1150	SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes. 2020 , 17, 1456-1462		115
1149	COVID-19 in the Eastern Mediterranean Region and Saudi Arabia: prevention and therapeutic strategies. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105968	14.3	55
1148	Drug repositioning is an alternative for the treatment of coronavirus COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105969	14.3	68
1147	Chloroquine as a prophylactic agent against COVID-19?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105980	14.3	24
1146	Art of prevention: Life in the time of coronavirus. 2020 , 6, 137-141		5
1145	Multilead QT Screening Is Necessary for QT Measurement: Implications for Management of Patients in the COVID-19 Era. 2020 , 6, 878-880		18
1144	Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. 2020 , 111, 102452		431
1143	Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. 2020 , 2, 100113		280
1142	Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan. 2020 , 53, 488-492		60
1141	Treatment options for COVID-19: The reality and challenges. 2020 , 53, 436-443		292
1140	A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. 2020 , 97, 1083-1088		238
1139	Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). 2020 , 95, 1213-1221		263
1138	Meeting the potential emergency global drug supply challenge of hydroxychloroquine for COVID-19. 2020 , 5, 100036		9
1137	[Recommendations of the Working Groups from the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) for the management of adult critically ill patients in the coronavirus disease (COVID-19)]. 2020 , 44, 371-388		30
1136	Chloroquine and COVID-19, where do we stand?. 2020 , 50, 229-230		13

1135	No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. 2020 , 50, 384	513
1134	[Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients]. 2020 , 40, 265-271	35
1133	Recommendations on management of the SARS-CoV-2 coronavirus pandemic (Covid-19) in kidney transplant patients. 2020 , 40, 265-271	14
1132	Epidemiology, genome, and clinical features of the pandemic SARS-CoV-2: a recent view. 2020 , 35, 100672	72
1131	Repurposing antimalarials and other drugs for COVID-19. 2020 , 34, 101658	33
1130	Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. 2020 , 34, 101663	479
1129	Role of Tissue Engineering in COVID-19 and Future Viral Outbreaks. 2020 , 26, 468-474	22
1128	The Late Arrival of Coronavirus Disease 2019 (COVID-19) in Africa: Mitigating Pan-continental Spread. 2020 , 71, 875-878	39
1127	COVID-19 disease: tackling a pandemic in 21st century. 2020 , 113, 519-520	6
1126	Response to: COVID-19 disease: tackling a pandemic in 21st century. 2020 , 113, 521-522	0
1125	Fact Versus Science Fiction: Fighting Coronavirus Disease 2019 Requires the Wisdom to Know the Difference. 2020 , 2, e0108	12
1124	A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19). 2020 , 23, 613-619	72
1123	Novel Coronavirus-19 (COVID-19) in the immunocompromised transplant recipient: #Flatteningthecurve. 2020 , 20, 1765-1767	78
1122	Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection. 2020 , 13, 642-645	28
1121	The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity. 2020 , 7, 176	0
1120	Pharmacological Therapeutics Targeting RNA-Dependent RNA Polymerase, Proteinase and Spike Protein: From Mechanistic Studies to Clinical Trials for COVID-19. 2020 , 9,	87
1119	COVID-19: A Brief Overview of the Discovery Clinical Trial. 2020 , 13,	25
1118	Antiviral treatment of COVID-19. 2020 , 50, 611-619	144

1117	COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. 2020 , 50, 620-632	232
1116	Novel coronavirus disease (COVID-19) in children. 2020 , 50, 592-603	90
1115	Chloroquine and its derivatives in the management of COVID-19: A scoping review. 2020 , 40, 80-95	4
1114	Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. 2020 , 3, e208857	648
1113	Caution Needed on the Use of Chloroquine and Hydroxychloroquine for Coronavirus Disease 2019. 2020 , 3, e209035	33
1112	A real-time dashboard of clinical trials for COVID-19. 2020 , 2, e286-e287	130
1111	Three insights on psychoneuroimmunology of mood disorders to be taken from the COVID-19 pandemic. 2020 , 5, 100076	12
1110	Dermatoethics: Self-prescribing Plaquenil during the COVID-19 pandemic. 2020 , 6, 156-158	2
1109	Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. 2020 , 176, 507-515	47
1108	Médicaments rhumatologiques pour le traitement de l'infection par le COVID-19. 2020 , 87, 150-152	2
1107	The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. 2020 , 26, 808-809	207
1106	Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach. 2021 , 39, 3092-3098	193
1105	Current pharmacological treatments for COVID-19: What's next?. 2020 , 177, 4813-4824	137
1104	COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency. 2020 , 105, 357-359	40
1103	What the oncologist needs to know about COVID-19 infection in cancer patients. 2020 , 16, 1153-1156	11
1102	ISIDOG Recommendations Concerning COVID-19 and Pregnancy. 2020 , 10,	45
1101	Does pandemic justify the use of hydroxychloroquine for treatment and prevention of COVID-19 in India?. 2020 , 92, 1391-1393	5
1100	[Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications]. 2020 , 93, 60.e1-60.e7	7

1099	Use of antimalarial drugs in the treatment of COVID-19: A window of opportunity?. 2020 , 155, 23-25	3
1098	Convalescent Plasma: Therapeutic Hope or Hopeless Strategy in the SARS-CoV-2 Pandemic. 2020 , 34, 145-150	47
1097	Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit. 2020 , 79, e62	9
1096	Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. 2020 , 19, 16	24
1095	Keeping people with epilepsy safe during the COVID-19 pandemic. 2020 , 94, 1032-1037	91
1094	Inpatient Care of Patients with COVID-19: A Guide for Hospitalists. 2020 , 133, 1019-1024	10
1093	Hydroxychloroquine in Covid-19: Does the end justify the means?. 2020 , 68, 81-82	1
1092	Senegal faces the coronavirus disease -19 challenge. 2020 , 37, 101687	1
1091	Oral hygiene risk factor. 2020 , 228, 569	13
1090	Covid-19 treatment update: follow the scientific evidence. 2020 , 50, 43-53	24
1089	COVID-19 in Children: Clinical Approach and Management. 2020 , 87, 433-442	53
1088	Novel Coronavirus 2019 (2019-nCoV) Infection: Part I - Preparedness and Management in the Pediatric Intensive Care Unit in Resource-limited Settings. 2020 , 57, 324-334	10
1087	COVID-19 pathophysiology: A review. 2020 , 215, 108427	761
1086	COVID-19: Immunology and treatment options. 2020 , 215, 108448	321
1085	In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. 2020 , 145, 104228	171
1084	A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2. 2021 , 39, 3213-3224	149
1083	Rheumatologists' view on the use of hydroxychloroquine to treat COVID-19. 2020 , 9, 830-832	10
1082	Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 2020 ,	432

1081	Two distinct cases with COVID-19 in kidney transplant recipients. 2020 , 20, 2269-2275	28
1080	A novel plan to deal with SARS-CoV-2 and COVID-19 disease. 2020 , 92, 1394-1395	5
1079	SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis. 2020 , 20, e00778	7
1078	Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given. 2020 , 72, 131-132	14
1077	COVID-19 and malaria: A symptom screening challenge for malaria endemic countries. 2020 , 94, 151-153	45
1076	What dentists need to know about COVID-19. 2020 , 105, 104741	95
1075	Inter nation social lockdown versus medical care against COVID-19, a mild environmental insight with special reference to India. 2020 , 728, 138914	118
1074	The Clinical Presentation and Immunology of Viral Pneumonia and Implications for Management of Coronavirus Disease 2019. 2020 , 2, e0109	8
1073	A Review of SARS-CoV-2 and the Ongoing Clinical Trials. 2020 , 21,	406
1072	Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department. 2020 , 21, 510-513	1
1071	Declaraci3n de consenso en medicina cr3tica para la atenci3n multidisciplinaria del paciente con sospecha o confirmaci3n diagn3stica de COVID-19. 2020 , 20, 287-333	6
1070	COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. 2020 , 123, 120-126	93
1069	Chloroquine paradox may cause more damage than help fight COVID-19. 2020 , 22, 154-156	14
1068	Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. 2020 , 35, 100684	48
1067	Hydroxychloroquine: A Familiar Agent to Combat the Pandemic of COVID-19. 2020 , 7, 192	
1066	Otolaryngology during COVID-19: Preventive care and precautionary measures. 2020 , 41, 102508	17
1065	Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. 2020 , 2, 335-343	85
1064	Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. 2020 , 92, 776-785	127

1063	Co-Infection with SARS-COV-2 and Parainfluenza in a young adult patient with pneumonia: Case Report. 2020 , 20, e00762	10
1062	Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105982	14.3 160
1061	Managing Asthma during Coronavirus Disease-2019: An Example for Other Chronic Conditions in Children and Adolescents. 2020 , 222, 221-226	44
1060	Commentary: COVID-19 and diabetes mellitus: What we know, how our patients should be treated now, and what should happen next. 2020 , 107, 154245	46
1059	Considerations for Obstetric Care during the COVID-19 Pandemic. 2020 , 37, 773-779	27
1058	Scientific research progress of COVID-19/SARS-CoV-2 in the first five months. 2020 , 24, 6558-6570	59
1057	Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. 2020 , 141, 1903-1914	302
1056	Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19. 2020 , 108, 201-211	100
1055	Care of immunocompromised patients with head and neck cancer during the COVID-19 pandemic: Two challenging and informative clinical cases. 2020 , 42, 1131-1136	11
1054	Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. 2020 , 72, 287-304	271
1053	Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. 2020 , 92, 770-775	103
1052	Chloroquine and Hydroxychloroquine in the Era of SARS - CoV2: Caution on Their Cardiac Toxicity. 2020 , 40, 387-388	21
1051	COVID-19 in otolaryngologist practice: a review of current knowledge. 2020 , 277, 1885-1897	99
1050	COVID-19 and the eye immunity: lesson learned from the past and possible new therapeutic insights. 2020 , 40, 1057-1060	25
1049	Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. 2020 , 22, 32	111
1048	CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement. 2020 , 16, 434-440	256
1047	Hydroxychloroquine prophylaxis for COVID-19 contacts in India. 2020 , 20, 1118-1119	74
1046	Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. 2020 , 8, 539-541	82

1045	Pharmacotherapy in COVID-19; A narrative review for emergency providers. 2020 , 38, 1488-1493	53
1044	Current status of potential therapeutic candidates for the COVID-19 crisis. 2020 , 87, 59-73	163
1043	Pathophysiological characteristics and therapeutic approaches for pulmonary injury and cardiovascular complications of coronavirus disease 2019. 2020 , 47, 107228	77
1042	Echoes of 2009 H1N1 Influenza Pandemic in the COVID Pandemic. 2020 , 42, 736-740	12
1041	Coronavirus disease 2019 and the cardiovascular system: Impacts and implications. 2020 , 72, 1-6	9
1040	Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105988	14-3 43
1039	Therapeutic management of patients with COVID-19: a systematic review. 2020 , 2, 100061	112
1038	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities. 2020 , 5, 501-517	9
1037	Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin. 2020 , 75, 2992-2993	44
1036	COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities. 2020 , 2, 254-269	8
1035	The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19. 2020 , 111, 102468	76
1034	Old and new antirheumatic drugs for the treatment of COVID-19. 2020 , 87, 195-197	11
1033	Joint Guidance from SGEI, ISG and INASL for Gastroenterologists and Gastrointestinal Endoscopists on the Prevention, Care, and Management of Patients With COVID-19. 2020 , 10, 266-270	22
1032	PAK1-blockers: Potential Therapeutics against COVID-19. 2020 , 6, 100039	54
1031	All about COVID-19 in brief. 2020 , 35, 100678	37
1030	A short review on antibody therapy for COVID-19. 2020 , 35, 100682	40
1029	COVID-19 and globalization. 2020 , 9, 100132	27
1028	Overview of Covid-19; its prevention and management in the light of Unani medicine. 2020 , 728, 138859	36

1027	Practical implementation of COVID-19 patient flags into an antimicrobial stewardship program's prospective review. 2020 , 41, 1108-1110	9
1026	Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment. 2021 , 39, 3409-3418	275
1025	Challenges in the Care of IBD Patients During the CoViD-19 Pandemic: Report From a "Red Zone" Area in Northern Italy. 2020 , 26, 793-796	36
1024	Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. 2020 , 9, 701-715	79
1023	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). 2020 , 7, ofaa130	122
1022	COVID-19 in solid organ transplant recipients: A single-center case series from Spain. 2020 , 20, 1849-1858	286
1021	COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine. 2020 , 20, 1902-1906	68
1020	Therapeutic uncertainties in people with cardiometabolic diseases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or COVID-19). 2020 , 22, 1942-1945	7
1019	Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak. 2020 , 33, e13437	25
1018	Coronavirus-days ñ dermatology. 2020 , 33, e13438	17
1017	Role of immunosuppressive therapy in rheumatic diseases concurrent with COVID-19. 2020 , 79, 737-739	25
1016	: hydroxychloroquine, COVID-19 and the role of the rheumatologist. 2020 , 79, 734-736	32
1015	Does hydroxychloroquine prevent the transmission of COVID-19?. 2020 , 79, e60	3
1014	Hydroxychloroquine and COVID-19. 2020 , 96, 550-555	77
1013	COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. 2020 , 18, 35	26
1012	Taking the Longer View of COVID-19. 2020 , 25, 455-457	5
1011	COVID-19 and the Heart. 2020 , 126, 1443-1455	395
1010	Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. 2020 , 192, E450-E453	132

1009	Hydroxychloroquine: A Potential Ethical Dilemma for Rheumatologists during the COVID-19 Pandemic. 2020 , 47, 783-786	15
1008	Covid-19: Pandemonium in our time. 2020 , 15,	8
1007	Update on use of chloroquine/hydroxychloroquine to treat coronavirus disease 2019 (COVID-19). 2020 , 14, 156-158	34
1006	Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing. 2020 , 108, 253-263	75
1005	Delayed Initiation of Remdesivir in a COVID-19-Positive Patient. 2020 , 40, 592-598	44
1004	COVID-19: Key Concepts for the Surgeon. 2020 , 98, 310-319	16
1003	Does hydroxychloroquine combat COVID-19? A timeline of evidence. 2020 , 83, e33-e34	21
1002	What We Know So Far (As of March 26, 2020) About COVID-19-An MRT Point of View. 2020 , 51, 200-203	4
1001	Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. 2020 , 41, 363-382	243
1000	Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?. 2021 , 80, e6	2
999	Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine. 2021 , 17, 483-486	40
998	Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?. 2021 , 80, e19	8
997	Pharmacists' readiness to deal with the coronavirus pandemic: Assessing awareness and perception of roles. 2021 , 17, 514-522	46
996	Hospital pharmacists' pharmaceutical care for hospitalized patients with COVID-19: Recommendations and guidance from clinical experience. 2021 , 17, 2027-2031	47
995	COVID-19 Pandemic: Considerations for Safe Medication Use in Older Adults with Multimorbidity and Polypharmacy. 2021 , 76, 1068-1073	9
994	When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19. 2021 , 17, 1954-1963	80
993	Chloroquine and hydroxychloroquine to treat COVID-19: between hope and caution. 2021 , 59, 70-71	23
992	Chloroquine and the potential adverse outcome in undiagnosed G6PD-deficient cases infected with COVID-19. 2021 , 28, 54	0

991	Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management. 2021 , 7, e53-e54	7
990	No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: comment by Joob and Wiwanitkit. 2021 , 80, e22	12
989	Response to 'Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?' by Moiseev. 2021 , 80, e20	2
988	An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic. 2021 , 17, 2012-2017	16
987	Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications. 2021 , 35, 1860-1865	21
986	Pandemic preparedness of community pharmacies for COVID-19. 2021 , 17, 1888-1896	30
985	Can Zn Be a Critical Element in COVID-19 Treatment?. 2021 , 199, 550-558	66
984	Chloroquine-Induced First-Episode Psychosis in a Patient Self-medicated for COVID-19. 2021 , 89, e9	10
983	Model informed dosing of hydroxychloroquine in COVID-19 patients: Learnings from the recent experience, remaining uncertainties and gaps. 2021 , 87, 674-682	3
982	Structural Basis of SARS-CoV-2- and SARS-CoV-Receptor Binding and Small-Molecule Blockers as Potential Therapeutics. 2021 , 61, 465-493	19
981	Outbreak of SARS-CoV2: Pathogenesis of infection and cardiovascular involvement. 2021 , 62, 13-23	19
980	Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection. 2021 , 33, 193-197	10
979	Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review. 2021 , 93, 275-299	33
978	COVID-19 and therapeutic drugs repurposing in hand: The need for collaborative efforts. 2021 , 56, 3-11	11
977	Immune responses and pathogenesis in persistently PCR-positive patients with SARS-CoV-2 infection. 2021 , 93, 760-765	1
976	Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic. 2021 , 190, 403-409	4
975	Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. 2021 , 93, 755-759	24
974	The cytokine storm and COVID-19. 2021 , 93, 250-256	377

973	SARS-CoV-2 infection in kidney transplant recipients: Early report of five cases. 2021 , 23, e13394	6
972	A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs. 2021 , 35, 205-214	13
971	Response to: Correspondence regarding research letter to the editor by Mathian , 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine' by Nikpour. 2020 ,	28
970	Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by PL. 2020 ,	
969	Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia. 2021 , 102, 110-114	3
968	MuLBSTA score is a useful tool for predicting COVID-19 disease behavior. 2021 , 27, 284-290	4
967	Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection. 2021 , 152, 104554	27
966	Adverse events associated with potential drugs for COVID-19: a case study from real-world data. 2021 , 22, 1232-1238	3
965	Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug. 2021 , 47, 570-575	1
964	Effect of pre-existing diseases on COVID-19 infection and role of new sensors and biomaterials for its detection and treatment. 2020 , 4, e10140	4
963	Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106216	14.3 25
962	An overview on the use of antivirals for the treatment of patients with COVID19 disease. 2021 , 30, 45-59	1
961	An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine. 2021 , 75, e13825	5
960	Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead. 2021 , 890, 173717	14
959	A Strategy to Treat COVID-19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study. 2021 , 14, 132-136	22
958	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. 2020 ,	26
957	SARS-CoV-2 and the pandemic of COVID-19. 2021 , 97, 110-116	61
956	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients : Results from a 'real-life' patient cohort. 2021 , 133, 284-291	22

955	Cytokine storm syndrome in coronavirus disease 2019: A narrative review. 2021 , 289, 147-161	84
954	Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?. 2021 , 17, 275-284	3
953	Los antimaláricos (cloroquina e hidroxiclороquina) en la pandemia COVID-19. 2021 , 28, 156-158	
952	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. 2021 , 19, 5-16	15
951	Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-Analysis. 2021 , 73, 36-47	34
950	Hydroxychloroquine Failure: The End Does Not Justify the Means. 2021 , 72, e439	1
949	Reply to Million et al. 2021 , 72, e440-e441	
948	Susceptibility to COVID-19 in Patients Treated With Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy. 2021 , 73, 48-52	5
947	Epigallocatechin gallate and theaflavin gallate interaction in SARS-CoV-2 spike-protein central channel with reference to the hydroxychloroquine interaction: Bioinformatics and molecular docking study. 2021 , 82, 86-96	28
946	Pathogenetic profiling of COVID-19 and SARS-like viruses. 2021 , 22, 1175-1196	20
945	Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned. 2021 , 29, 220-227	1
944	The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City. 2021 , 93, 463-471	34
943	Heart failure and COVID-19. 2021 , 26, 1-10	55
942	Co-infection of influenza B virus and SARS-CoV-2: A case report from Taiwan. 2021 , 54, 336-338	14
941	Editorial: Demystifying the Placebo Effect. 2021 , 190, 2-9	1
940	Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19. 2021 , 82, 12-26	5
939	Successful treatment of 28 patients with coronavirus disease 2019 at a medical center in Taiwan. 2021 , 120, 713-719	2
938	Systematic review and meta-analysis of effectiveness of treatment options against SARS-CoV-2 infection. 2021 , 93, 775-785	11

937	COVID-19 in solid organ transplant recipients. 2021 , 23, e13419	3
936	Elevated Liver Biochemistries in Hospitalized Chinese Patients With Severe COVID-19: Systematic Review and Meta-analysis. 2021 , 73, 1521-1530	18
935	Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection. 2021 , 36, 115-120	11
934	[Pharmacological treatment of COVID-19: Narrative review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]. 2021 , 45, 104-121	8
933	Recomendaciones para reumatólogos sobre el manejo farmacológico durante la emergencia sanitaria por COVID-19: opinión de un grupo de expertos. 2021 , 28, 134-140	
932	Primed for global coronavirus pandemic: Emerging research and clinical outcome. 2021 , 209, 112862	10
931	Clinical trial protocols of repurposed prophylaxis for COVID-19: A review. 2021 , 51, 7-13	3
930	Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle. 2021 , 85, 153361	46
929	COVID-19: Between Past and Present. 2021 , 34, 145-157	2
928	Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. 2021 , 44, 13-34	59
927	An Assessment on Impact of COVID-19 Infection in a Gender Specific Manner. 2021 , 17, 94-112	23
926	Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis. 2021 , 76, 30-42	70
925	Chloroquine and hydroxychloroquine in the prophylaxis and therapy of COVID-19 infection. 2021 , 538, 156-162	4
924	Paradigm Shifts in Cardiac Care: Lessons Learned From COVID-19 at a Large New York Health System. 2021 , 46, 100675	3
923	Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure. 2021 , 35, 1329-1344	19
922	High-speed large-scale automated isolation of SARS-CoV-2 from clinical samples using miniaturized co-culture coupled to high-content screening. 2021 , 27, 128.e1-128.e7	5
921	SARS-COV-2 (COVID-19): Cellular and biochemical properties and pharmacological insights into new therapeutic developments. 2021 , 39, 10-28	5
920	Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing. 2021 , 46, 17-27	14

919	The impact of novel coronavirus COVID-19 on noncommunicable disease patients and health systems: a review. 2021 , 289, 450-462	41
918	Impact of the COVID-19 pandemic on patients with systemic lupus erythematosus: Observations from an Indian inception cohort. 2021 , 30, 158-164	14
917	COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. 2021 , 97, 312-320	172
916	Role of ACE2 receptor and the landscape of treatment options from convalescent plasma therapy to the drug repurposing in COVID-19. 2021 , 476, 553-574	22
915	Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia. 2021 , 54, 109-112	6
914	Does IHU-Mediterran� Infection influence Gilead Sciences' stock price?. 2021 , 39, 100711	1
913	Outcomes of persons with coronavirus disease 2019 in hospitals with and without standard treatment with (hydroxy)chloroquine. 2021 , 27, 264-268	10
912	Pharmacological insight into potential therapeutic agents for the deadly Covid-19 pandemic. 2021 , 890, 173643	10
911	QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study. 2021 , 75, e13767	5
910	Efficacy and safety outcomes of proposed randomized controlled trials investigating hydroxychloroquine and chloroquine during the early stages of the COVID-19 pandemic. 2021 , 87, 1758-1767	4
909	COVID-19 lockdown: animal life, ecosystem and atmospheric environment. 2020 , 23, 1-18	18
908	Familiar Dermatologic Drugs as Therapies for COVID-19. 2021 , 112, 118-126	1
907	Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients. 2021 , 77, 389-397	8
906	Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action. 2021 , 183, 114296	44
905	COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. 2021 , 892, 173751	126
904	Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update. 2021 , 147, 111887	6
903	Novel coronavirus disease (COVID-19) update on epidemiology, pathogenicity, clinical course and treatments. 2021 , 75, e13868	23
902	COVID-19 mortality risk factors in older people in a long-term care center. 2021 , 12, 601-607	27

8901	DFT and molecular docking study of chloroquine derivatives as antiviral to coronavirus COVID-19. 2021 , 33, 101248	28
900	Interferon-inducer antivirals: Potential candidates to combat COVID-19. 2021 , 91, 107245	17
899	Repurposing medications. 2021 , 19, 336-340	4
898	Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106238	14.3
897	Identification of antiviral antihistamines for COVID-19 repurposing. 2021 , 538, 173-179	31
896	A comparative analysis for anti-viral drugs: Their efficiency against SARS-CoV-2. 2021 , 90, 107232	16
895	American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3. 2021 , 73, e1-e12	46
894	SARS-CoV-2: Targeted managements and vaccine development. 2021 , 58, 16-29	21
893	Hydroxychloroquine lung pharmacokinetics in critically ill patients with COVID-19. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106247	14.3 4
892	COVID-19; current situation and recommended interventions. 2021 , 75, e13886	11
891	Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. 2021 , 75, e13896	8
890	Drug repurposing approach to combating coronavirus: Potential drugs and drug targets. 2021 , 41, 1375-1426	11
889	Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies. 2021 , 52, 261-269	6
888	Inclusion complexation of chloroquine with β -cyclodextrin: Theoretical insights from the new B97-3c composite method. 2021 , 1227, 129696	6
887	Clinical characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room: a single-center retrospective study. 2021 , 16, 1051-1060	22
886	Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine. 2021 , 133, 111008	14
885	Composition analysis of falsified chloroquine phosphate samples seized during the COVID-19 pandemic. 2021 , 194, 113761	5
884	Transition metal complexes as potential tools against SARS-CoV-2: an in silico approach. 2021 , 45, 1924-1933	14

883	Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin. 2021 , 54, e12953		8
882	An effective drug against COVID-19: reality or dream?. 2021 , 15, 505-518		4
881	Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. 2021 , 106, 104488		14
880	Management of Arrhythmias Associated with COVID-19. 2020 , 23, 2		27
879	A comprehensive review on potential therapeutics interventions for COVID-19. 2021 , 890, 173741		24
878	Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106239	14.3	10
877	Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106240	14.3	3
876	Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106243	14.3	14
875	Dendritic cells in COVID-19 immunopathogenesis: insights for a possible role in determining disease outcome. 2021 , 40, 108-125		24
874	Assessment of COVID-19 Treatment containing both Hydroxychloroquine and Azithromycin: A natural clinical trial. 2021 , 75, e13856		7
873	Decoding the silent walk of COVID-19: Halting its spread using old bullets. 2021 , 133, 110891		1
872	Pharmacokinetics under the COVID-19 storm. 2020 ,		3
871	Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. 2021 , 90, 107228		12
870	Research response to coronavirus disease 2019 needed better coordination and collaboration: a living mapping of registered trials. 2021 , 130, 107-116		9
869	IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development. 2021 , 6, e10196		9
868	A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19. 2021 , 21, 159-168		2
867	Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions. 2021 , 10, 100-107		12
866	Cardiac Toxicity of Chloroquine or Hydroxychloroquine in Patients With COVID-19: A Systematic Review and Meta-regression Analysis. 2021 , 5, 137-150		21

865	Inhalable Hydroxychloroquine Powders for Potential Treatment of COVID-19. 2021 , 34, 20-31	7
864	It is time to control the worst: testing COVID-19 outbreak, energy consumption and CO emission. 2021 , 28, 19008-19020	47
863	Potential antibacterial and antifungal activities of novel sulfamidophosphonate derivatives bearing the quinoline or quinolone moiety. 2021 , 354, e2000291	10
862	Synthesis of Green/Blue Light Emitting Quinolines by Aza-D-A Reaction Using InCl Catalyst. 2021 , 31, 247-257	1
861	Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study. 2021 , 40, 41-46	14
860	COVID19- clinical presentation and therapeutic considerations. 2021 , 538, 125-131	9
859	Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites. 2021 , 31, 101890	23
858	Potential harm caused by physicians' a-priori beliefs in the clinical effectiveness of hydroxychloroquine and its impact on clinical and economic outcome - A simulation approach. 2021 , 62, 138-144	0
857	Recurrent SARS-CoV-2 infection resulting in acute respiratory distress syndrome and development of pulmonary hypertension: A case report. 2021 , 33, 101314	4
856	Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection and in a mouse model expressing human ACE2. 2021 , 66, 925-936	11
855	Repurposing drugs for the management of COVID-19. 2021 , 31, 295-307	23
854	SARS-CoV-2 infection, gut dysbiosis, and heterogeneous clinical results of hydroxychloroquine on COVID-19 therapy-Is there a link?. 2021 , 85, 111115	4
853	Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails. 2021 , 16, 385-397	13
852	A retrospective comparison of drugs against COVID-19. 2021 , 294, 198262	2
851	The virus that shook the world: questions and answers about SARS-CoV-2 and COVID-19. 2021 , 35, 74-102	7
850	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. 2020 , 7, 585899	6
849	Mitigating arrhythmia risk in Hydroxychloroquine and Azithromycin treated COVID-19 patients using arrhythmia risk management plan. 2021 , 32, 100685	4
848	The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions. 2021 , 14, 214-220	10

847	Self-medication practices during the COVID-19 pandemic among the adult population in Peru: A cross-sectional survey. 2021 , 29, 1-11	69
846	COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease. 2021 , 232, 13-36	26
845	The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules. 2021 , 7, 1389-1408	39
844	Can chloroquine/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. 2021 , 146, 110434	
843	Taking a stand against the politicization of medical research: how 'swinging the pendulum' poses a hazard to clinical trials, study participants, and the progress of science. 2021 , 17, 101-103	1
842	Can drug repurposing strategies be the solution to the COVID-19 crisis?. 2021 , 16, 605-612	10
841	Exploring the Mental Health Needs of Persons With Autoimmune Diseases During the Coronavirus Disease 2019 Pandemic: A Proposed Framework for Future Research and Clinical Care. 2021 , 3, 25-33	0
840	[The COVID-19 Pandemic Changes the Scientific Publication System]. 2021 , 57, 17-18	
839	A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients. 2021 , 44, 63-73	7
838	HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers. 2021 , 73, 74-76	0
837	Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106222	14.3 13
836	Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity. 2021 , 60, 359-364	2
835	Next-generation computational tools and resources for coronavirus research: From detection to vaccine discovery. 2021 , 128, 104158	8
834	Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel. 2021 , 893, 173813	14
833	COVID-19 and Solid Organ Transplantation: A Review Article. 2021 , 105, 37-55	111
832	Impact of COVID-19 in solid organ transplant recipients. 2021 , 21, 925-937	37
831	Clinical features, comorbidities, complications and treatment options in severe and non-severe COVID-19 patients: A systemic review and meta-analysis. 2021 , 8, 1077-1088	7
830	Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019). 2021 , 4, 1-13	10

829	Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases. 2021 , 57, 13-20	10
828	Biocatalytic routes to anti-viral agents and their synthetic intermediates. 2021 , 50, 1968-2009	13
827	Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review. 2021 , 155, 793-801	2
826	COVID-19: An Update on the Epidemiological, Clinical, Preventive, and Therapeutic Management of 2019 Novel Coronavirus Disease. 2021 , 44, 128-137	10
825	The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience. 2021 , 106, 340-345	0
824	COVID-19: Clouds Over the Antimicrobial Resistance Landscape. 2021 , 52, 123-126	9
823	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. 2021 , 116, 102545	18
822	Emerging treatment strategies for COVID-19 infection. 2021 , 21, 167-179	81
821	COVID-19 and antimalarials. Have we been doing it wrong all along?. 2021 , 891, 173694	
820	Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review. 2021 , 54, 27-36	8
819	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. 2021 , 53, 117-134	26
818	Viral pandemic preparedness: A pluripotent stem cell-based machine-learning platform for simulating SARS-CoV-2 infection to enable drug discovery and repurposing. 2021 , 10, 239-250	12
817	Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response. 2021 , 76, 277-279	1
816	Repurposed Drugs, Molecular Vaccines, Immune-Modulators, and Nanotherapeutics to Treat and Prevent COVID-19 Associated with SARS-CoV-2, a Deadly Nanovector. 2020 , 4, 2000172	14
815	Has the door closed on hydroxychloroquine for SARS-COV-2?. 2021 , 27, 3-5	3
814	Recent progress of antiviral therapy for coronavirus disease 2019. 2021 , 890, 173646	16
813	Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19. 2021 , 58, 32-48	9
812	Comparison of antiviral effect for mild-to-moderate COVID-19 cases between lopinavir/ritonavir versus hydroxychloroquine: A nationwide propensity score-matched cohort study. 2021 , 102, 275-281	7

811	Hydroxychloroquine for treatment of nonsevere COVID-19 patients: Systematic review and meta-analysis of controlled clinical trials. 2021 , 93, 1265-1275	8
810	Exploring the growth of COVID-19 cases using exponential modelling across 42 countries and predicting signs of early containment using machine learning. 2021 , 68, 1001-1018	14
809	Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic. 2021 , 268, 1580-1591	19
808	Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study. 2021 , 72, e533-e541	131
807	Patient Characteristics and Outcomes of 11 721 Patients With Coronavirus Disease 2019 (COVID-19) Hospitalized Across the United States. 2021 , 72, e558-e565	61
806	Concerns About the Special Article on Hydroxychloroquine and Azithromycin in High-Risk Outpatients With COVID-19. 2021 , 190, 491-495	5
805	Risk Assessment of Drug-Induced Long QT Syndrome for Some COVID-19 Repurposed Drugs. 2021 , 14, 20-28	22
804	Successfully treated severe COVID-19 and invasive aspergillosis in early hematopoietic cell transplantation setting. 2021 , 23, e13470	4
803	Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. 2021 , 87, 1432-1442	26
802	Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen. 2021 , 324, 242-248	12
801	Azithromycin in viral infections. 2021 , 31, e2163	36
800	Hydroxychloroquine use and progression or prognosis of COVID-19: a systematic review and meta-analysis. 2021 , 394, 775-782	10
799	Effects of Antimalarial Drugs on Neuroinflammation-Potential Use for Treatment of COVID-19-Related Neurologic Complications. 2021 , 58, 106-117	21
798	Football and COVID-19 risk: correlation is not causation. 2021 , 27, 291-292	3
797	Public Perceptions of Resuming Elective Surgery During the COVID-19 Pandemic. 2021 , 36, 397-402.e2	13
796	Immunopathology of Hyperinflammation in COVID-19. 2021 , 191, 4-17	143
795	Impact of COVID-19 on the Cardiovascular System: A Review of Available Reports. 2021 , 35, 411-425	15
794	Patients with rheumatoid arthritis exposed to COVID-19: A family cluster report. 2021 , 31, 514-517	


- 793 Emergency Use Authorization for Remdesivir and Its Potential Implications. **2021**, 55, 270-271 2
- 792 Optimization of hydroxychloroquine dosing scheme based on COVID-19 patients' characteristics: a review of the literature and simulations. **2021**, 51, 127-138 4
- 791 Multicenter Interim Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2. **2021**, 10, 34-48 37
- 790 Safety and Utility of Chloroquine/ Hydroxychloroquine in Palliative Care Patients. **2021**, 38, 480-488
- 789 SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects.. **2021**, 31, e2168 14
- 788 Hydroxychloroquine and chloroquine retinal safety concerns during COVID-19 outbreak. **2021**, 41, 719-725 2
- 787 Hydroxychloroquine at usual doses as an option for coronavirus disease 2019 treatment. **2021**, 224, 121
- 786 Systematic benefit-risk assessment for the use of chloroquine or hydroxychloroquine as a treatment for COVID-19: Establishing a dynamic framework for rapid decision-making.
- 785 Diabetes and COVID-19: A Review. **2020**, 35, 40-48 2
- 784 A Silent Attacker SARS-CoV-2 - A Review. **2020**, 2,
- 783 Chloroquine and hydroxychloroquine effectiveness in human subjects during coronavirus: a systematic review.
- 782 Drug Safety Issues in Therapy COVID-19. **2020**, 10, 165-187 2
- 781 Space-time COVID-19 monitoring in Morocco. **2020**, 35, 41 2
- 780 1-C Nonlinear Covid-19 Epidemic Model and Application to the Epidemic Prediction in France. 0
- 779 La formation lade, pour trancher entre passion et raison face au Covid-19. **2020**, 33, 10-12
- 778 Different Cases of SARS-CoV-2 Infection and Its Impact on Health and Economy with Special Emphasis on Antiviral Drug Targets. **2020**, 14, 799-816
- 777 A systematic review protocol of the antiviral activity of chloroquine and hydroxychloroquine against COVID-19.
- 776 Viral Dynamics Matter in COVID-19 Pneumonia: the success of early treatment with hydroxychloroquine and azithromycin in Lebanon.

- 775 COVID-19: an unprecedented pandemia with a potential arrhythmic undertone. **2020**, 132, 601-603 1
- 774 Drug-Drug interactions between COVID-19 treatments and antipsychotics drugs: integrated evidence from 4 databases and a systematic review. 1
- 773 Non-SHEF2 Model related containment and control measures against COVID-19 in Africa. **2020**, 35, 86 1
- 772 (Facts and thoughts on COVID-19 pandemic). **2020**, 62, 11-14 1
- 771 Toward in vivo-relevant hERG safety assessment and mitigation strategies based on relationships between non-equilibrium blocker binding, three-dimensional channel-blocker interactions, dynamic occupancy, dynamic exposure, and cellular arrhythmia. 1
- 770 Repurposed prophylaxis strategies for COVID-19: a review.
- 769 Serious Adverse Events Associated With Hydroxychloroquine Amidst COVID-19 Pandemic: Case Series and Literature Review. **2020**, 12, e8415 2
- 768 Multi-Disciplinary Opinions Focused on Healthcare Sector for Global Pandemic: COVID-19 (Preprint).
- 767 Orienta  s COVID-19 para o ginecologista e obstetra. **2020**, 130, 4-44
- 766 Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of COVID-19 Spike pseudotype virus.
- 765 Covid-19 in Chile. The experience of a Regional reference Center. Preliminary report. 1
- 764 Rapid systematic review on clinical evidence of chloroquine and hydroxychloroquine in COVID-19: critical assessment and recommendation for future clinical trials. 1
- 763 Global Pandemic Conditions and List of Possible Medications and Vaccines for the Treatment of COVID-19: A Review. **2020**, 3, 90-102 1
- 762 Combating Outbreak of nCoV-19: Prevention Strategies, Possible Medication and Its Predominance in Pakistan. **2020**, 39-45
- 761 In silico multi-epitope vaccine against covid19 showing effective interaction with HLA-B*15:03.
- 760 Hydroxychloroquine plus standard care compared with the standard care alone in COVID-19: a meta-analysis of randomized controlled trials.
- 759 COVID-19 Clinical Research. **2020**, 1, 23-30
- 758 variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19. **2020**,

757	Profil clinique, biologique et radiologique des patients Algériens hospitalisés pour COVID-19: données préliminaires. 2020 , 35, 77	7
756	Hydroxychloroquine and mortality risk of patients with COVID-19: a systematic review and meta-analysis of human comparative studies.	
755	SARS-CoV-2 and hypokalaemia: evidence and implications. 2020 , 9, 587	7
754	Re-tasking the use of pre-existing medications and potential therapeutic options for coronavirus disease (COVID-19): systematic review of clinical studies. 2020 , 14, 109-116	2
753	Mapping the Global Research and Clinical Trials in COVID-19.	1
752	Repurposing of drugs for Covid-19: a systematic review and meta-analysis.	0
751	As Drugs Assemble to Treat SARS-COV-2, Which Drug will Prove Efficacious : A Search for Suitable Drug or Vaccine to Manage COVID-19 Pandemic. 2020 , 1, 1-18	
750	A multi centre randomized open label trial of chloroquine for the treatment of adults with SARS-CoV-2 infection in Vietnam. 2020 , 5, 141	1
749	Global research trend in the treatment of the new Coronavirus diseases (COVID-19) : bibliometric analysis. (Preprint).	
748	Empiric Therapies for COVID-19: Destined to Fail by Ignoring the Lessons of History. 2020 , 15, 434-436	1
747	The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis.	3
746	Expert Opinions on the Most Promising Treatments and Vaccine Candidates for COVID-19: Global Cross-sectional Survey of Virus Researchers in the Early Months of the Pandemic (Preprint).	
745	Adaptive Evolution of Peptide Inhibitors for Mutating SARS-CoV-2. 2020 ,	1
744	Cardiovascular Considerations of Experimental Hydroxychloroquine Therapy on Patients Diagnosed With COVID-19: A Case Series Review. 2020 , 12, e9151	3
743	Adapting for the COVID-19 pandemic in Ecuador, a characterization of hospital strategies and patients.	
742	Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis.	0
741	Evaluation of the current therapeutic approaches for COVID-19: a meta-analysis.	
740	Coronaviral Infection (COVID-19) in Children (Situation on June 2020). 2020 , 17, 162-178	3

- 739 Treatment of Coronavirus Disease 2019: Shooting in the Dark. **2020**, 15, e59 2
- 738 A pragmatic approach and treatment of coronavirus disease 2019 (COVID-19) in intensive care unit. **2020**, 66, 1157-1163 2
- 737 Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine. 2
- 736 Cytokine storm is the cryptic killer behind coronavirus disease-2019 infections, review of the current evidence to identify therapeutic options. **2021**, 32, 57-65 0
- 735 Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.
- 734 Arrhythmias in COVID-19: clinical significance and management. 4, 1
- 733 Comprehensive Systematic Review to Identify putative COVID-19 Treatments: Roles for Immunomodulator and Antiviral Treatments.
- 732 Meta-analysis. **2020**, 8, 73-87
- 731 Review of current clinical management guidelines for COVID-19 with special reference to India. **2020**, 14, 171-176 3
- 730 Trying to Find the Answer for Two Questions in Patients with COVID-19: 1. Is pulmonary infiltrate of COVID-19 infective or inflammatory in nature (Pneumonia or Pneumonitis)? 2. Is Hydroxychloroquine plus Azithromycin or Favipiravir plus Dexamethasone more effective in the COVID-19 treatment?
- 729 Avaliação de tecnologias em saúde: tensões metodológicas durante a pandemia de Covid-19. **2020**, 34, 77-96 1
- 728 Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. **2021**, 73, 233-262 5
- 727 Imaging Findings of COVID-19-Related Cardiovascular Complications.. **2022**, 14, 79-93 0
- 726 Analysis of the antibiotic consumption on the backdrop of the COVID-19 pandemic: hospital level. **2021**, 118-128 1
- 725 El impacto sobre la salud colectiva de las conductas censurables en la investigación sanitaria. **2021**, 1, 33-41
- 724 Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro. **2021**, 22, 7
- 723 On the deformation and frequency analyses of SARS-CoV-2 at nanoscale. **2022**, 170, 103604 2
- 722 First evidence of human-to-dog transmission of SARS-CoV-2 B.1.160 variant in France. **2021**, 3

- 721 Telehealth and Pharmacological Strategies of COVID-19 Prevention: Current and Future Developments. **2022**, 897-927
- 720 Synthesis and potential antimicrobial activity of novel 5-aminophosphonates derivatives bearing substituted quinoline or quinolone and thiazole moieties. **2021**, 1-15 2
- 719 COVID-19 Drug Repositioning: Present Status and Prospects. **2022**, 645-671 0
- 718 Immunosuppression for liver transplant recipients during the COVID-19 pandemic. **2021**,
- 717 Cardiovascular Complications Related to COVID-19 Disease. **2020**, 14, 359-365 2
- 716 AI Based Covid19 Analysis-A Pragmatic Approach. **2020**, 191-207
- 715 COVID-19 THERAPY: WHAT HAVE WE LEARNED IN 8 MONTHS?. **2020**, 59, 207-225 0
- 714 In times of COVID-19, epidemiology is a unifying science. **2020**, 66Suppl 2, 27-30 0
- 713 COVID-19 in Pregnancy: A Clinical Review. **2020**, 3, 47-52
- 712 Enteral Medication for the Tube-Fed Patient: Making This Route Safe and Effective. **2021**, 36, 111-132 5
- 711 Screening of Kabasura Kudineer Chooranam against COVID-19 through Targeting of Main Protease and RNA-Dependent RNA Polymerase of SARS-CoV-2 by Molecular Docking Studies. **2021**, 5, 319-331
- 710 Drug-Nutrition Interactions in Infectious Diseases. **2021**, 367-410 2
- 709 Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. **2020**, 1, 16 2
- 708 COVID-19 Treatment at a Glance. **2020**, 21, 438-445 1
- 707 Cardiac Complications in Patients with COVID-19: An Integrative Literature Review. **2020**, 20, 1-13 1
- 706 Progress in the risk assessment of hydroxychloroquine in frail elderly people. **2021**, 4, 53-57
- 705 Outcomes of COVID-19 Patients Hospitalized at Acute Care Services: Real-World Experience in the New York Metropolitan Area During the Early Pandemic Before Initiation of Clinical Trials. **2021**, 29, e88-e96
- 704 Self-Defeating Codes of Medical Ethics and How to Fix Them: Failures in COVID-19 Response and Beyond. **2021**, 21, 4-13 11

- 703 Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India. **2020**, 9, 1888
- 702 Clarithromycin use for adjunct surgical prophylaxis before non-elective cesarean deliveries to adapt to azithromycin shortages in COVID-19 pandemic. **2020**, 15, e0244266 1
- 701 Host-microbe-drug triad: Role of chloroquine/hydroxychloroquine in Covid-19 treatment-focus on inflammatory cytokine inhibition. **2020**, 14, 644-647
- 700 Deep Learning for COVID-19 prediction. **2020**, 3
- 699 The study of cardiotoxicity of hydroxychloroquine and azithromycine combination in hospitalized patients with COVID-19. **2020**, 11, 29-39
- 698 Clinical efficacy of low-dose emetine for patients with COVID-19: a real-world study. **2021**, 4, 53-59 2
- 697 Symptomatic and optimal supportive care of critical COVID-19: A case report and literature review. **2020**, 8, 6173-6181
- 696  COVID-19.
- 695 Major drugs used in COVID-19 treatment: molecular mechanisms, validation and current progress in trials. **2020**, 01, 1
- 694 Content analysis and characterization of medical tweets during the early Covid-19 pandemic.
- 693 Pharmacotherapy of COVID-19: Considerations for Pregnancy and Breastfeeding. **2022**, 7, 1-6 1
- 692 Drug-drug interactions. **2022**, 241-265 0
- 691 COVID-19 and antimicrobial resistance: A cross-study. **2021**, 807, 150873 12
- 690 Theoretical, single crystal and molecular docking analysis of tetrazolo[1,5-a]pyrimidine-6-carboxylate derivatives. **2022**, 1250, 131706 1
- 689 Oral Manifestations of Chloroquine and Hydroxychloroquine: Differential Diagnoses. **2020**, 10, 321-332
- 688 COVID-19 management: who needs electrocardiographic monitoring and why. **2020**, 123, 45
- 687 Therapeutic options in SARS-CoV-2 infection. **2020**, 4, 14
- 686 Clinical trials during the COVID-19 pandemic: Challenges of putting scientific and ethical principles into practice. **2020**, 11, 59-63 6

- 685 nCOVID-19: Its diagnosis, possible preventive measures, therapeutic interventions and management. **2020**, 115-129
- 684 COVID-19. 2
- 683 Chloroquine/hydroxychloroquine in the treatment and prophylaxis of COVID-19 disease. **2020**, 2, 5
- 682 Effect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderate coronavirus disease 2019. **2021**, 25, 184-190 1
- 681 COVID-19 pandemic: Case studies and perspectives. **2020**, 42, 291-297 1
- 680 Glycemic efficacy and safety of hydroxychloroquine in type 2 diabetes mellitus: A systematic review and meta.analysis of relevance amid the COVID-19 pandemic. **2020**, 5, 184 0
- 679 Observations on healthcare workers & SARS-CoV-2 infection. **2020**, 152, 137-138 0
- 678 Rational Drug Usage Suggestion for COVID-19 Patients at Prime Stage. **2020**, 09, 181-185
- 677 Tratamiento de COVID-19 en receptores de trasplante renal. **2020**, 9, 173-187
- 676 Severe Cardiovascular Complications of COVID-19: a Challenge for the Physician. **2020**, 33, 572-581
- 675 Treatment of COVID19 with antimalarial medicines: clinical pharmacology analysis. **2020**, 22, 164-174
- 674 Perspectives on repositioning chloroquine and hydroxychloroquine for the treatment of Covid-19. **2020**, 20, 4-9 1
- 673 Cómo estimar la letalidad del COVID-19. **2020**, 67, 4-8 1
- 672 The Socially Distanced Social Animal - In The New Covid-19 Era. **2020**, 23, S1-S4
- 671 Guía COVID-19 para la atención del paciente crítico con infección por SARS-coV-2 Colegio Mexicano de Medicina Crítica. **2020**, 33, 7-42 5
- 670 Protocolo para la prevención de arritmias ventriculares debido al tratamiento en pacientes con COVID-19. **2020**, 31, 222-228
- 669 Macrolide-Clarithromycin Task-Force for the Treatment and Prophylaxis of Covid-19 as a Single Agent. **2020**, 11, 85-104
- 668 Immunotherapy for the Post-Infectious Sequela of SARS-CoV-2 Infection. **2020**, 10, 117-120 1

- 667 A Review on Probable Lysosomotropic Properties of Sodium Bicarbonate to Restrain Viral Entry of Coronavirus 2 (SARS-CoV-2).
- 666 Infecção por coronavirus em pacientes con diabetes. **2020**, 31, 235-246 1
- 665 Management of COVID-19: A brief overview of the various treatment strategies. **2020**, 3, 233 1
- 664 COVID 19-Fighting an unseen enemy. **2020**, 8, 114
- 663 Controvérsias em torno do uso experimental da cloroquina / hidroxiclорокина contra a Covid-19: âBô magic bulletâ2020, 30,
- 662 Authors' response. **2020**, 152, 138-140
- 661 Hydroxychloroquine: the story of one drug during the COVID-19 pandemic. **2020**, 123, 74
- 660 Cutaneous Virus Infections. **2020**, 1-40
- 659 Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials. **2020**, 20, 350-357
- 658 Coronavirus Disease-2019 Pandemic: Hopes Ride High on Targeting Known Drugs against Unkown. **2020**, 52, 75-78 0
- 657 A comparative analysis of the COVID-19 pandemic response: The case of Turkey. **2020**, 7, 443-451 0
- 656 THE ROLE OF HYDROXYCHLOROQUINE IN THE TREATMENT OF HIV AND COVID-19: A REVIEW.. **2020**, 9, 20-29
- 655 Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment. **2020**, 61, 321-334 1
- 654 Management of COVID infection. **2020**,
- 653 Basic Critical Care for Management of COVID-19 Patients: Position Paper of Indian Society of Critical Care Medicine, Part-I. **2020**, 24, S244-S253 0
- 652 Changing drug regimen during COVID-19 pandemic lockdown: An experience from a Tertiary Eye Care Hospital as a cornea specialist. **2020**, 52, 435-436 0
- 651 Searching an Effective Therapy for the Coronavirus Pandemic: Do We See Light at the End of the Tunnel?. **2020**, 12, e7415 1
- 650 OTOTOXICITY OF DRUGS USED IN THE TREATMENT OF COVID-19. **2020**, 10, 9-20 0

649	Evidence Based Treatment of SARS-CoV2: A Narrative Review. 2020 , 21, 221-222	1
648	TRATAMENTO DO COVID-19 COM MEDICAMENTOS EXPERIMENTAIS EM TESTES CLÍNICOS: DESAFIOS E PERSPECTIVAS. 2020 , 32, 3-5	2
647	Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population.	1
646	Editor Responsibility and Scientific Integrity During the COVID-19 Outbreak. 2020 , 37, 176-177	1
645	COVID-19 (SARS Cov-2) Tedavisi.	1
644	COVID-19 and Heart Disease. 2020 , 7,	
643	COVID-19 (An International Trauma): A Brief Analysis on Research Trends, Impacts and Solutions. 2020 , 07, 1-8	1
642	Capturing the surge of public interest towards Hydroxychloroquine, Azithromycin and BCG vaccine during COVID-19 Pandemic (Preprint).	
641	Repositioned chloroquine and hydroxychloroquine as antiviral prophylaxis for COVID-19: A protocol for rapid systematic review of randomized controlled trials.	
640	SARS-Cov-2 Viral Kinetics in Mild COVID-19 Patients Treated with Chloroquine Regimens or Standard of Care. 2021 , 3, 1-14	
639	Effects of hydroxychloroquine and its metabolites in patients with connective tissue diseases. 2021 , 29, 1795-1805	
638	An Update on Pharmacological Relevance and Chemical Synthesis of Natural Products and Derivatives with Anti SARS-CoV-2 Activity.. 2021 , 6, 11502-11527	3
637	Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. 2021 , 10, 294	0
636	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. 2021 , 25, 101417	1
635	Surface modification of thin-film nanocomposite forward osmosis membrane with super-hydrophilic MIL-53 (Al) for doxycycline removal as an emerging contaminant and membrane antifouling property enhancement. 2021 , 133469	0
634	The immunomodulatory effects of macrolide antibiotics in respiratory disease. 2021 , 71, 102095	5
633	COVID-19-Associated acute respiratory distress syndrome (CARDS): Mechanistic insights on therapeutic intervention and emerging trends. 2021 , 101, 108328	2
632	Clinical features and mechanistic insights into drug repurposing for combating COVID-19. 2021 , 142, 106114	6

631	Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine. 2021 ,	2
630	Inadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy. 2021 , 21, 1144	10
629	A short focus, azithromycin in the treatment of respiratory viral infection COVID-19: efficacy or inefficacy?. 2021 , 1	1
628	Identification and Development of Therapeutics for COVID-19. 2021 , e0023321	5
627	Interaction between favipiravir and hydroxychloroquine and their combined drug assessment: in silico investigations. 2021 , 1-8	5
626	Signals were broadly positive for months, but never definitive: the tocilizumab story. 2021 ,	1
625	Recent scientific research progress and challenges of COVID-19 pandemic: a global public health event.	
624	Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. 2021 , 3, e0566	0
623	Efficacy of chloroquine and hydroxychloroquine in treating COVID-19 infection: a meta-review of systematic reviews and an updated meta-analysis.	1
622	COVID-19'DA SIKOKU SALINIM SENDROMU VE TEDAVI YAKLAMALARI. 55-59	
621	COVID-19 Hastalıkları Fizyopatolojisi ve Holistik Hemirelik Yaklaşımı. 15-24	1
620	FARMACOS ANTIMICROBIANOS E ANTIVIRAIS COM POTENCIAL USO TERAPUTICO PARA A COVID-19. 2020 , 32, 109-119	
619	Treatment of Severe Acute Respiratory Syndrome Coronavirus 2: It Is Time to Produce Our Own Evidence Base. 2020 , 21, 283-284	
618	Discussing Evidence in the Fog of the Pandemic. 2020 , 29, 246-248	1
617	A Patient with COVID-19 Pneumonia Who Developed Ventricular Fibrillation during Treatment with Hydroxychloroquine, Azithromycin and Favipiravir. 2020 , 94, 600-603	
616	COVID-19 Management: What We Need to Know?. 2020 , 41, 441-445	
615	Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir. 2020 , 6, e19538	0
614	Going Further: Comprehensive Disease Control of Rheumatoid Arthritis, Targeting Cytokines and Chemokines. 2021 , 27, e432-e439	0

- 613  COVID-19:  1
- 612 Acute COVID-19 Infection in a Pediatric Patient with ROHHAD. 1
- 611 Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?. **2020**, 28, 246-247 1
- 610 COVID-19 and Uncertainty: Lessons from the Frontline for Promoting Shared Decision Making. **2020**, 115, 149-151 1
- 609 COVID-19: A review of the pandemic with emphasis on the role of imaging. **2020**, 41, 640-651
- 608 What is Efficacy of Chloroquine/Hydroxychloroquine in Clinical Cure of SARS-CoV 2?; Evidence From an Iranian Population. **2020**, 7,
- 607 Potential Drugs for Treating COVID-19 Infection. **2020**, 7,
- 606 Saudi Heart Rhythm Society Task Force on Management of Potential Arrhythmogenicity Associated with Pharmacotherapy for COVID-19. **2020**, 40, 365-372 0
- 605 Evidence and decision-making in times of pandemic. **2020**, 48, 0
- 604 Core Concept: The pandemic is prompting widespread use-and misuse-of real-world data. **2020**, 117, 27754-27758 3
- 603 Change of opinion on the use of hydroxychloroquine for COVID-19 treatment and prevention. **2020**, 90-91
- 602 A Flare of Lupus Nephritis in an 11-Year-Old SLE Patient with a Mild COVID-19-Associated Pneumonia. **2020**, In Press,
- 601 Maxingshigan decoction for treating COVID-19: A protocol for systematic review and meta analysis. **2020**, 99, e23224 2
- 600 Management of Irrational Self-Purchase of Hydroxychloroquine During the COVID-19 Pandemic: Experiences From the Largest Healthcare System in Taiwan. **2021**, 17, e43-e44
- 599 Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients.
- 598 Differences and similarities in diagnostic methods and treatments for Coronavirus disease 2019 (COVID-19): a scoping review.
- 597 Personalized Prescription of ACEI/ARBs for Hypertensive COVID-19 Patients.
- 596 The efficacy and safety of hydroxychloroquine in COVID19 patients : a multicenter national retrospective cohort.

- 595 Predictors of QT Interval Prolongation in Critically-ill Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine.
- 594 Hydroxychloroquine and the risk of respiratory infections among RA patients. **2020**, 6, 1
- 593 Diabetes mellitus and COVID-19: current issues of pathogenesis, clinic and therapy. Literature review. **2020**, 8-21 1
- 592 The Comprehensive Appraisal of COVID-19: Its Clinical Panorama from Virology till Management and Beyond. **2020**, 1, 57-72 0
- 591 The effects and reliability of the hydroxychloroquine-azithromycin combination on the cardiac conduction system in patients with coronavirus disease 2019. **2020**, 4, 1082-1085
- 590 COVID-19 ON BEHET'S DISEASE PATIENT : SHED LIGHT ON SHADOWS (CASE REPORT). **2020**, 8, 49-52
- 589 Farmacoterapia aplicada ^ COVID-19. 58-81
- 588 Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients. **2021**, 11, 6-7 0
- 587 COVID-19: Clinical Characteristics and Molecular Levels of Candidate Compounds of Prospective Herbal and Modern Drugs in Indonesia. **2020**, 26, S12-S23 2
- 586 Investigational Drugs for the COVID 19 Pandemic –A Concise Review. **2020**, 26, S36-S48
- 585 A Summary of Coronavirus Disease 2019: What We Should Know?. **2020**, 26, S24-S35
- 584 Analysis of Structure, Mechanism of Action and Efficacy of Potential and Ideal COVID-19 Treatments. **2020**, 1, 197-208
- 583 The Role of Hydroxychloroquine in COVID-19 Treatment: A Systematic Review and Meta-Analysis. **2020**, 1
- 582 Therapeutic options in the treatment of severe acute respiratory syndrome coronavirus 2 in pregnant patient. **2020**, 2, 100224 0
- 581 Drug Re-purposing from SARS-CoV Led the Identification of Potential Candidate Drug Target and Alternate Drug Molecules Against SARSCoV- 2. **2020**, 17, 1325-1327 1
- 580 New insights on potential therapeutic options and vaccines for corona virus disease-2019. **2021**, 32, 67-74
- 579 Current Status and Prevention of COVID-19?What Do We Know?. 1-7
- 578 Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness.

577 Hydroxicloroquine for Pre-Exposure Prophylaxis for SARS-COV-2.

576 Arylpyrazoles: Heterocyclic Scaffold of Immense Therapeutic Application. **2020**, 24, 1555-1581

1

575 The clinical manifestations and interval changes of reverse-transcriptase quantitative polymerase chain reactions among different specimens of coronavirus disease 2019 patients. **2021**, 84, 151-157

0

574 Predicting clinical outcome with phenotypic clusters in COVID-19 pneumonia: an analysis of 12,066 hospitalized patients from the Spanish registry SEMI-COVID-19.

573 Hydroxychloroquine (HCQ) reverses anti-PD-1 immune murine checkpoint blockade: TCF1 as a marker in humans for COVID-19 and HCQ therapy.

572 COVID-19 and Cancer Patients. **2020**, 3, 40-48

6

571 Antiviral Therapy during the Coronavirus Disease (COVID-19) Pandemic: Is It Appropriate to Treat Patients in the Absence of Significant Evidence?. **2020**, 73, 167-170

2

570 Clinical interventions for severe and critical COVID-19: what are the options. **2020**, 12, 2110-2117

2

569 Management of Leprosy in the Context of COVID-19 Pandemic: Recommendations by SIG Leprosy (IADVL Academy). **2020**, 11, 345-348

10

568 Hydroxychloroquine in Dermatology and Beyond: Recent Update. **2020**, 11, 453-464

5

567 Glucocorticoids in COVID19; a friend not foe. **2020**, 25, 45

2

566 COVID 19: A Clinical Primer-Overview and Plaquenil/Zithromax. **2020**, 19, 12-14

565 Pharmacological approaches to the treatment of COVID-19 patients. **2020**, 6,

564 Implications of SARSr-CoV 2 infection in thalassemias: Do patients fall into the "high clinical risk" category?. **2020**, 91, 50-56

7

563 Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View. **2020**, 19, 112-121

562 Investigating the factors affecting the survival rate in patients with COVID-19: A retrospective cohort study. **2020**, 34, 88

3

561 Is there a place for anti-inflammatory therapy in COVID-19?. **2020**, 12, 7076-7080

560 Therapeutic strategies against COVID-19. **2020**, 91, e2020038

2

559	Diagnostic and Therapeutic Approaches to Novel COVID-19 in Intensive Care Unit: A Narrative Review. 2020 , 48, 443-453	
558	The Danger of Misinformation in the COVID-19 Crisis. 2020 , 117, 510-512	1
557	Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review. 2020 , 19, 258-281	1
556	A brief review of the latest pharmacological treatments of COVID-19. 2020 , 11, 460-465	
555	Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?. 2020 , 12, 7702-7708	4
554	Cardiovascular Complications of COVID-19 and Associated Concerns: A Review. 2021 , 37, 9-17	1
553	[A retrospective analysis of medication in children with SARS-CoV-2 infection in Wuhan, China]. 2021 , 23, 61-66	2
552	The Pathogenesis and Treatment of COVID-19: A System Review. 2021 , 34, 50-60	3
551	Cardiovascular Manifestations of COVID-19. 2020 , 21, 171-186	3
550	Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial. 2020 , 91, e2020102	8
549	It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. 2021 , 17, 546-550	
548	Medication use during COVID-19: Review of recent evidence. 2021 , 67, 171-179	1
547	. 2021 , 67, e69-e78	
546	Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials. 2021 , 11, 93-107	9
545	SARS-CoV-2 infection in pediatric population. 2020 , 91, e2020003	5
544	Chemo-Preventive Effect of Vegetables and Fruits Consumption on the COVID-19 Pandemic. 2021 , 4,	1
543	Knowledge, risk perception and adherence to COVID-19 prevention advisory among police officers in Makurdi Metropolis Benue State, 2020. 2021 , 38, 199	
542	Coronavirus Disease and Cardiovascular Disease: A Literature Review. 2021 , 7, 156-162	2

- 541 Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An approach. **2021**, 153, 132-143
- 540 A Narrative Review of Antiviral Drugs Used for COVID-19 Pharmacotherapy. **2021**, 13, 163-171 1
- 539 Prophylactic Medications Taken by Healthcare Workers for COVID-19; A Mixed Methods Study from South India. **2021**, 12, 90
- 538 Clinical Evidences and Pathophysiology of Cardiac Arrhythmia in the Era of Coronavirus Disease-2019. **2021**, 22, 121-126
- 537 Computational methods directed towards drug repurposing for COVID-19: advantages and limitations.. **2021**, 11, 36181-36198 2
- 536 A comparative study of HPLC and UV spectrophotometric methods for remdesivir quantification in pharmaceutical formulations. **2021**, 15, 507-513 4
- 535 Kittens and Jesus : What would remain in a newsless Facebook?.
- 534 Treatment and therapeutic agents. **2022**, 121-176
- 533 Hydroxychloroquine treatment on SARS-CoV-2 receptor ACE2, TMPRSS2 and NRP1 expression in human primary pterygium and conjunctival cells. **2021**, 214, 108864 0
- 532 Introduction to COVID-19. **2022**, 3-16 0
- 531 The potential of drug delivery nanosystems to treat COVID-19. **2022**, 307-337
- 530 Socio-economic impact of COVID-19. **2022**, 153-190 4
- 529 Delineating the impact of COVID-19 on antimicrobial resistance: An Indian perspective. **2021**, 151702 0
- 528 Off-label use of hydroxychloroquine in COVID-19: analysis of reports of suspected adverse reactions from the Italian National Network of Pharmacovigilance. **2021**, 1
- 527 Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. **2021**, 22, 304 0
- 526 Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. **2021**, 2021, 4078713 1
- 525 Application of the Pluripotent Stem Cells and Genomics in Cardiovascular Research-What We Have Learnt and Not Learnt until Now. **2021**, 10, 1
- 524 Current status of therapeutic approaches and vaccines for SARS-CoV-2. **2021**, 2

523	Treatment of SARS-CoV-2 (COVID-19): A safety perspective. 2021 , 10, 1-32	0
522	Role of lipid Nanoparticles in COVID-19 inrepurposing drugs and vaccines. 2021 , 17,	
521	[Citation misuse and its effects on public health]. 2021 , 37, 1035-1041	1
520	Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. 2021 , 71, 39	3
519	Demographic and Clinical Features Associated with in-Hospital Mortality in Egyptian COVID-19 Patients: A Retrospective Cohort Study. 2021 , 9, 1068-1075	0
518	Mutual Pan-African support paradigm to produce scientific evidence of traditional medical practices for use against COVID-19 and emerging pandemics. 2021 , 14, e01046	1
517	COVID-19, Pre-Eclampsia, and Complement System. 2021 , 12, 775168	5
516	TREATMENT PATTERN OF COVID-19 PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL OF NORTHERN INDIA. 48-51	1
515	Effects of hypertonic alkaline nasal irrigation on COVID-19.. 2021 , 6, 1240	1
514	Recent Updates in Experimental Research and Clinical Evaluation on Drugs for COVID-19 Treatment. 2021 , 12, 732403	2
513	Misinformation: an empirical study with scientists and communicators during the COVID-19 pandemic.. 2021 , 5, e100188	0
512	Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation. 2021 ,	1
511	Therapies to Prevent Progression of COVID-19, Including Hydroxychloroquine, Azithromycin, Zinc, and Vitamin D3 With or Without Intravenous Vitamin C: An International, Multicenter, Randomized Trial.. 2021 , 13, e19902	2
510	A Narrative Review of Existing Options for COVID-19-Specific Treatments. 2021 , 2021, 8554192	
509	Pharmaceutical messianism and the COVID-19 pandemic. 2021 , 292, 114567	2
508	Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV. 2021 , 16, 1341-1370	9
507	Efficacy of chloroquine and hydroxychloroquine for the treatment of hospitalized COVID-19 patients: a meta-analysis. 2021 ,	2
506	Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. 2021 , 16, 1415-1451	1

505	Knowledge and perceptions of pharmacists' readiness during coronavirus pandemic: the case of United Arab Emirates. 2021 , 14, 102	1
504	Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An approach. 2020 , 153,	1
503	Management of leprosy in the context of COVID-19 pandemic: Recommendations by SIG leprosy (IADVL academy). 2020 , 11, 345	14
502	Hydroxychloroquine in dermatology and beyond: Recent update. 2020 , 11, 453	10
501	Reversible blurred vision with hydroxychloroquine in a COVID-19 patient. 2021 , 59, 404	
500	Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials. 2021 , 3, 85-88	
499	A review on molecular docking analysis of phytocompounds against SARS-CoV-2 druggable targets. 2021 , 14, 1100-1128	1
498	Top 100 cited articles in one year of COVID-19 research - A bibliometric analysis.. 2021 , 65, 375-379	
497	COVID-19 in hemodialysis patients: Experience from a Western Indian center. 2021 ,	0
496	Arrhythmias in COVID-19.. 2021 , 17, 73-82	3
495	COVID-19, An early investigation from exposure to treatment outcomes in Tehran, Iran.. 2021 , 26, 114	2
494	Study of epidemiological, clinical and evolutionary characteristics of a population of patients hospitalized for COVID-19 in Morocco. 2021 , 319, 01035	
493	COVID-19 in Patients with Myasthenia Gravis: Mechanisms of Respiratory Failure.. 2021 , 69, 1772-1776	2
492	Almost two years with COVID-19: some aspects of antibiotic use. 2021 , 23, 248-253	0
491	Safety profile assessment of drug products used for the pathogenetic treatment of COVID19. 2021 , 23, 314-329	
490	Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications.. 2022 , 98, 153930	2
489	The landscape of antibiotic usage among COVID-19 patients in the early phase of pandemic: a Malaysian national perspective.. 2022 , 15, 4	4
488	Translational Modeling of Chloroquine and Hydroxychloroquine Dosimetry in Human Airways for Treating Viral Respiratory Infections.. 2022 , 39, 57	0

- 487 Thermodynamic properties of active pharmaceutical ingredients that are of interest in COVID-19. **2022**, 37, 100820
- 486 COVID-19: Invasion, pathogenesis and possible cure - A review.. **2022**, 300, 114434 2
- 485 Application of activated carbon functionalized with graphene oxide for efficient removal of COVID-19 treatment-related pharmaceuticals from water. **2021**, 289, 133213 6
- 484 A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.. **2021**, 146, 112550 4
- 483 Zinc ionophores: chemistry and biological applications.. **2021**, 228, 111691 1
- 482 Pharmaceutical compounds used in the COVID-19 pandemic: A review of their presence in water and treatment techniques for their elimination.. **2021**, 152691 7
- 481 Efficacy and safety of Hydroxychloroquine in treating COVID-19 pneumonia: uncertainty of data and changing treatment protocols. **2020**, 7, 51-54 1
- 480 It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?. **2020**, 17, 546-550 0
- 479 Diagnostic and Therapeutic Approaches to Novel COVID-19 in Intensive Care Unit: A Narrative Review. **2020**, 48, 443-453
- 478 Is there a place for anti-inflammatory therapy in COVID-19?. **2020**, 12, 7076-7080
- 477 COVID-19 and Diabetes Mellitus: A Life Threatening Reciprocal Association. **2021**, 12, 104-109
- 476 Searching and designing potential inhibitors for SARS-CoV-2 Mpro from natural sources using atomistic and deep-learning calculations.. **2021**, 11, 38495-38504 2
- 475 The Importance of Glycosylation in COVID-19 Infection. **2021**, 1325, 239-264 3
- 474 COVID-19: A Catalyst for Transforming Randomized Trials. **2022**, 34, 107-112 0
- 473 Immunoinformatics approaches to design: A novel multi-epitope vaccine candidate against SARS-CoV-2 and its *in silico* expression (Preprint).
- 472 Immunity-Boosting Natural Herbs to Combat COVID-19 Pandemic: A Narrative Review. **2021**, 4, 260-272
- 471 DIABETES COVID -19.
- 470 Negative Nasopharyngeal SARS-CoV-2 PCR Conversion in Response to Different Therapeutic Interventions.. **2022**, 14, e21442 2

469	Examination of Medication Use Patterns by Age Group, Comorbidity, and Month in COVID-19 Positive Patients in a Large Statewide Health System During the Pandemic in 2020.. 2022 , 38, 75-87	0
468	Mesenchymal Stem Cell-Based COVID-19 Therapy: Bioengineering Perspectives.. 2022 , 11,	0
467	Liver Injury in Patients Hospitalized for COVID-19: Possible Role of Therapy.. 2022 , 10,	2
466	Insights on Epidemiology, Pathogenesis, Diagnosis and Possible Treatment of COVID-19 Infection.. 2022 , 1-9	0
465	High SARS-CoV-2 Prevalence among Healthcare Workers in Cochabamba, Bolivia.. 2022 , 14,	0
464	Naturally occurring anthraquinones as potential inhibitors of SARS-CoV-2 main protease: an integrated computational study.. 2022 , 77, 1-14	1
463	Cross-species virus transmission and its pandemic potential.. 2022 , 46, 18	0
462	Adverse Effects of COVID-19 Treatments: A Special Focus on Susceptible Populations. 2022 ,	
461	Repurposing Novel Antagonists to p7 Viroporin of HCV Using in silico Approach. 2022 , 19,	
460	Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases.. 2022 , 12, 1075	3
459	Novel antiviral effects of chloroquine, hydroxychloroquine, and green tea catechins against SARS-CoV-2 main protease and 3C-like protease for COVID-19 treatment.. 2022 ,	3
458	Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro. 2021 , 53, 116523	1
457	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy.. 2022 , 18, 459-472	7
456	First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy.. 2022 , 12, e054069	0
455	Repurposing Covid-19 Drug : Current Issues. 2022 , 13, 9-16	
454	Comparison of Maternal, Perinatal, and Neonatal Outcomes of Asymptomatic and Symptomatic Pregnant Women with Coronavirus Disease-2019.. 2022 , 37, 44-53	
453	The use of convalescent plasma therapy in the management of a pregnant woman with COVID-19: a case report.. 2022 , 20, eRC6550	
452	LC-MS/MS Method for Determination of Hydroxychloroquine and Metabolites: Application in a Pharmacokinetic Study.. 2022 , 2022, 6058445	0

451	Comparisons of treatment protocols for SARS-CoV-2 in early pandemic: Single center experience in Turkey. 2022 , 12, 1-1	
450	SARS-CoV-2 and the Host Cell: A Tale of Interactions. 2022 , 1,	3
449	Modelling upper respiratory viral load dynamics of SARS-CoV-2.. 2022 , 20, 25	1
448	ENT Manifestations in Patients Suffering from COVID-19: Study from a COVID Hospital in North India.. 2022 , 26, e148-e151	0
447	A Peek into Pandora's Box: COVID-19 and Neurodegeneration.. 2022 , 12,	0
446	An overview on the current available treatment for COVID-19 and the impact of antibiotic administration during the pandemic.. 2021 , 55, e11631	1
445	Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis.. 2022 ,	1
444	EVALUATION OF THE THERAPEUTIC EFFECTS OF COMBINED HYDROXYCHLOROQUINE AND AZITHROMYCINE IN PATIENTS WITH COVID-19.	0
443	"The new normal"? Lessons from the treatment of emerging infectious diseases with old drugs.. 2022 , 41, 165-165	
442	In silico Design and Characterization of Multi-epitopes Vaccine for SARS-CoV2 from Its Spike Protein.. 2022 , 28, 37	
441	Hydroxychloroquine for COVID-19: Variation in Regional Political Preferences Predicted New Prescriptions after President Trump's Endorsement.. 2022 ,	0
440	Stem cells or their exosomes: which is preferred in COVID-19 treatment?. 2022 , 1	1
439	Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children.. 2022 , 1	0
438	Insight into COVID-19's epidemiology, pathology, and treatment.. 2022 , 8, e08799	6
437	Predictive factors of clinical outcomes in patients with COVID-19 treated with tocilizumab: A monocentric retrospective analysis.. 2022 , 17, e0262908	0
436	Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWN-AZITHRO).. 2022 , 8,	1
435	A review on covid-19: From molecular variability, drug development to status of vaccine clinical trials. 2022 , 12, 55-71	
434	Azithromycin consumption during the COVID-19 pandemic in Croatia, 2020.. 2022 , 17, e0263437	4

433 MOLECULAR DOCKING OF GANOMESTENOL WITH SARS-COV-2 MPRO. 46-47

432 The p97 Inhibitor UPCDC-30245 Blocks Endo-Lysosomal Degradation.. **2022**, 15,

0

431 The "Invisible Enemy" SARS-CoV-2: Viral Spread and Drug Treatment.. **2022**, 58,

0

430 Changes in QTc interval after hydroxychloroquine therapy in patients with COVID-19 infection: a large, retrospective, multicentre cohort study.. **2022**, 12, e051579

1

429 Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges.. **2022**, 11, 20

1

428 Ocular Manifestations in Patients with Coronavirus Disease 2019 (COVID-19): A Real World Multicenter Observational Study in Egypt. **2022**, 16,

0

427 "H" is not for hydroxychloroquine-"H" is for heparin: lack of efficacy of hydroxychloroquine and the role of heparin in COVID-19-preliminary data of a prospective and interventional study from Brazil.. **2022**, 22, 120

0

426 Ocular Manifestations in Patients with Coronavirus Disease 2019 (COVID-19): A Real World Multicenter Observational Study in Egypt. **2022**, 16,

425 COVID-19: comprehensive review on mutations and current vaccines. **2021**, 204, 8

5

424 Cholesterol-Rich Lipid Rafts as Platforms for SARS-CoV-2 Entry.. **2021**, 12, 796855

5

423 Antibiotic Prescribing Trends in Belgian Out-of-Hours Primary Care during the COVID-19 Pandemic: Observational Study Using Routinely Collected Health Data.. **2021**, 10,

4

422 Identification of Repurposable Drugs and Adverse Drug Reactions for Various Courses of COVID-19 Based on Single-Cell RNA Sequencing Data. **2020**,

421 Identification and Development of Therapeutics for COVID-19. **2021**,

420 Management of COVID-19 in the Intensive Care Unit.. **2021**, 1353, 81-89

419 Toll-Like Receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective.. **2021**, 1352, 87-109

1

418 Mucormycosis of the bones of the facial skull, nasal cavity and paranasal sinuses in patients with COVID19. **2021**, 23, 347-358

3

417 TREATMENT OF MYASTHENIA GRAVIS PATIENTS WITH COVID-19: REVIEW OF THE LITERATURE.. **2022**, 60, 496-509

0

416 The QTc interval and treatment outcome of inpatients with COVID-19. **2021**, 18, 63-73

- 415 DIAGNOSIS AND TREATMENT OF COVID-19 PATIENTS ADMITTED TO THE PEDIATRIC INTENSIVE CARE UNIT IN OUR CENTER. **2021**, 10, 26-31
- 414 Biological Activities of Some Natural Compounds and Their Cytotoxicity Studies against Breast and Prostate Cancer Cell Lines and Anti-COVID19 Studies.. **2022**, 71, 587-597 1
- 413 Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. **2022**, 205-226
- 412 The Role of Hyaluronic Acid in Tissue Engineering. **2022**, 1063-1116
- 411 Brief History, Pathophysiology, Transmission of SARS-CoV-2 Virus, and Recent Advances on Transition Metal Complexes and Nanocomposites as the Potent Antiviral Agents from COVID-19 Perspectives. **2022**, 1-48
- 410 Demand of COVID-19 medicines without prescription among community pharmacies in Jodhpur, India: Findings and implications.. **2022**, 11, 503-511 1
- 409 Computer-aided discovery, design, and investigation of COVID-19 therapeutics. **2022**, 0
- 408 SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants.. **2022**, 11, 4
- 407 Modeling the impact of the COVID -19 outbreak on environment, health sector and energy market. 0
- 406 Synergistic Adverse Effects of Azithromycin and Hydroxychloroquine on Human Cardiomyocytes at a Clinically Relevant Treatment Duration.. **2022**, 15, 1
- 405 Polymeric nanoparticles and nanomicelles of hydroxychloroquine co-loaded with azithromycin potentiate anti-SARS-CoV-2 effect.. **2022**, 1-19 0
- 404 NF- κ B Signaling and Inflammation-Drug Repurposing to Treat Inflammatory Disorders?. **2022**, 11, 0
- 403 Efficacy of repurposed antiviral drugs: Lessons from COVID-19.. **2022**, 2
- 402 Analytical Methods for the Determination of Major Drugs Used for the Treatment of COVID-19. A Review.. **2022**, 1-35 0
- 401 COVID-19: A systematic review and update on prevention, diagnosis, and treatment.. **2022**, 3, e115 2
- 400 COVID-19 in HIV-positive patients: A systematic review of case reports and case series.. **2022**, e24308 4
- 399 -Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.. **2022**, 58, 1
- 398 . **2022**,

- 397 Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application.. **2022**, 15, 0
- 396 Reporting COVID-19 preprints: fast science in newspapers in the United States, the United Kingdom and Brazil.. **2022**, 27, 957-968 1
- 395 Prolonged fecal shedding of SARS-CoV-2 in a young immunocompetent COVID-19 patient: a case report and literature overview.. **2022**, 0
- 394 Social Media and COVID-19-Perceptions and Public Deceptions of Ivermectin, Colchicine and Hydroxychloroquine: Lessons for Future Pandemics.. **2022**, 11, 3
- 393 Evolution of prescribing practices and outcomes in the COVID-19 pandemic in metropolitan areas.. **2022**, 30, 86-95
- 392 Clinical presentation and outcomes of chronic dialysis patients with COVID-19: A single center experience from Greece.. **2022**, 11, 58-72 0
- 391 Synthesis, characterization, theoretical calculation, DNA binding, molecular docking, anticovid-19 and anticancer chelation studies of some transition metal complexes. 1-16 1
- 390 Hydroxychloroquine non-availability during COVID-19 pandemic and its relation to anxiety level and disease activity in rheumatoid arthritis and lupus patients: a cross-sectional study. **2022**, 49,
- 389 Linking genomic and epidemiologic information to advance the study of COVID-19.. **2022**, 9, 121 0
- 388 Can anti-parasitic drugs help control COVID-19?. **2022**, 1
- 387 Clinical Outcomes of Zinc Supplementation Among COVID-19 Patients.. **2022**,
- 386 Clusters of inflammation in COVID-19: descriptive analysis and prognosis on more than 15,000 patients from the Spanish SEMI-COVID-19 Registry.. **2022**, 1 0
- 385 Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.. **2022**, 28, 82 0
- 384 Graphite based sensor amended with fumed silica for electro-detecting Azithromycin. 0
- 383 Recent advances in understanding SARS-CoV-2 infection and updates on potential diagnostic and therapeutics for COVID-19. **2022**, 03,
- 382 Pharmacists' knowledge, attitude and practice in the UAE toward the public health crisis of COVID-19: A cross-sectional study.. **2022**, 20, 2628 0
- 381 Prescribing errors in post - COVID-19 patients: prevalence, severity, and risk factors in patients visiting a post - COVID-19 outpatient clinic.. **2022**, 22, 35 0
- 380 Pharmacological consideration of COVID-19 infection and vaccines in pregnancy.. **2022**, 1

- 379 Antiviral Potential of Indian Medicinal Plants Against Influenza and SARS-CoV: A Systematic Review. **2022**, 17, 1934578X2210869 2
- 378 COVID-19 Drug Repurposing: A Network-Based Framework for Exploring Biomedical Literature and Clinical Trials for Possible Treatments.. **2022**, 14, 1
- 377 Cardiac arrest and coronavirus disease 2019.. **2022**, 0
- 376 Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.. **2022**, 14, 97-115
- 375 Repurposing drugs as COVID-19 therapies: a toxicity evaluation.. **2022**, 0
- 374 Prognosis and treatment of complications associated with COVID-19: a systematic review and meta-analysis. **2022**, 1, 0
- 373 Care of the Hepatology Patient in the COVID-19 Era.. **2022**, 1-12 0
- 372 Signal of safety due to adverse drug reactions induced by tacrolimus with or without azithromycin.. **2022**, 0
- 371 Anti-COVID-19 potential of (Neem) leaf extract.. **2022**, 16, e01184 0
- 370 Targeting natural products against SARS-CoV-2.. **2022**, 1 2
- 369 Methodology and experiences of rapid advice guideline development for children with COVID-19: responding to the COVID-19 outbreak quickly and efficiently.. **2022**, 22, 89
- 368 Coronavirus Disease 2019 and Hypertension: How Anti-Hypertensive Drugs Affect COVID-19 Medications and Vice Versa.. **2022**,
- 367 High-cited favorable studies for COVID-19 treatments ineffective in large trials.. **2022**, 1
- 366 Emergence, evolution, and vaccine production approaches of SARS-CoV-2 virus: benefits of getting vaccinated and common questions.. **2021**, 0
- 365 Bioinformatics and System Biology Approach to Identify the Influences of COVID-19 on Rheumatoid Arthritis.. **2022**, 13, 860676 0
- 364 Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.. **2022**, 99, 105254 2
- 363 Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.. **2022**, 50, 3000605221090363
- 362 Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS).. **2022**, 1 4

- 361 Factors predicting in-hospital all-cause mortality in COVID 19 patients at the Laquintinie Hospital Douala, Cameroon.. **2022**, 47, 102292
- 360 Zinc augments the antiviral potential of HCQ/CQ and ivermectin to reduce the risks of more serious outcomes from COVID-19 infection.. **2022**, 71, 126954 1
- 359 Assessment of Recovery Time, Worsening and Death, among COVID-19 inpatients and outpatients, under treatment with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.. **2022**, 0
- 358 Clinical update on COVID-19 for the emergency and critical care clinician: Medical management.. **2022**, 56, 158-170 2
- 357 The Role of Molecular Modeling and Bioinformatics in Treating a Pandemic Disease: The Case of COVID-19. **2021**, 1, 216-234 0
- 356 A Review Article on the Therapeutic Potential of Medicinal Plants for Prevention and Treatment of secondary infection in patients with COVID-19. **2021**, 08,
- 355 Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases.. **2021**, 13, 1850-1874 1
- 354 Acute respiratory syndrome-2 (SARS-CoV-2): A solution of hydrogen peroxide and sodium bicarbonate as an expectorant for recanalization of the respiratory tract and blood oxygenation in respiratory obstruction (review). **2021**, 19, 383-393
- 353 A sequential test to compare the real-time fatality rates of a disease among multiple groups with an application to COVID-19 data. **2021**, 9622802211061927 0
- 352 Tratamiento farmacológico en pacientes con COVID-19: una revisión integradora. 6, e250
- 351 Outpatient prescription patterns of COVID-19 drugs in the metropolitan area of Mexico City.. **2021**, 1
- 350 Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. **2021**, 39-68
- 349 Antibiotic treatment issues in patients with COVID-19. **2021**, 67, 448-454
- 348 A critical analysis about the supposed role of azithromycin in the treatment of covid-19. **2021**, 11, 11-21
- 347 Real-world response of COVID-19 patients in Mexico.
- 346 Implementation of a fully remote randomized clinical trial with cardiac monitoring. **2021**, 1, 0
- 345 Common Infections and Antibiotic Prescribing during the First Year of the COVID-19 Pandemic: A Primary Care-Based Observational Cohort Study.. **2021**, 10, 1
- 344 A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. 10, 1313 1

- 343 Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial. **2021**, 21, 1218 0
- 342 Clinical trials during the COVID-19 pandemic: research design and lessons. **2021**, 214-231
- 341 ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. **2021**, 3
- 340 Comparison of Computerized Prescription Support Systems in COVID-19 Patients: INTERCheck and Drug-PIN.. **2021**, 4, 3 0
- 339 Computational modeling of human-nCoV protein-protein interaction network.. **2021**, 1
- 338 Hydroxychloroquine (HCQ) Exhibits Better Binding to the Main Protease (Mpro) Compared to Spike Protein (S protein) of SARS-CoV-2: An In-silico Analysis. **2021**, 8, 106-115
- 337 Prediction of Drug-Target Interactions Using Molecular Graph and GDNet-DTI Model. **2021**,
- 336 Current strategies in diagnostics and therapeutics against novel coronavirus disease (COVID-19). **2022**, 72, 171-197 0
- 335 Increased antimicrobial use during COVID-19: The risk of advancing the threat of antimicrobial resistance.. **2021**, 4, e459 1
- 334 Recent Advancements on COVID-19: A Comprehensive Review.. **2021**, 14, 10351-10372 2
- 333 Clinical characteristics and outcomes of COVID-19 in kidney transplant recipients. **2021**, 13, 339-355
- 332 The Overall Scenario of COVID-19-Associated Coagulopathy. **2022**, 87-101
- 331 Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. **2021**, 13, 14 4
- 330 A Systematic Review on the Therapeutic Relevance of Hydroxychloroquine/Chloroquine in the Management of COVID-19. **2021**, 46, 380-388 0
- 329 Bad science in the time of COVID-19. **2020**, 3, 434 0
- 328 Evaluation of the Efficacy of Chloroquine and Hydroxychloroquine in the Treatment of Individuals with COVID-19: A Systematic Review. **2022**, 2111-2116
- 327 COVID-19 Treatment Options and Their Mechanism of Action up to Now: An Overview of Clinical Trials. **2022**, 30, 75-85
- 326 The Significance of Coordinated Research Against SARS-CoV-2. **2022**, 698-713

- 325 Drug safety of frequently used drugs and substances for self-medication in COVID-19.. **2022**, 13, 20420986221094141
- 324 Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease.. **2022**, 12, 4925 5
- 323 Health and science-related disinformation on COVID-19: A content analysis of hoaxes identified by fact-checkers in Spain.. **2022**, 17, e0265995 3
- 322 Malaria Epidemiology and COVID-19 Pandemic: Are They Interrelated?. **2022**, 26, 179-188 1
- 321 Anurans against SARS-CoV-2: A review of the potential antiviral action of anurans cutaneous peptides.. **2022**, 198769 1
- 320 Metoprololâ Potential Beneficial Effects On Covid-19 Patients. 22-29
- 319 Challenges and implementation of the basic education learning continuity plan in the lens of elementary teachers toward enhanced school-based management operation. **2022**, 11,
- 318 Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?.. **2022**, 37, 1077-1082 2
- 317 A Study on Methodologies of Drug Repositioning Using Biomedical Big Data: A Focus on Diabetes Mellitus.. **2022**,
- 316 Children with SARS-CoV-2 infection during the novel coronaviral disease (COVID-19) outbreak in Iran: an alarming concern for severity and mortality of the disease.. **2022**, 22, 382 0
- 315 Development of Evidence-Based COVID-19 Management Guidelines for Local Context: The Methodological Challenges.. **2022**, 2022, 4240378 0
- 314 Development of a Novel Human CD147 Knock-in NSG Mouse Model to Test SARS-CoV-2 Viral Infection.. **2022**, 0
- 313 Very high-resolution remote sensing-based mapping of urban residential districts to help combat COVID-19.. **2022**, 126, 103696 1
- 312 Data_Sheet_1.pdf. **2020**,
- 311 Image_1.TIF. **2020**,
- 310 Table_1.pdf. **2020**,
- 309 Data_Sheet_1.docx. **2020**,
- 308 Data_Sheet_1.docx. **2020**,

307 Data_Sheet_2.docx. **2020**,

306 Image_1.tif. **2020**,

305 Image_2.TIF. **2020**,

304 Image_3.TIF. **2020**,

303 Image_4.TIF. **2020**,

302 Table_1.doc. **2020**,

301 Data_Sheet_1.pdf. **2020**,

300 Table_1.docx. **2020**,

299 Image_1.pdf. **2020**,

298 Image_1.pdf. **2020**,

297 Table_1.docx. **2020**,

296 Image_1.pdf. **2021**,

295 Table_1.docx. **2021**,

294 Table_1.docx. **2020**,

293 DataSheet_1.pdf. **2020**,

292 DataSheet_2.pdf. **2020**,

291 Image_1.pdf. **2020**,

290 DataSheet_1.xlsx. **2020**,

289 Image_1.pdf. **2020**,

288 DataSheet_1.docx. **2020**,

287 Table_1.xlsx. **2020**,

286 Data_Sheet_1.docx. **2020**,

285 Mechanism of action, resistance, synergism, and clinical implications of azithromycin.. **2022**, e24427

1

284 COVID-19 and Spanish flu-18: review of medical and social parallelisms between two global pandemics.. **2021**, 62, E613-E620

1

283 Higher coronavirus disease-19 mortality linked to comorbidities: A comparison between low-middle income and high-income countries.. **2021**, 10, 377

0

282 A narrative review of antiviral drugs used for COVID-19 pharmacotherapy. **2021**, 13, 163

2

281 Medication use during COVID-19. **2021**, 67, 171-179

2

280 Mdicaments utilis\$ durant la COVID-19. **2021**, 67, e69-e78

279 Update of the recommendations of the Sociedade Portuguesa de Cuidados Intensivos and the Infection and Sepsis Group for the approach to COVID-19 in Intensive Care Medicine.. **2022**, 33, 487-536

278 Clinical update on the use of mesenchymal stem cells in COVID-19.. **2021**, 13, 12195-12205

0

277 Green aspects of photocatalysts during corona pandemic: a promising role for the deactivation of COVID-19 virus.. **2022**, 12, 13609-13627

1

276 Overview of Drug Therapy of COVID-19 with Safety and the Potential Clinical Benefits. **2022**, 17,

275 The Cytokine Storm in COVID-19: The Strongest Link to Morbidity and Mortality in the Current Epidemic. **2022**, 2, 540-552

0

274 Anti-inflammatory and immune therapy in severe coronavirus disease 2019 (COVID-19) patients: An update.. **2022**, 109022

2

273 Cardiac complications in patients with COVID-19: a systematic review. **2022**, 2,

1

272 The effects of combined hydroxychloroquine and azithromycin therapy on QRS wave in COVID-19 patients. **2022**, 6, 483-487

0

- 271 Antimicrobial Dispensing Practice in Community Pharmacies in Russia during the COVID-19 Pandemic. **2022**, 11, 586 2
- 270 Cumulative Incidence and Risk Factors for Severe COVID-19 in French People with Cystic Fibrosis.. **2022**, 0
- 269 A Phase II Study on the Effect of Taurisolo Administered via AEROSol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study.. **2022**, 11, 0
- 268 Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic.. **2022**, 13, 84-100
- 267 Why Trust Raoult? How Social Indicators Inform the Reputations of Experts. **2022**, 36, 299-316 1
- 266 Machine Learning-Based Research for COVID-19 Detection, Diagnosis, and Prediction: A Survey.. **2022**, 3, 286 6
- 265 Recent evidence-based treatments for COVID-19: A Review. **2022**, 20,
- 264 Repurposing of Doxycycline to Hinder the Viral Replication of SARS-CoV-2: From in silico to in vitro Validation. **2022**, 13, 0
- 263 Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study.. **2022**, 17, e0267645 0
- 262 Antibiotics in the prophylaxis of COVID or in the treatment of mild COVID.. **2022**, 68, 553-556
- 261 Teleconsultation in family medicine amid the Covid-19 pandemic: an adequate tool?. **2022**,
- 260 Therapeutic approaches and vaccination in fighting COVID-19 infections: A review.. **2022**, 27, 101619 0
- 259 Delayed intubation is associated with mortality in patients with severe COVID-19: A single-centre observational study in Switzerland.. **2022**, 101092 1
- 258 Hydroxychloroquine and Chloroquine Toxicity as Reported by Medical Toxicologists to the Toxicology Investigators Consortium (ToxIC) Registry.. **2022**, 1
- 257 A novel textual track-data-based approach for estimating individual infection risk of COVID-19.. **2022**, 1
- 256 Hydroxychloroquine safety in Covid-19 vs non-Covid-19 patients: analysis of differences and potential interactions.. **2022**, 1-9 0
- 255 Oxytocin, the panacea for long-COVID? a review.. **2022**, 1
- 254 Hydroxychloroquine and Mortality in SARS-Cov-2 Infection; The HOPE- Covid-19 Registry.. **2022**, 20,

- 253 Topical Repute on Artificial Intelligence-Based Approaches in COVID-19 Supervision. **2022**, 180-210
- 252 Use of hydroxychloroquine and azithromycin combination to treat the COVID-19 infection. **2022**, 12, 44-52 0
- 251 Mapping of new pharmacological alternatives in the face of the emergence of antibiotic resistance in COVID-19 patents treated for opportunistic respiratory bacterial pathogens.. **2022**, 1
- 250 Clinical and Laboratory Differences Between Delta and UK Variants of SARS-CoV-2: B.1.617.2 and B.1.1.7. **2022**,
- 249 Redox aspects of cytotoxicity and anti-neuroinflammatory profile of chloroquine and hydroxychloroquine in serum-starved BV-2 microglia. **2022**, 116084
- 248 Impact of the ABCB1 Drug Resistance Gene on the Risk Factors of Patients with COVID-19 and Its Relationship with the Drugs Used. Volume 15, 2661-2669
- 247 Treatment paradigms in Parkinson's Disease and Covid-19. **2022**,
- 246 Efficacy of COVID-19 treatments among geriatric patients: a systematic review. **2022**, 9, 204993612210956 0
- 245 Pharmaceutics Informatics: Bio/Chemoinformatics in Drug Delivery. **2022**, 705-724
- 244 The relationship between hydroxychloroquine plasma concentration and COVID-19 outcomes in rheumatoid arthritis patients in Saudi Arabia. **2022**, 0
- 243 Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications. 1
- 242 Complementing RNA Detection with Pharmaceutical Monitoring for Early Warning of Viral Outbreaks through Wastewater-Based Epidemiology. 1
- 241 Pharmacometric and electrocardiographic evaluation of chloroquine and azithromycin in healthy volunteers. 1
- 240 A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives. **2022**, 20, 1
- 239 Nauka w czasach pandemii. **2021**,
- 238 Drug combination therapies for SARS-CoV-2 (COVID-19) treatment. **2022**, 181-203
- 237 Herbal Immunomodulators and COVID-19. **2022**, 349-367
- 236 The ethical limits of physicians's autonomy and the Brazilian Federal Council of Medicine. **2022**, 38,

235 Therapeutic options in coronavirus treatment. **2022**, 101-135

234 Current therapeutic strategies to combat coronavirus disease 2019. **2022**, 137-151

233 Understanding COVID-19 Situation in Nepal and Implications for SARS-CoV-2 Transmission and Management. **2022**, 16, 117863022211043

232 COVID-19 outbreak. **2022**, 17-36

231 SARS-CoV-2 vaccine development. **2022**, 227-247

0

230 Investigation on anti-Corona viral potential of Yarrow tea. 1-13

0

229 Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis. Volume 18, 603-617

0

228 Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. **2022**, 7,

3

227 The indiscriminate use of azithromycin during COVID-19 era: A potential driver for antimicrobial resistance. **2022**, 103957

226 COVID-19 tanışyla evde takip edilen hastaların hidroksiklorokin tedavisine uyumları ve geri bildirimleri.

225 A Knowledge Graph Embedding Based Approach to Predict the Adverse Drug Reactions Using a Deep Neural Network. **2022**, 104122

1

224 A prospective longitudinal study evaluating the influence of immunosuppressives and other factors on COVID-19 in autoimmune rheumatic diseases. **2022**, 6,

1

223 Lessons from SARS-CoV-2 and its variants (Review). **2022**, 26,

0

222 Clinical characteristics of patients with COVID-19 in Huangshi, China. **2022**,

221 Impact of Perceived Stress During the SARS-CoV-2 Pandemic on Rheumatoid Arthritis Patients' Disease Activity. Publish Ahead of Print,

0

220 Computing Basis and Dimension of Chloroquine and Hydroxychloroquine by Using Chemical Graph Theory. 1-17

1

219 A computational biology approach for the identification of potential SARS-CoV-2 main protease inhibitors from natural essential oil compounds.. 10, 1313

0

218 Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial. **2022**, 40, 289-295

- 217 Ethical review of off-label drugs during the COVID-19 pandemic. **2022**, 10, 5541-5550
- 216 Robust, Automated Analysis of Electrophysiology in iPSC-Derived Micro-Heart Muscle for Drug Toxicity.
- 215 Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?. **2022**, 15, 739 2
- 214 Co-infecci3n por Chlamydia pneumoniae y SARS-CoV-2: una revisi3n de la literatura. **2022**,
- 213 Medications and Adherence to Treatment Guidelines Among Children Hospitalized With Acute COVID-19.
- 212 Qualitative healthcare worker survey: Retrospective cross-sectional case study on COVID-19 in the African context. **2022**, 79, 103918 0
- 211 Prophylactic use of hydroxychloroquine (HCQS) in COVID-19: A questionnaire-based study in health care professionals. **2022**, 21, 113
- 210 Molecular docking and molecular dynamic simulation approaches for drug development and repurposing of drugs for severe acute respiratory syndrome-Coronavirus-2. **2022**, 207-246 0
- 209 Hydroxychloroquine in a COVID-19 patient on chronic Pregabalin therapy- Is it safe?. **2022**, 38, 127 1
- 208 Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2. **2022**, 451-488
- 207 Repurposing of drugs and leading vaccines work against COVID-19. **2022**, 23, 39-48
- 206 Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey. **2022**, 10, 1284 1
- 205 Development of a novel human CD147 knock-in NSG mouse model to test SARS-CoV-2 viral infection. **2022**, 12, 0
- 204 Indicaci3n y prescripci3n de macr3nticos en una poblaci3n colombiana. **2022**, 42, 302-314 0
- 203 Impact of the COVID-19 Pandemic on Inpatient Antibiotic Consumption in Switzerland. **2022**, 11, 792 1
- 202 Publication practices during the COVID -19 pandemic: Expedited publishing or simply an early bird effect?.
- 201 Early Alterations of QTc in Patients with COVID-19 Treated with Hydroxychloroquine or Chloroquine in Libreville, Gabon. **2022**, 12, 482-490
- 200 Leveraging Real-World Data in COVID-19 Response. 1-33

- 199 Overview of HCQ and Remdesivir on SARS-CoV-2 (COVID-19). o
- 198 Ivermectin role in COVID-19 treatment (IRICT): single-center, adaptive, randomized, double-blind, placebo-controlled, clinical trial. 1-10
- 197 Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. **2022**, 3,
- 196 Blue Patient and Brown Blood: A Case Series. **2022**, 1, 41-43
- 195 Autophagy in health and disease: From molecular mechanisms to therapeutic target. **2022**, 3, 7
- 194 A RECENT REVIEW ON: CORONAVIRUS DISEASE 2019. 17-24 o
- 193 Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. **2022**, 11, 269-297 o
- 192 The rise in antimicrobial resistance: An obscure issue in COVID-19 treatment. **2022**, 2, e0000641 o
- 191 Enhanced antibacterial activity of a novel protein-arginine deiminase type-4 (PADI4) inhibitor after conjugation with a biocompatible nanocarrier. **2022**, 74, 103549
- 190 Allosteric inhibitors of the main protease of SARS-CoV-2. **2022**, 205, 105381 6
- 189 Mild COVID- 19 Infection: Do we have any Effective Drugs? A Narrative Review. **2022**,
- 188 âDonâLook UpâYour ScienceâHerd Immunity or Herd Mentality?. **2022**, 10, 1463
- 187 Reduction in SARS-CoV-2 Oral Viral Load with Prophylactic Mouth Rinse.
- 186 Self-medication against COVID-19 in health workers in Conakry, Guinea. **2022**, 13, o
- 185 Microorganisms in Pathogenesis and Management of Systemic Lupus Erythematosus (SLE). **2022**, 507-551
- 184 Are the Current Processes and Regulations Fit for Purpose to Deliver Novel Therapies During Pandemics? A Perspective on COVID-19 from the UK.
- 183 An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19. o
- 182 Efficacy and safety of etiotropic antiviral therapy in COVID-19 in outpatient patients. **2022**, 23-26 1

181	Smoking, nicotine, and COVID-19. 2022 ,	
180	Investigation of Antibiotic Resistome in Hospital Wastewater during the COVID-19 Pandemic: Is the Initial Phase of the Pandemic Contributing to Antimicrobial Resistance?.	1
179	Tolerability and pharmacokinetic evaluation of inhaled dry powder hydroxychloroquine in healthy volunteers. 2022 , 17, e0272034	0
178	Demarcating Patriotic Science on Digital Platforms: Covid-19, Chloroquine and the Institutionalisation of Ignorance in Brazil. 1-25	2
177	Managing Rheumatic Diseases in COVID-19. 2022 , 32, 159-165	
176	Vascular Implications of COVID-19: Role of Radiological Imaging, Artificial Intelligence, and Tissue Characterization: A Special Report. 2022 , 9, 268	1
175	Environmental and ecotoxicological effects of drugs used for the treatment of COVID 19. 10,	0
174	Azithromycin through the Lens of the COVID-19 Treatment. 2022 , 11, 1063	1
173	Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.	0
172	Immunomodulatory therapies for COVID-19. 9,	0
171	Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review. Volume 15, 4457-4466	2
170	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. 2022 , 28, 2211-2233	
169	Statistical Analysis Methods Applied to Early Outpatient COVID-19 Treatment Case Series Data. 2022 , 2, 1139-1182	0
168	Antibiotics in Paediatrics: A Boon or a Bane?. 2022 , 20,	
167	Neutrophil autophagy and NETosis in COVID-19: perspectives. 1-10	0
166	A review of clinical efficacy data supporting emergency use authorization for COVID -19 therapeutics and lessons for future pandemics.	1
165	Ventricular Tachycardia or Fibrillation Storm in Coronavirus Disease. 2022 , 2022, 1-9	0
164	COVID-19 pandemic: A multidisciplinary perspective on the pathogenesis of a novel coronavirus from infection, immunity and pathological responses. 13,	1

- 163 Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. **2022**, 111, 109161 2
- 162 Emetine in Combination with Chloroquine Induces Oncolytic Potential of HIV-1-Based Lentiviral Particles. **2022**, 11, 2829 0
- 161 Clinical features and outcomes of patients with myasthenia gravis affected by COVID-19: A single-center study. **2022**, 222, 107441 0
- 160 Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses. **2022**, 4, 100054 0
- 159 Emerging impacts of steroids and antibiotics on the environment and their remediation using constructed wetlands: A critical review. **2023**, 451, 138759 0
- 158 In vitro and computational investigations of novel synthetic carboxamide-linked pyridopyrrolopyrimidines with potent activity as SARS-CoV-2-MPro inhibitors. **2022**, 12, 26895-26907 4
- 157 Contribution of Computed Tomography in the Diagnosis of Pulmonary Lesions Due to Coronavirus Disease (SRAS-CoV-2), COVID-19. **2022**, 12, 68-77 0
- 156 Microorganisms as potential source of drug for SARS-CoV-2 (COVID-19). **2022**, 171-189 0
- 155 I believe in science and in all vaccines: Older adult and the intention for a vaccine against COVID-19. **2022**, 5, 108 2
- 154 Clinical Impact of Empirical Antibiotic Therapy in Patients With Coronavirus Disease 2019 Requiring Oxygen Therapy. **2022**, 37, 2
- 153 To investigate the internal association between SARS-CoV-2 infections and cancer through bioinformatics. **2022**, 19, 11172-11194 1
- 152 SARS-CoV-2 in the Environment: Its Transmission, Mitigation, and Prospective Strategies of Safety and Sustainability. **2022**, 260, 0
- 151 COVID-19 and Cardiovascular Manifestations. **2022**, 102-136 0
- 150 Diabetes Mellitus and COVID-19. **2022**, 29-50 0
- 149 A multicenter evaluation of antibacterial use in hospitalized patients through the SARS-Cov-2 pandemic waves. 0
- 148 Imiquimod-induced ROS production causes lysosomal membrane permeabilization and activates caspase-8-mediated apoptosis in skin cancer cells. **2022**, 107, 142-150 0
- 147 Long COVID-19 and the heart: is cardiac mitochondria the missing link?. 0
- 146 Identification of Suitable Drug Combinations for Treating COVID-19 Using a Novel Machine Learning Approach: The RAIN Method. **2022**, 12, 1456 0

- 145 Consumption of Antibiotics in Primary Care Setting before and during COVID-19 Pandemic in Republic of Srpska, Bosnia and Herzegovina. **2022**, 11, 1319 1
- 144 The Effect of Short Treatment with Nigella Sativa on Symptoms, the Cluster of Differentiation (CD) Profile, and Inflammatory Markers in Mild COVID-19 Patients: A Randomized, Double-Blind Controlled Trial. **2022**, 19, 11798 o
- 143 Targeting intracellular Neu1 for Coronavirus Infection Treatment. o
- 142 Review of Hydroxychloroquine Cardiotoxicity: Lessons From the COVID-19 Pandemic. o
- 141 Effect of Graphite Exfoliation Way on the Efficiency of Exfoliated Graphene for the Determination of Hydroxychloroquine in Urine and Waste Water. **2022**, 169, 097505 o
- 140 AMMI Canada Practice Point: Treatments for adults with COVID-19 in 2021â2022. **2022**, 7, 163-169 o
- 139 The impact of COVID-19 on antimicrobial prescription and drug resistance in fungi and bacteria. o
- 138 A Review on Effectiveness of Plasma Therapy in Severe COVID-19 Patients. **2022**, o
- 137 Reacciones adversas a medicamentos utilizados para la COVID-19 en cinco países de América Latina. **2022**, 46, 1 o
- 136 Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture. **2022**, 5, o
- 135 Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia. **2022**, 2022, 1-10 o
- 134 Hydroxychloroquine/chloroquine for the treatment of hospitalized patients with COVID-19: An individual participant data meta-analysis. **2022**, 17, e0273526 o
- 133 Home design features post-COVID-19. **2022**, 69, o
- 132 Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. 6
- 131 A Study on COVID-19, Its Origin, Phenomenon, Variants, and IoT-Based Framework to Detect the Presence of Coronavirus. **2023**, 1-13 o
- 130 Transmission, Medical Consequences, and Prevention/Treatment of COVID-19 Infection. **2021**, 45-67 o
- 129 Candidate Drugs for the Potential Treatment of Coronavirus Diseases. **2021**, 85-114 o
- 128 Computational Modeling of ACE2 Inhibitors for Development of Drugs Against Coronaviruses. **2021**, 615-629 o

127	CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine. 2021 , 36, 99-111	0
126	Design and Development of a Robust CPAP Device for Respiratory Support. 2021 ,	0
125	Citation Misuses in the Biomedical Literature and Its Effects on Public Health. 2022 , 417-426	0
124	La rencontre scientifique-journaliste, une hybridation hasardeuse des cultures professionnelles. 2022 ,	0
123	Protein structure-based in-silico approaches to drug discovery: Guide to COVID-19 therapeutics. 2022 , 101151	3
122	The effect of selective serotonin and norepinephrine reuptake inhibitors on clinical outcome of COVID-19 patients: A systematic review and meta-analysis. 2022 , 5,	1
121	Mechanism of N-0385 blocking SARS-CoV-2 to treat COVID-19 based on molecular docking and molecular dynamics. 13,	0
120	Cellular Landscaping of COVID-19 and Gynaecological Cancers: An Infrequent Correlation. 2022 , 2022, 1-15	0
119	Acute and chronic kidney disease and risk of hospital mortality during COVID-19 pandemic waves in the pre-vaccination era.	0
118	Antiviral and Anti-Inflammatory Plant-Derived Bioactive Compounds and Their Potential Use in the Treatment of COVID-19-Related Pathologies. 2022 , 12, 289-306	1
117	Electrochemical Response of Redox Amino Acid Encoded Fluorescence Protein for Hydroxychloroquine Sensing.	0
116	The Prevalence of Bacterial and Fungal Coinfections among Critically Ill COVID-19 Patients in the ICU in Jordan. 2022 , 2022, 1-8	0
115	The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence. 2022 , 44,	0
114	In silico screening of potential antiviral inhibitors against SARS-CoV-2 main protease. 1-11	0
113	State-of-the-art tools to elucidate the therapeutic potential of TAT-peptide (TP) conjugated repurposing drug against SARS-CoV-2 spike glycoproteins. 2022 , 29,	0
112	COMPREHENSIVE THERAPEUTIC INTERVENTIONS AGAINST SARS-COV-2: A REVIEW AND PROSPECTIVE. 1-12	0
111	Novel Aminophosphonate derivatives synthesis, theoretical calculation, Molecular docking, and in silico prediction of potential inhibition of SARS-CoV-2. 2023 , 1272, 134196	1
110	In silico analysis for such natural compounds and COVID-19. 2023 , 463-489	0

- 109 Attitudes and beliefs regarding the use of herbs and supplementary medications with COVID-19: A systematic review. **2022**, o
- 108 Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD). **2022**, 27, 1
- 107 A country-based review in COVID-19 related research developments. o
- 106 Outpatient purchasing patterns of hydroxychloroquine and ivermectin in the USA and Canada during the COVID-19 pandemic: an interrupted time series analysis from 2016 to 2021. o
- 105 Modeling studies on the role of vitamins B1 (thiamin), B3 (nicotinamide), B6 (pyridoxamine), and caffeine as potential leads for the drug design against COVID-19. **2022**, 28, o
- 104 Arzneimittelnutzung unter Pandemiebedingungen. **2022**, 171-187 o
- 103 Cardiopulmonary and hematological effects of infrared LED photobiomodulation in the treatment of SARS-COV2. **2023**, 238, 112619 o
- 102 An in-silico pharmacophore-based molecular docking study to evaluate the inhibitory potentials of novel fungal triterpenoid Astrakurkurone analogues against a hypothetical mutated main protease of SARS-CoV-2 virus. **2023**, 152, 106433 o
- 101 Chloroquine chaos and COVID-19: Smart delivery perspectives through pH sensitive polymers/micelles and ZnO nanoparticles. **2023**, 16, 104468 o
- 100 An overview of antibiotic and antibiotic resistance. **2023**, 11, 100331 o
- 99 COVID-19 experiences and vaccine confidence among health workers and non-health workers. **2022**, 31, 591 o
- 98 Lessons learned from a global perspective of COVID-19. **2022**, o
- 97 Antiviral activity of amiodarone in SARS-CoV-2 disease. **2022**, 71, 869-875 o
- 96 Analyzing the Difference in the Length of Stay (LOS) in Moderate to Severe COVID-19 Patients Receiving Hydroxychloroquine or Favipiravir. **2022**, 15, 1456 o
- 95 Study In-Silico Oleanane Triterpenoids in Aquilaria spp. as a Covid-19 Antiviral. **2022**, 1104, 012027 o
- 94 A Cross-Sectional Analysis of Self-Medication Patterns during the COVID-19 Pandemic in Ecuador. **2022**, 58, 1678 o
- 93 Homoeopathy as an Adjuvant to Standard Care in Moderate and Severe Cases of COVID-19: A Single-Blind, Randomized, Placebo-Controlled Study. o
- 92 Publication ethics during the Covid times: Reflections on research integrity, authorship, peer review and editorial policies. 35, 177-179 o

91	Fomepizole should not be used more liberally in paracetamol overdose.	0
90	Synthesis, characterization of some substituted Quinolines derivatives : DFT, Computational, in Silico ADME, Molecular Docking and Biological Activities. 2022 , 100977	0
89	Knowledge And Attitudes Toward the COVID-19 Vaccine Among India's General Rural Population. 2022 ,	0
88	In vitro screening of anti-viral and virucidal effects against SARS-CoV-2 by Hypericum perforatum and Echinacea. 2022 , 12,	1
87	The Effect of Preventive Measures and Vaccination against SARS-CoV-2 on the Infection Risk, Treatment, and Hospitalization: A Cross-Sectional Study of Algeria. 2022 , 14, 2771	1
86	Spotlight on 4-substituted quinolines as potential anti-infective agents: Journey beyond chloroquine.	0
85	Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview. 2022 , 19,	0
84	Repurposing of Chemotherapeutics to Combat COVID-19. 2022 , 22, 2660-2694	1
83	Comparative Analysis of the Efficiency of Medicinal Plants for the Treatment and Prevention of COVID-19. 2022 , 2022, 1-14	0
82	COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics).	1
81	Science communication and public trust in science. 1-16	0
80	The ðhyth of Hydroxychloroquine (HCQ) as post-exposure prophylaxis (PEP) for the prevention of COVID-19âs far from reality. 2023 , 13,	0
79	The outcome of Covid-19 Infection on Kidney Transplantation Recipients in Southern Saudi Arabia, Single Center Experience. 2023 ,	0
78	Changes in Medication Prescribing Due to COVID-19 in Dental Practice in CroatiaâNational Study. 2023 , 12, 111	0
77	Effectiveness of different treatment regimens on patients with COVID-19, hospitalized in Sanandaj hospitals: a retrospective cohort study. 2023 , 16,	1
76	Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis. 2023 , 23,	1
75	Amentoflavone derivatives against SARS-CoV-2 main protease (MPRO): An in 'silico study. 2023 , 1-15	0
74	A Review on COVID-19: Primary Receptor, Endothelial Dysfunction, Related Comorbidities, and Therapeutics.	0

- 73 Discovery of Natural Bisbenzylisoquinoline Analogs from the Library of Thai Traditional Plants as SARS-CoV-2 3CLPro Inhibitors: In Silico Molecular Docking, Molecular Dynamics, and In Vitro Enzymatic Activity. 1
- 72 Safety, Tolerability, and Pharmacokinetics of Nebulized Hydroxychloroquine: A Pilot Study in Healthy Volunteers. 0
- 71 Knowledge, beliefs, and practices about COVID-19 among students and the general public in Tamil Nadu: A cross-sectional study. **2023**, 0 0
- 70 Spray freeze dried niclosamide nanocrystals embedded dry powder for high dose pulmonary delivery. **2023**, 415, 118168 0
- 69 COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte. **2023**, 16, 233-249 0
- 68 Modulation of post-pacing action potential duration and contractile responses on ventricular arrhythmogenesis in chloroquine-induced long QT syndrome. **2023**, 941, 175493 0
- 67 "Quick and dirty" Intuitive cognitive style predicts trust in Didier Raoult and his hydroxychloroquine-based treatment against COVID-19. **2020**, 15, 889-908 1
- 66 Highly efficacious and safe neutralizing DNA aptamer of SARS-CoV-2 as an emerging therapy for COVID-19 disease. **2022**, 19, 0
- 65 The length of hospital stays and clinical and therapeutic characteristics of patients with COVID-19 early in the pandemic in Taif City, KSA: A retrospective study. **2022**, 101, e32386 0
- 64 Pharmacologic Therapeutics for COVID-19. **2023**, 290-318 0
- 63 COVID-19: Inpatient Management. **2023**, 182-232 0
- 62 Detection and Diagnosis of Lung Cancer using Machine Learning Convolutional Neural Network Technique. **2022**, 0
- 61 The dangers of non-randomized, observational studies: experience from the COVID-19 epidemic. 1
- 60 The Role of Hyaluronic Acid in Tissue Engineering. **2021**, 1-55 0
- 59 Management of acute COVID-19 in the pediatric population and role of antimicrobial therapy. **2023**, 99-139 0
- 58 Investigation on Phyto-active Constituent of Clerodendrum paniculatum as Therapeutic Agent against Viral Diseases. **2023**, 8, 0
- 57 Seasonal variation in azithromycin prescription. **2023**, 0
- 56 Impact of Antibiotic Consumption on Antimicrobial Resistance to Invasive Hospital Pathogens. **2023**, 12, 259 0

- 55 Use of Systemic Antibiotics in Patients with COVID-19 in Colombia: A Cross-Sectional Study. **2023**, 12, 252 ○
- 54 Electrostatic Surface Potential as a Key Parameter in Virus Transmission and Evolution: How to Manage Future Virus Pandemics in the Post-COVID-19 Era. **2023**, 15, 284 ○
- 53 Convergent Evolution Dynamics of SARS-CoV-2 and HIV Surface Envelope Glycoproteins Driven by Host Cell Surface Receptors and Lipid Rafts: Lessons for the Future. **2023**, 24, 1923 ○
- 52 Efficacy of hydroxychloroquine in pre-exposure severe acute respiratory syndrome coronavirus 2 prophylaxis among high-risk healthcare workers: A multicenter study. **2023**, 12, 3 ○
- 51 Antimalarial drugs. **2023**, 363-396 ○
- 50 Antimalarials and macrolides: a review of off-label pharmacotherapies during the first wave of the SARS-CoV-2 pandemic. 59, ○
- 49 On the role of benchmarking data sets and simulations in method comparison studies. 2200212 ○
- 48 Comprehensive evaluation of six interventions for hospitalized patients with COVID-19: A propensity score matching study. **2023**, 31, 517-525 ○
- 47 Prescription of antibiotics by general practitioners for patients with a diagnosis of SARS- CoV-2 infection: Analysis of an electronic French health record. **2023**, 61, 106778 ○
- 46 Analytical review of Tiryaq-i-Wabih: A Unani panacea for the control of COVID-19. **2023**, 39, 100653 ○
- 45 Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin: A review. **2023**, 152, 110682 ○
- 44 Targeting intracellular Neu1 for coronavirus infection treatment. **2023**, 26, 106037 ○
- 43 Impact of COVID-19 Pandemic in Antibiotic Consumption in Navarre (Spain): An Interrupted Time Series Analysis. **2023**, 12, 318 ○
- 42 Antibiotic Utilization during COVID-19: Are We Over-Prescribing?. **2023**, 12, 308 ○
- 41 An overview on the treatments and prevention against COVID-19. **2023**, 20, ○
- 40 COVID -19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats. **2023**, 11, ○
- 39 Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial. **2023**, 18, ○
- 38 The Democratic Virtues of Randomized Trials. **2022**, ○

- 37 The Mouth-COVID-19 Connection: The Importance of the Oral Cavity for the Coronavirus Disease â Part II. **2022**, 50, 175-181 o
- 36 Severe COVID-19 as a Possible Mediator of Autoimmunity and Sjögrenâ Syndrome. **2023**, o
- 35 Community purchases of antimicrobials during the COVID-19 pandemic in Uganda: An increased risk for antimicrobial resistance. **2023**, 3, e0001579 o
- 34 An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. **2023**, 9, e13952 o
- 33 Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics. **2023**, 24, 4401 o
- 32 Administration of macrolide antibiotics increases cardiovascular risk. 10, o
- 31 Assessment of GO-Based Protein Interaction Affinities in the Large-Scale HumanâCoronavirus Family Interactome. **2023**, 11, 549 o
- 30 Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial. **2023**, 16, o
- 29 New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention. **2023**, 29, 101478 1
- 28 A Scoping Review on COVID-19-Induced Cardiovascular Complications. **2023**, 3, 348-369 o
- 27 In silico screening of potential compounds from begonia genus as 3CL protease (3CL pro) SARS-CoV-2 inhibitors. o
- 26 Concerted and multidisciplinary management of COVID-19 drug therapies during the first two epidemic waves in a tertiary hospital in Marseille, France: Results of the PHARMA-COVID study. **2023**, 18, e0283165 o
- 25 Computational studies of potential antiviral compounds from some selected Nigerian medicinal plants against SARS-CoV-2 proteins. **2023**, 38, 101230 o
- 24 Knowledge, Concept on severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). A Review of the Literature and Future perspective. **2023**, 441-446 o
- 23 Phenyl Pentyl Ketone and m-isobutyl Methoxy Benzoate Produced by Streptomyces Chrestomyceticus ADP4 are Potent Antimicrobial Agents Displaying Broad Spectrum Activities. o
- 22 A comment-driven evidence appraisal approach to promoting research findings into practice when only uncertain evidence is available. **2023**, 21, o
- 21 Synthesis and structure of new modified derivatives based on the quinine molecule and their biological activity. **2023**, 25, 28-34 o
- 20 Long COVID in autoimmune rheumatic diseases. o

- 19 Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. **11**, 2140-2159 ○
- 18 Therapeutic Targets in the Virological Mechanism and in the Hyperinflammatory Response of Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2). **2023**, **13**, 4471 ○
- 17 Truth and lies about the use of old drugs against COVID-19: have we learned the lesson?. **2023**, **15**, 399-403 ○
- 16 Features of Liver Injury in COVID-19 Pathophysiological, Biological and Clinical Particularities. **2023**, **14**, 156-169 ○
- 15 A perspective on new dilemmas in scientific publishing in the time of a pandemic. **2023**, 100366 ○
- 14 Early Treatment with Hydroxychloroquine and Azithromycin: A "Real-Life" Monocentric Retrospective Cohort Study of 30,423 COVID-19 Patients. ○
- 13 Association between self-reported evidence-based medicine competencies and prescribing of drugs without scientific evidence against mild COVID-19 among recently graduated physicians in Peru. **2023**, **9**, e15366 ○
- 12 Current Strategies to Combat COVID-19. **2023**, 361-374 ○
- 11 Exploring the Link Between Malaria and COVID-19. **2023**, 311-338 ○
- 10 High-Affinity Neutralizing DNA Aptamers against SARS-CoV-2 Spike Protein Variants. **2023**, **3**, 520-542 ○
- 9 The Use of Azithromycin and Lopinavir-Ritonavir in the Treatment of COVID-19. **2023**, 339-360 ○
- 8 COVID-19: Correlation between HRCT findings and clinical prognosis and analysis of parenchymal pattern evolution. **13**, 10 ○
- 7 Efficacy of convective-diffusion models to study the transient behaviour of a sewage-sludge-filled packed column for aqueous phase adsorption of fluoroquinolones: Consideration of pseudo-kinetics driven depletion of species. **2023**, **11**, 109896 ○
- 6 Small molecules in the race of COVID-19 drug development. 1-22 ○
- 5 Factors Related to Severity, Hospitalization, and Mortality of COVID-19 Infection among Patients with Autoimmune Diseases. **2023**, **8**, 227 ○
- 4 COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations. **15**, 441-459 ○
- 3 Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies. ○
- 2 Bibliographie. **2023**, 137-181 ○

- 1 Hydroxychloroquine induces long QT syndrome by blocking hERG channel. **2023**, 3, 105-113

o